Directing the Assembly of Multicomponent Organic Crystals. Synthesis, characterisation and structural analysis of multicomponent organic systems formed from dynamic processes. by Alomar, Taghrid S.
 University of Bradford eThesis 
This thesis is hosted in Bradford Scholars – The University of Bradford Open Access 
repository. Visit the repository for full metadata or to contact the repository team 
  
© University of Bradford. This work is licenced for reuse under a Creative Commons 
Licence. 
 
  
Directing the Assembly of Multicomponent Organic Crystals 
 
Synthesis, characterisation and structural analysis of multicomponent organic 
systems formed from dynamic processes 
 
 
 
 
 
 
 
 
T.S. ALOMAR  
 
PhD 
 
 
 
 
UNIVERSITY OF BRADFORD 
 
 
2014 
 
i 
 
Directing the Assembly of Multicomponent Organic Crystals 
 
Synthesis, characterisation and structural analysis of multicomponent organic 
systems formed from dynamic processes 
 
 
 
 
 
BY  
TAGHRID SAAD ALOMAR 
 
 
 
 
Submitted for the degree of Doctor of Philosophy 
 
 
 
 
 
School of Life Sciences  
University of Bradford  
 
2014 
ii 
Abstract 
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Directed assembly of molecular solids continues to attract widespread 
interest with its fundamental application in a wide range of commercial 
settings where control of the crystalline state of materials corresponds with 
product performance. These arenas include pharmaceuticals, personal care 
formulations, foods, paints and pigments and explosives. 
In recent times, the assembly of multicomponent organic systems has 
achieved considerable impetus with the widespread interest in co-crystal 
systems. However, cogent assembly (or engineering) of multicomponent 
materials is still in its infancy. Considerable advances in crystal design have 
been made through consideration of intermolecular ‘synthons’ – identifiable 
motifs utilising hydrogen bonds – but the translation of other molecular 
information (conformation, chirality, etc.) into solid state properties (e.g. long-
range (translational) symmetry, crystal chirality) remains poorly understood. 
In this study, we have attempted to evaluate the influence of a chiral centre 
adjacent to molecular synthons to identify potential translation of information 
into the solid form. We have compared the co-crystallisation of nicotinamide 
with both the racemic mixture of malic acid against that with an 
enantiomerically pure form of the acid (L-malic acid). As well as DL-
phenyllactic acid and L-phenyllactic acid. 
iii 
It is apparent that recognition between enantiomeric molecular forms play a 
significant role in the assembly of these systems. This mechanism can be 
considered independently from the H-bonding networks supporting the 
hetero-molecular interactions (e.g. acid-amide recognition). Discrimination 
and control of such interactions may play a role in transmitting chiral 
molecular information into solid state multi-component assemblies. In order 
to develop an understanding of co-crystal formation in chiral and achiral 
forms with intermolecular interactions, the CSD and crystal structures were 
obtained to do the analysis of how co-crystals pack.  
 
This study has also investigated the use of boronic acids. The aim of this 
study was to investigate the modification of the hydrogen bonding 
environment within the hydrogen bonded multi-component systems of 
boroxines. The study also attempted to determine how the starting materials 
drive the systems between the boronic acid co-crystal and the boroxine 
adduct. 
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1.0  Introduction 
The directed assembly of molecular solids continues to attract widespread 
interest because of its fundamental application in a wide range of 
applications; thus, the control of the crystalline state of materials is important. 
In recent times, the assembly of multicomponent organic systems has 
achieved considerable impetus with the widespread interest in co-crystal 
systems. However, the cogent assembly (or engineering) of multicomponent 
materials is still in its infancy1. Considerable advances in crystal design have 
been made through consideration of intermolecular “synthons” – identifiable 
motifs utilising hydrogen bonds – but the translation of other molecular 
information (conformation, chirality, etc.) into solid state properties (e.g. long-
range [translational] symmetry, crystal chirality) remains poorly understood. 
The design and synthesis of stable solid state structures, based on non-
covalent interactions, is included in the field of supramolecular chemistry. 
The construction of a variety of organised frameworks, often with potentially 
useful chemical and physical properties, is one of the important applications 
of crystal engineering2.  
1.1 Aims and Objectives 
This project aims to investigate the probability of creating new 
multicomponent crystalline materials, using mixtures of chiral and achiral 
formers with intermolecular interactions. The relative control over molar ratios 
of the starting materials will be determined by using different solvents, to 
illustrate, this research aims to:  
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 Prepare solid state co-crystal systems from mixtures of chiral and 
achiral formers. 
 Study vibrational modes and hydrogen bonded complexes of acids 
and amides in the framework of its different polymorphic forms at 
harmonic levels in order to investigate the hydrogen bonding 
interactions. 
 Select systems based on their known synthons: acid–acid, 
(homosynthons), acid–amide (hetrosynthon). 
 Characterise the system by single crystal analysis. 
 Perform a comparative study of selected multicomponent systems by 
both single crystal and by its powder x-ray diffraction (PXRD) pattern. 
 Investigate the systematic changes in molecular features. 
 Fully characterise the resultant multicomponent systems using powder 
x-ray diffraction, nuclear magnetic resonance (NMR) and infrared 
spectroscopy (IR) analysis. 
 Study the effect of the different molar ratios (1:1, 2:1, 1:2) of the 
starting materials and solvents (acetone, acetonitrile and methanol) on 
the multicomponent system formation. 
1.2 Crystal Engineering 
Crystal engineering describes the exploitation of non-covalent bonding to 
allow control of the arrangement of molecules and ions, in relation to one 
another in the solid state. Most of the work in this area has focused on the 
organic molecules and hydrogen bonding.  The term “crystal engineering” 
was first introduced by Schmidt3 in 1971, in relation to the photo- dimerisation 
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reactions in cinnamic acid crystallisation. Since then it has been redefined 
many times and this term now covers many aspects of supramolecular 
chemistry in the solid state.  
The outstanding challenges posed by crystal engineering in the modern day 
were reviewed by Desiraju4, who defined it as:  
“The understanding of intermolecular interactions in the context of crystal 
packing and in the utilisation of such understanding in the design of new solids 
with desirable physical and chemical properties”
4
. 
Much focus has more recently been centred on the importance of predicting 
crystal structures, especially in the pharmaceutical environment whereby the 
different polymorphs of the same drug have been assessed. Crystal 
engineering is becoming an increasingly important tool, since many of the 
bulk properties of materials are dictated by the molecular assembly within the 
solid state, therefore having control over this assembly affords great control 
over the properties of the material5. 
1.3 Multicomponent Complexes 
Co-crystals have been the topic of investigation for a number of years, even 
when specific co-crystal titles have not been identified6. The first example of 
co-crystallisation occurred in 1893 with the formation of quinhydrone from the 
equimolar amount of P-benzoquinone and hydroquinone7. The definition of 
co-crystals is still a matter of debate8, a simple definition notes that: 
“multicomponent crystals, in which two or more components that are solids 
under ambient conditions, coexist through non-covalent interactions”. A more 
precise description was stated by Kitaigorodsky6 as: “a constituent part of a 
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system, such that its composition, at least in one state of aggregation does 
not depend on the concentration of the other parts”6. 
For the purpose of this paper, only compounds that contain two chemically 
and molecularly distinct functional groups will be used. These are widely 
studied systems, so it is possible to predict, with a good level of accuracy, 
how these complexes will form. These assembly types utilise the following 
three main bonding types: hydrogen bonding, charge transfer interactions 
and proton transfer interactions9. A number of studies have focused 
predominately on using hydrogen bonding to create a whole new crystal 
packing system10,11,12. The hydrogen bonding approach uses a molecule with 
two or more hydrogen bonding sites, these can be either accepting or 
donating, and therefore allow components to bond at these different sites.  
This approach however requires careful balancing of the hydrogen bond 
strengths, against the other intermolecular interactions.  
1.4 Non-Bonded Interactions between Organic Molecules  
Hydrogen bonding, -  stacking, and N-H---  and C-H---  interactions play 
a considerable role in governing the specific functional structures of important 
biomolecules13,14,15. These non-covalent interactions also form the basis of 
crystal engineering16,17,18. Hydrogen bonding arises from electrostatic 
interactions, while dispersion forces dominate the stacking and -hydrogen 
bonding interactions13. Although crystal engineering focuses on 
understanding the intermolecular interactions and connectivities that lead to 
the construction of multicomponent complexes, the hydrogen bond remains 
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an important tool in the formation of co-crystals, because of its strength and 
directionality.  
1.4.1 Dispersive Forces – Van der Waals’ Interactions  
Van der Waals’ forces are simply a specific group of interactions resulting 
from temporary dipole interactions. These forces are a group of relatively 
weak intermolecular interactions which generally result when a molecule or 
group of molecules become polarised into a magnetic dipole. This happens 
most often as a result of uneven or shifting distributions within the atoms’ 
electron cloud19 . These attractions are much weaker than a chemical bond, 
but they can cause molecules to cohere as liquids or solids, and they are 
therefore responsible for surface tension and capillary actions19. 
1.4.2 Charge Transfer Interactions 
Charge transfer interactions are observed between an electron donor ( 
base) and an electron acceptor ( acid), and an adduct is formed when 
donation occurs from the base to the acid. Two types of adducts can be 
formed by these interactions: firstly, if the electron transfer is complete then 
an ionic solid is formed; and, secondly, if the electron transfer is only partial 
then the system may delocalise the charge to form a charge transfer 
complex20. In  systems, charge transfer interactions are not fully 
understood, but it is believed that they comprise of the following three 
interactions: Van der Waals, hydrophobic and electrostatic interactions21. The 
electrostatic component of the interaction is able to push the  systems into a 
number of geometries (see also Figure 1.1)22. 
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Figure 1.1: Known geometries of aromatic charge transfer systems
22 
1.4.3 Hydrogen Bonding 
Hydrogen bonds are bonds between molecules that contain an 
electronegative atom which possesses lone pairs of electrons (usually O, N 
or F), these are called acceptors (A); in addition, the molecules containing 
covalent bonds between a hydrogen and an electronegative atom (usually O-
H, N-H, and S-H) are called donors (D). Hence, the polarised nature of the X-
H bond (X=O, N) results in a highly electropositive hydrogen which is 
attracted toward bond formation with electron rich electronegative acceptor 
atoms23. 
The ideal geometry of the hydrogen bond is linear, with the hydrogen atom 
positioned along the line connecting the hetero-atoms. The linear geometry is 
not always obtained, as neighbouring covalent bonds affect the geometry of 
the hydrogen bonds. It is this property of the hydrogen bond that leads to its 
directionality. The strength of the individual hydrogen bonds (1-10 kcal/mol) 
is much weaker than the covalent bonds (70-110 kcal/mol)24. It should also 
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be noted that the hydrogen bond is also sensitive to external environmental 
factors, such as the polarity of the medium as well as the presence of 
solvents and water.  
1.4.3.1 Etter’s Rule for Hydrogen Bonding 
Etter, and other co-workers, developed a method of systematising the 
interactions in the organic solid state through the use of a system of graph 
sets to describe the motifs observed in the hydrogen bonding patterns25. 
They also set a number of rules, including the following which state: 
All good proton donors and acceptors are used in hydrogen bonding;  
Six-membered ring intramolecular hydrogen bonds form in preference to 
intermolecular hydrogen bonds;  
The best proton donors and acceptors, remaining after intramolecular 
hydrogen bond formation, form intermolecular hydrogen bonds26. 
1.4.3.2 Supramolecular Synthons 
Hydrogen bonding is one of the most important fundamental interactions that 
causes association of organic molecules, these form the building block units 
that are known as supramolecular synthons26,27,28. 
Supramolecular synthons are defined by Schmidt3 as “structural units within 
supramolecules, which are formed or assembled by intermolecular 
interactions”.  The hydrogen bond is still believed to be the most important 
intermolecular interaction; the synthons are formed by utilising those 
hydrogen bonds which can be from the same functional group called 
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homosynthons, these include: carboxylic acids, oximes, pyridones and 
amides, and different functional groups known as heterosynthons with 
examples such as: carboxylic acid···pyridine, acid···amide, and 
alcohol···pyridine interactions.  The concept of supramolecular synthons is 
employed to construct co-crystals; thus, co-crystals are a consequence of 
self-assembly between these different molecular species27,28.   
The arrangement of supramolecules is based on the strong hydrogen bonds 
which include: N-H…O, O-H…O, N-H….N, and O-H….N, as well as weak 
hydrogen bonds which include: C-H….O-N and C-H…O=C, these are 
presented, below, in Figure 1.229. 
 
 
Figure 1.2: Common synthons utilised in the assembly of supramolecules
29 
In the design of co-crystals it is important to recognise synthons that are 
capable of forming a suitable network structure based on the consequences 
of selective and directed hydrogen bonds; therefore, functional groups that 
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are self complementary are able to form homodimers – they are called 
supramolecular homosynthons. Figure 1.3a shows the formation of 
carboxylic acid-carboxylic acid or the amide-amide dimers and Figure 1.3b 
shows that when two complementary functional groups are engaged in the 
formation of carboxylic-amide dimers then this interaction is called a 
supramolecular heterosynthon29. 
 
Figure 1.3a: Homosynthons – the formation of homo supramolecular synthons are 
acid-acid and amide-amide dimers  
 
Figure 1.3b: Heterosynthons – the formation of hetero supramolecular synthons in the 
acid-amide dimer
29 
Numerous papers have reported the synthesis of co-crystals and significant 
success has been achieved with the interaction of carboxylic acid and N-
heterocycle moieties, as with carboxylic acid and pyridines; thus, if the amide 
is used instead of the carboxylic acid, then a hydrogen bond is not formed 
between N-H---N and the differences in the behaviour of these functional 
groups may be related to the differences in the acidity of the protons30. 
Some supramolecular synthons, including carboxylic acid-pyridine, carboxylic 
acid-amide and alcohol-pyridine, tend to favour co-crystal formation. CSD 
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studies have shown that a carboxylic acid-pyridine synthon II (Figure 1.4b) is 
more favoured than a carboxylic acid homosynthon I (Figure 1.4a), whereas 
calculations show that a carboxylic acid-amide synthon IV (Figure 1.4d) is 
more stable than an acid (I) or amide homosynthon (III) (Figure 1.4a or 
1.4c)31. 
                                    
   a)      b) 
                                  
    c)           d) 
Figure 1.4: Various supramolecular synthons, including: a) carboxylic acid 
homosynthon; b) carboxylic acid-pyridine synthon; c) acid or amide homosynthon; d) 
carboxylic acid-amide synthon 
 
1.4.4 Chiral Recognition  
The origins of single handed molecules occurring in the natural environment 
have been of much interest, as all biological molecules adopt single 
handedness. Pasteur first discovered, in 1848, that tartaric acid existed as a 
single handed molecule in nature, whereas synthesised tartaric acid existed 
as an enantiomer32.  Several theories have been proposed as to how single 
handedness arose from racemic mixtures in nature33,34. 
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Recently McBride proposed that a fundamental physical bias exists, this is 
what generates a particular molecular handedness35. In 1953 Frank, a 
theoretical physicist , proved mathematically that if an initial random event 
provided a tiny excess of one hand then this would lead to the exclusive 
formation of that form36. However, in 1990 Kaufman et al. demonstrated, by 
dissolving a concentrated solution of sodium chlorate of no handedness, that 
after stirring it crystals of a single hand were isolated37. In 2005, Viedma 
illustrated that it was possible to grow single handed crystals of sodium 
chlorate from a slurry of mixed mirror image crystals, as long as the mixture 
contained an excess of one hand; furthermore, by stirring the slurry, this 
resulted in a complete conversion of the crystals of the more dominant form. 
In addition, grinding has also been shown to work in converting a mixture to 
one hand38. 
1.4.4.1 Chirality in Nature  
Chiral molecules are mirror images that are not superimposable upon one 
another. Conversely, chiral compounds have superimposable mirror images. 
The word chirality is derived from the Greek word for hand and it means 
“handedness” with regards to the reflecting of either the left- or right-
handedness of molecules that are chiral in nature. Stereoisomers and 
enantiomers are types of chiral compounds39. 
Stereoisomers are compounds that have the same atoms connected in the 
same order, but they differ from each other in the way in which the atoms are 
orientated in space. The chiral molecules that are structurally different from 
each other, only in terms of the left- or right-handedness of their orientations, 
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are called enantiomers. Enantiomers have the same physical properties, but 
they behave differently under certain conditions; as such, they react at 
different rates with other chiral compounds and they may also react at 
different rates in the presence of chiral catalysts and optically active solvents. 
When polarised light is passed through a pure sample of each enantiomer, 
the plane of the polarised light is rotated, in opposite directions and in equal 
amounts by the two enantiomers. If rotation of the plane of the polarised light 
occurs, the material is considered to be optically active. An isomer that 
rotates light to the left is called “levo-” and is indicated with a negative 
notation (-). However, an isomer that rotates light to the right is called 
“dextro-” and is notated as being positive (+). 
The absolute configuration of a molecule indicates the actual arrangements 
of the substituents within the chiral compound. The direction of rotation of the 
plane’s polarised light does not indicate the absolute configuration of a chiral 
molecule. In fact, it is possible for various unrelated compounds, with the 
same absolute configuration, to rotate light in opposite directions. In the early 
part of the century there were no empirical methods for determining absolute 
configuration. But, Rosanoff chose glyceraldehyde to set the standard for 
configuration by assigning the isomer that rotates plane polarised light to the 
right as the D isomer, and the isomer that rotates plane polarised light to the 
left as the L isomer40. Only amino acids and carbohydrates, and their 
derivatives, are still commonly assigned the D and L descriptors. 
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1.4.4.2  Chiral Separation and Resolution of Enantiomers  
The separation of chiral compounds has been of great interest because the 
majority of bioorganic molecules are chiral31. Amino acids, sugars, proteins 
and nucleic acids are all composed of chiral molecules; for example, amino 
acids exist in the L form and sugars in the D form.   
Chirality is a major concern in the modern pharmaceutical industry36,37, since 
the case of thalidomide. The body interacts with each racemic drug differently 
and metabolises each enantiomer using separate pathways to produce 
different pharmacological activities. Thus, one isomer may produce the 
desired therapeutic activities, while the other may be inactive or, in worst 
cases, produce unwanted effects. Therefore, separation of these is important 
as different biological responses can be seen as a pair of enantiomers in 
drugs35.  
Some examples of pharmaceuticals, whereby one isomer has the desired 
effect and the other has harmful properties, will now be included; to illustrate, 
in thalidomide41 the R-enantiomer is a sedative and the S-enantiomer is 
teratogenic. In addition, there is ethambutol42, where the S-enantiomer 
shows antiarthritic properties and the R-enantiomer is extremely toxic. 
Nonetheless, thalidomide is the best known of these drugs.  
The separation of two enantiomers into the two mirror forms is described as 
resolution. The separation can be carried out using a number of different 
techniques. Firstly, resolution via diastereomeric salt formation involves 
forming an acid-base reaction of a racemate with an enantiopure resolving 
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agent. This gives two diastereomers with different physical properties, a 
difference in solubility is often used to separate the diastereomers35. 
Secondly, kinetic resolution is another technique where the reaction rate of 
one enantiomer is different to the reaction rate of the other enantiomer. The 
difference in rate between the two enantiomers is caused by the use of an 
enzyme or chiral catalyst. The slower reacting enantiomer will be the 
dominant form if the reaction is stopped before completion. The two 
diastereomeric transition states must be different in energy in order for the 
strategy to be successful43. 
Thirdly, Dutch resolution is a term given to the use of mixtures of resolving 
agents in classical resolution. This technique uses the concept of “families”, 
where the resolving agent is structurally related. The enantiomeric excess is 
increased from between 20 and 30% to between 90 and 95% when this 
technique is used.  Not many families of resolving agents exist, however 
common ones include cyclic phosphoric acids, quinine and brucine44. 
This technique leads to precipitation of crystalline diastereomeric salts of high 
yield and enantiomeric purity. The mechanism behind Dutch resolution is not 
clear at the moment and the reality is that in many cases the resulting 
diastereomeric salts are solid solutions which suggests a thermodynamic 
origin3. 
1.4.5 Dynamic Covalent Bonds 
When diboronic acid or polyboronic acid undergo self-condensation, this 
results in the formation of crystalline porous materials which are termed 
16 
covalent organic frameworks (COFs). As in the current research project, this 
diboronic acid is phenylboronic acid. Recently, research publications have 
been related to COF-1 (Figure 1.5) which has had drastic expanded interest 
in the boroxine-containing materials; thus highlighting the versatility of the 
B3O3 ring system
45. 
 
Figure 1.5: Dehydration of 1,4-benzenediboronic acid  
results in the formation of COF-1
46
 
Yaghi, and various co-workers in 2007, showed how COFs were based 
exclusively on the reversible formation of the boroxine linkages. Optimising 
the crystallinity of boroxine-based materials requires careful choice of solvent 
and temperature in order to maximise the error correction associated with the 
boroxine ring-forming reactions47. Recently, Cooper and other co-workers 
published a paper showing the synthesis and purification of a COF-102 and 
boronate-based COF-5, using microwave heating48. This method was 200 
times faster than other reported solvothermal methods49. The output of these 
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new methodologies demonstrated the discovery of new COFs and other 
microporous polymers.  
Boroxines, also known as boronic acid anhydrides, are formed by the 
dehydration of boronic acids. Boroxine research has gained significant 
attention in recent years because of its aromatic character and its tendency 
to form Lewis acid-base adducts with nitrogen-containing ligand. 
1.5 Crystallisation 
Crystallisation is the process of phase transformation whereby molecules are 
initially self-assembled in a solution, they then undergo nucleation. This 
whole process is governed by the laws of thermodynamics and kinetics, as 
crystallisation is a phase forming route. Consequently, it is important to 
realise that the formation of the stable form, during crystallisation, is a 
thermodynamic process, while the formation of the metastable form is a 
kinetic process. The crystallisation process is affected if stirring is applied, 
even for slightly soluble substances; to illustrate, Smith and Sweet50, and 
Sohnel and Handerson51,52, found that stirring increases nucleation, the 
induction time for crystallisation, the growth rate and the number of particles. 
The crystallisation process is initiated with the formation of a labile solution, 
whereby, the solubility equilibrium between solid and solution needs to be re-
established, as a degree of solubility mismatch exists. Stability of the 
crystallisation system depends on the forces of attraction between the solid 
particles and the thermodynamic conditions are fundamental in the crystal 
growth process53. The formation of the nuclei is defined by the relationship 
between the critical nuclei size and the degree of supersaturation, other 
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conditions persuade the nucleation process and relate to the bulk and 
surface free energies and the kinetics of the process. These nuclei are nano-
sized units either from a spontaneous centre (homogeneous nucleation) or 
from an artificial centre (heterogeneous nucleation)54. Nucleation can be 
induced by agitation, friction or mechanical shock which is dominant at low 
supersaturation. The growth of crystals can be defined when the size of the 
particles becomes greater than the critical size, and is therefore visible in a 
supersaturated or supercooled system. Various theories explain the process 
of crystal growth, including the following:  
The surface energy theory explains that the shape of the crystal is related to 
the free energy of the faces, and the growth rate of the crystal faces is 
proportional to their surface energy. Within this model the growth rate and the 
surface energy are inversely proportional to the lattice density of the plane, 
so the growth will be faster for the faces having low lattice density54. 
The diffusion theory, proposed by Noyes and Whitney, demonstrates that 
crystallisation is the reverse process to dissolution, and the growth of the 
crystal face is a diffusion process. Within this model the difference between 
the concentration in the bulk solution and the solid surface governs the 
diffusion and dissolution process3. 
The adsorption layer theory, proposed by Volmer, states that when a unit 
reaches the crystal face it has to lose one degree of freedom so that it can 
migrate freely over the crystal face; thus, a dynamic equilibrium between this 
layer and the bulk of the solution should be attained to adsorb this unit on the 
layer50. 
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The mechanism of crystal growth and the rate of the process may be 
determined by the size and morphology of the solid, the shape will be cubes 
or octahedral if the growth takes place on the surface, and it is an elongated 
shape such as needles, rods or plates if the growth rate is anisotropic. 
1.5.1 Methods for Preparation of Multi Component Organic Systems 
An important aspect of the successful co-crystal development remains the 
identification of suitable co-formers. Although the literature review shows 
many developed synthetic pathways, such as neat or liquid assisted 
grinding55,56, slow evaporation of mixed solutions57, solution-mediated phase 
transformation (slurrying)58 and hot-stage microscopy melt interface59, a trial-
and-error approach will be used to screen a large set of possible candidates 
of co-former identification. 
1.5.1.1  Solution Crystallisation 
The slow evaporation technique is a basic method whereby a saturated 
solution must be prepared in a suitable solvent – this solution is left until the 
crystals are formed. One condition that must be considered is the solubility of 
both compounds in the same solvent – they must both be comparable and if 
they are not then the least soluble compound will be recrystallised. 
1.5.2  Phase Diagram  
1.5.2.1  Phase Diagram in Co-Crystallization 
Crystal growth is influenced by various elements, including: crystallographic 
characteristics, technical parameters of the method used to grow crystals and 
by kinetics and thermodynamics. The growth of crystals from a solution is 
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dependent on good knowledge of liquid curves – this is useful when seed 
crystals are inserted into the solution in order to help the growth of specific 
forms of crystals; this procedure requires conditions that are close to those of 
thermal equilibrium60. 
Phase diagrams identify the need or presence of an element or a compound 
in graphical form by identifying the specific conditions (such as: temperature, 
pressure and concentration of compounds) at equilibrium in order to reflect 
the thermodynamic laws and rules between the different phases50. The 
phase diagram is also very useful as it reveals information about the 
interactions among the components of the solutions.  
1.5.2.2 Binary System and Eutectic Points 
All of the stable phases which are formed from a two component system can 
be represented in a binary phase diagram as a function of the concentration 
and the temperature or pressure. Any changes in the concentration or the 
temperature are the major factors that control the crystallisation process; 
therefore, a profile for the overall process can be obtained from the 
construction of a binary phase diagram as a function of the overall 
concentration and temperature which are the simplest form of a two 
component system. To illustrate, Figure 1.6 provides an example of an A and 
B phase diagram. 
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Figure 1.6: A two component binary phase diagram with a simple eutectic
51
  
This digram shows that the temperature is the ordinate while the overall 
composition is the abscissa; furthermore, it it scaled as a molar percentage, 
but it could also be scaled in a mole fraction. The relation between the 
temperature and the composition appears as lines or curves, these are called 
the phase boundries. As can be seen, TmA  and TmB are the melting points of 
component A and component B respectively, the curves TmA  E and TmB E 
are liquidous boundary curves, and the horizontal line separating phase A + 
liquid and phase B + liquid is the solidus line. Point E is the eutectic point 
where solid A and solid B, and their liquid, were all in equilibrium; 
furthermore, the number of phase is recorded as three in accordance with the 
phase rule whereby the system has zero degrees of freedom and the system 
is invarient at the eutectic point. By applying the phase rule for a two 
component system, the degree of freedom is F = 4 – P. 
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1.5.2.3  Ternary System 
The construction of ternary phase diagrams is a new approach used to 
rationalise the preparation of crystals from solutions. The importance of the 
knowledge of the ternary phase diagram was highlighted in the literature 
presented by Rodrigues et al.61, and Chiarella et al.62.    
The phase equilibria, of a three component system, can be represented on 
an equilateral triangle in which each component is represented by one of the 
apices of the triangle, the binary system is represented by each side of the 
triangle and any point within the triangle will represent the three components 
of the ternary system. The composition of each component is expressed as 
being a mole or mass fractions, but it was found that it could lead to some 
difficulties in the determination of the absolute composition; therefore, it is 
better to express the composition as being either a molar or mass 
percentage63.   
1.6 Strategies for Addressing the Project Aims 
In order to successfully address the aims of this project a systematic 
approach will be taken, this will involve first establishing a stable co-crystal 
using acid-amide interaction and hydrogen bonding through the use of 
different solvents (acetone, acetonitrile, methanol) of the 1:1, 1:2 and 2:1 
molar ratios of the starting materials. 
The compounds chosen have complementary donor and acceptor functional 
groups; to illustrate, isonicotinamide and nicotinamide differ in the position of 
the nitrogen atom and are co-crystallised with a number of carboxylic acids of 
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optically pure and racemic compounds in order to determine whether chirality 
is translated into the secondary structure.  
The acid group was chosen as it has been widely studied in the area of 
crystal engineering and is therefore a good starting point. The 
complementary hydrogen bonding donor and acceptor sites also makes them 
good synthons. However carboxylic acid and N interactions are more 
favoured and form an acid-amide heterosynthon.  Therefore we have used 
the carboxylic acid-amide for the formation of these co-crystals. Nicotinamide 
has been successfully utilised as a co-former in the preparation of co-crystals 
with carboxylic acids16. 
1.6.1 α- Hydroxyl Carboxylic Acids in Crystal Engineering 
In recent times, amide to carboxylic acid hydrogen bonds have become 
important in molecular recognition chemistry, where amide hosts have been 
designed64 and constructed for binding carboxylic acid65 and carboxylate ion 
guests66. The hydrogen bonding associated with amide and carboxylic acid 
functional groups can act as either a proton donor or acceptor. In the 
literature, many examples of complementary acid-acid and amide-amide 
association have been acknowledged67. 
Racemic (DL-) and enantiomeric (L- and D-) malic acid species, are very 
important biological molecules68,69,70. They have the same molecular formula, 
but both the racemic and enantiomeric forms exhibit dissimilarities in terms of 
their vibrational behaviour which is as a result of differences in their structural 
features, including: crystal symmetry and geometric distinctions in some 
functional groups69. 
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Malic acids are all capable of forming intramolecular hydrogen bonds that are 
between an alcohol group and a carboxylic acid group. Among the molecules 
of malic acid, there are two kinds of hydrogen bond interactions, see Figures 
1.7, 1.8 and 1.9.  
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Figure 1.7: Intramolecular hydrogen bonding within malic acid
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Figure 1.8: Intermolecular hydrogen bonding between malic acid-malic acid
64 
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Figure 1.9: Intermolecular hydrogen bonding between malic acid-isonicotinamide
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1.6.2 Phenylboronic Acids in Crystal Engineering 
Boronic acids and their derivatives are well known in crystal engineering, 
bioorganic and medicinal chemistry71,72. Boronic acids have a tendency to 
form hydrogen bonded networks, where the boron atom maintains its trigonal 
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planar geometry which shows a topological resemblance to the 
centrosymmetric dimer motifs in carboxylic acids and amides73. 
Boronic acids are used in the synthesis of co-crystals and, in addition to the 
study of centrosymmetric dimer assemblies and condensation products, it 
should be noted that the interactions made by –B(OH)2 with heterocycles in 
terms of topology and selectivity are different from the interaction types 
observed in the assemblies of acids and amides74. 
An important aspect of phenylboronic acid is that it can exist, in principle, in 
three different conformers (syn-syn; syn-anti and anti-anti, see Figures 1.10a, 
1.10b and 1.10c) each of which have separate energy profiles75.  However in 
nature these compounds are predominately found in the syn-anti-
conformation because it is energetically more favoured. In molecular 
complexes, the functionality exhibits conformational variety and three 
conformations are possible for the -B(OH)2 functionality. 
                         
      a)          b)    c) 
Figure 1.10: Phenylboronic acid with three different conformers: a) syn-anti; b) syn-
syn; and, c) anti-anti  
Boronic acids also form boroxines, which resemble a six-membered B3O3 
(boroxine) ring, these are formed when three boronic acid units converge and 
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undergo cyclodehydration. This property has been efficiently exploited to 
achieve highly porous covalent organic frameworks73,74,75. 
Various literature has revealed that phenylboronic acids have a tendency  to 
form O-H···N hydrogen bonds with several pyridine based linear spacer 
ligands45.This tendency of non-covalent interactions with N-donor 
compounds mutually with the conformational flexibility make this functionality 
an appealing aspect in crystal engineering.  In a co-crystallisation study, by 
Raju et al., where the system under investigation was 1,2-diazo fragment 
(alprazolam, 1H-tetrazole, acetazolamide and benzotriazole), and 1,10-
phenanthroline and 2,2’-bipyridine, the results obtained revealed that simply 
the presence of the 1,2-diazo fragment in the co-former does not give 
assurance of the successful configuration of co-crystals with a syn-syn-
conformation of the boronic acid74. 
The complexity in employing phenylboronic acids in the design and synthesis 
of molecular adducts is obvious from the six types of hydrogen bonding 
motifs experimentally observed in the adducts of boric/boronic acids with 
4,4’-bipyridine.  In another study by Desiraju et al., the molecular complexes 
after synthesis of BPY-BDBA (1,4-benzene-diboronic acid) did not contain 
cyclic O-H···N hydrogen bonds76. Instead, the rotational sovereignty enjoyed 
by the bipyridyl (known as BPY or bpy) unit adopted a completely different 
pattern. In the complex, although the boronic acid was found in its preferred  
syn-anti conformation, a linear chain was found connecting the two boronic 
acid functionalities. These chains are consistent with the heteroatoms of the 
anti-orientated bipyridyl linkers through O-H···N hydrogen bonds. This leads 
to the formation of a ladder assembly, the ladders belonging to the adjacent 
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planes are arranged in a staggered manner so as to evade any possible 
empty space. 
1.6.3  Pyridines and Pyridinecarboxamides in Crystal Engineering 
The literature indicates that there are many reported complexes of 
isonicotinamide and nicotinamide.  Although it is apparent, from the literature 
reviewed, that carboxylic acid, and specifically isonicotinamide, form 
supramolecular synthons which are responsible for molecular complexes. 
Miranda et al.77 studied the co-crystal engineering phenomena of 
stoichiometric molar ratio co-crystal of nicotinamide with lamotrigine (1:1) (a), 
and lamotrigine nicotinamide co-crystal monohydrate (1:1:1) (b). Single 
crystal analysis of (b) showed an asymmetric unit which consisted of one 
molecule of lamotrigine, one molecule of nicotinamide and one water 
molecule.     
The single crystal x-ray structure of nicotinamide (Nic1) was first reported in 
195478 with a more accurate determination appearing in 1999 (known as 
CSD refcode: NICOAM01)79. The polymorphism of nicotinamide was first 
discussed in 2001. 
Additionally, isonicotinamide is a pyridine derivative with an amido group in 
∂Ỵ position, this has pharmaceutical importance since it has anti-tubercular, 
anti-pyretic and antibacterial properties80.  
The crystal structures of two polymorphs of isonicotinamide were reported in 
2003. These two forms, herein designated Iso1 (CSD refcode: EHOWIH02) 
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and Iso2 (CSD refcodes: EHOWIH, EHOWIH01) which were evidently the 
only known polymorphs of isonicotinamide31. 
Nicotinamide has two hydrogen bonding groups suitable for the formation of 
an intermolecular hydrogen bond. The amide group has two hydrogen bond 
donors and two lone pairs on the carbonyl O atom. A second hydrogen bond 
acceptor is the lone pair on the N atom of the pyridine ring.  
Nicotinamide exist in four polymorphic forms, attained by the recrystallising 
technique which has four commercially available forms: I, with a melting point 
of between 126 and 128°C; II, with a melting point of between 112 and 
117°C; III, with a melting point of between 107 and 111°C; and, IV, with a 
melting point of between 101 and 103°C. Form I is the most stable one, with 
the other three being metastable (the four forms are known as: NICOAM, 
NICOAM01, NICOAM02 and NICOAM03)31. The most stable crystallize in a 
monoclinic form.31 
Hydrogen bonded interactions, between the acidic proton of the carboxylic 
acid with the basic N atom of the pyridine, are very important for the 
formation of supramolecular structures. This is in accordance with Etter’s 
empirical rule, which states that the best proton donors and acceptors 
remaining after intramolecular hydrogen bond formation form intermolecular 
hydrogen bonds52.  
The carboxylic acid proton, being the most acidic proton, is the best 
hydrogen bonding donor which interacts with the best hydrogen bonding 
acceptor – this is the basic lone pair of the pyridine N (synthon I). The second 
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best donor/acceptor pair is the amide syn-proton and the carbonyl oxygen of 
the amide, which can form a homomeric hydrogen bond ring. 
1.6.4 Analytical Strategy  
X-ray crystallography was utilised in this project in order to determine the 
crystal structures and to evaluate the different bonding types used within 
them. FT-IR analysis showed how the vibration modes will be affected by the 
formation of supramolecular synthons; this will also indicate the magnitude of 
deviation of vibrational frequency involved within the modes. 
1.6.4.1  Powder X-Ray Diffraction (PXRD) 
Each crystalline substance has a unique x-ray diffraction pattern. The 
number of observed peaks is related to the symmetry of the unit cell (higher 
symmetry generally means fewer peaks).  The d-spacing of the observed 
peaks are directly related to the repeating distances between the planes of 
atoms in the structure.  Finally, the intensities of the peaks will be noted in 
terms of how they relate to the different kinds of atoms that are in the 
repeating planes.  The scattering intensities for x-rays are directly related to 
the number of electrons in the atom; hence, light atoms scatter x-rays 
weakly, while heavy atoms scatter x-rays more effectively.   
These three features of a diffraction pattern: the number of peaks, the 
positions of the peaks and the intensities of the peaks, define a unique 
fingerprint x-ray powder pattern for each and every crystalline material. X-ray 
powder diffraction is a powerful tool that can be used to characterise the 
products of a solid state synthesis reaction.  At the simplest level, diffraction 
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patterns can be analysed for phase identification; thus, they determine what 
crystalline substances are present in a given sample. 
Each peak in a diffraction pattern arises from a unique set of repeating 
planes within the structure.  These sets of planes are orientated in all 
directions in three-dimensional space.  However, in order to see diffraction 
from a specific set, the planes must be orientated relative to the incident x-
ray beam.  Therefore, x-ray powder diffraction relies on a large number of 
crystallites in random orientations in order to observe the most diffraction 
peaks.  Of course, the proper orientation is only one factor, as diffraction from 
a particular set of planes may not be observed or the peak intensity may be 
low due to symmetry (patterns of systematic absences) or other factors that 
contribute to low intensity. 
X-ray diffraction is a useful technique for determining the shape and type of 
crystal unit cells, as well as the arrangement of atoms within the unit cell. 
When an x-ray is directed onto an atom, the electrons of the atom will absorb 
the incoming x-ray and then re-emit it. If the atoms are located on a 
crystallographic plane, the scattering of x-ray will be mathematically 
equivalent to the reflection made by the plane. Since the crystallographic 
planes are parallel to and equally spaced with each other, there will be a path 
difference between the x-ray diffracted by the two planes (see Figure 1.11)81. 
Thus, it can be noted: 
Path difference = AB + BC = 2dhkl sinθ 
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For scattering-in-phase, the path difference must be equal to an integral 
number of wavelengths, such as: 
nλ = 2dhkl sinθ 
Where n is an integer and λ is the wavelength of the impinging x-ray – this 
condition is known as “Bragg’s law”.   
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Figure 1.11: X-ray diffracted by two crystallographic planes 
1.6.4.2 Symmetry within Crystals 
As would be expected the repeating nature of the crystal lattice gives rise to 
a number of different arrangements, these are described based on the 
symmetry within the unit cell. This classification describes seven separate 
crystal systems and the corresponding 32 point groups.  A unit cell which 
possesses only a centre of symmetry, or even no symmetry, is the only 
system in which there are no shape restrictions. In this case each of the 
angles ᾳ, β and   must be specified and the crystal system is observed to be 
triclinic (see Table 1.1)82. 
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Table 1.1: The 32 crystal classes and the corresponding crystal systems 
Crystal system Crystal classes Metric parameters of the unit cell 
Triclinic 
1; 1  a  b  c;     90  
Monoclinic 2; m; 2/m a  b  c;  =  = 90    90  
( =  = 90 ,   90 ) 
Orthorhombic 2 2 2; m m 2; m m m  a  b  c;  =  =  = 90  
Tetragonal 
4; 4 ; 4 / m; 4 2 2; 4 m m;  
4  2 m, 4 / m m m 
a = b  c;  =  =  = 90   
Trigonal 
3; 3 ; 3 2; 3 m; 3 m a = b  c;  =  = 90 , 
  = 120  
Hexagonal 
6; 6 ; 6 / m; 6 2 2; 6 m m;  
6  2 m; 6 / m m m 
a = b  c;  =  = 90 , 
  = 120  
Cubic 
2 3; m 3; 4 3 2; 4  3 m;  
m 3  m 
a = b = c;  =  =  = 90  
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2.0 Experimental 
2.1  Instrumental  
2.1.1  Powder X-Ray Analysis 
Powder x-ray diffraction was recorded with a Bruker D8 diffractometer 
(wavelength of x-rays: 0.154nm Cu source; voltage: 40kV; filament emission: 
30mA). The samples were placed on a sample holder and mounted on the 
diffractometer, the samples were then scanned from 5 to 50° (2θ) using a 
0.01° step width and a one second time count. The receiving slit was 1° and 
the scatter slit 0.2°. The collected data were analysed using Eva software. It 
is also worth noting that the data were collected at room temperature.  
2.1.2  Infrared (IR) Spectroscopy  
The IR spectra of solid samples were recorded as 15mm KBr discs (typically 
0.5mg of dry samples in 35mg of dry KBr) and spectra for liquids were 
obtained as capillary films using NaCl plates. The spectra were recorded with 
a Nicolet 140 FT-IR spectrophotometer for the range 4000 to 600cm-1. For 
the solid samples, background spectra were also obtained from the KBr of 
the same batch that was used in the preparation of the samples. For liquids, 
the background was recorded as air. All of the discs were prepared 
immediately before the spectral determination. 
2.1.3  NMR Spectra 
For 1HNMR Spectra, 20mg of the dry sample was typically placed for 
dissolution in 0.7cm3 of the appropriate deuterated solvent. The data were all 
recorded at 400MHz on a Bruker AC300 spectrometer. 
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2.2  Reagents 
Various general purpose reagent grade (GPR) reagents were purchased 
from sigma-Aldrich; as such, they could be used without any further 
purification (see Table 1.2).  
Table 2.1: The origin and purity of reagents 
Reagents Source Purity 
Phenylboronic acid Sigma-Aldrich ≥98% ( TLC) 
DL-malic acid Sigma-Aldrich 97% 
L-malic acid Sigma-Aldrich 98% 
L-phenyllactic acid  Sigma-Aldrich ≥98% 
DL-phenyllactic acid Sigma-Aldrich ≥98% 
4,4’-bipyridine Sigma-Aldrich ≥98% 
4-phenylpyridine  Sigma-Aldrich ≥98% 
Nicotinamide Sigma-Aldrich ≥98% 
Isonicotinamide Sigma-Aldrich ≥98% 
Methanol Fischer Scientific, UK ≥ 99.5% 
Acetone Fischer Scientific, UK ≥ 99.5% 
Acetonitrile Fischer Scientific, UK ≥ 99.5% 
 
2.3  Co-Crystallisation Studies with α-Hydroxy Acids  
2.3.1  Crystallisation Studies of DL-Malic Acid with Pyridinecarboxamides  
Generally the following method was used, DL-malic acid and isonicotinamide 
or nicotinamide were dissolved individually in a minimum amount of the 
solvent (methanol, acetone or acetonitrile), and in accordance with the 
following stoichiometric starting ratios (1:1, 1:2 and 2:1). The solutions were 
stirred and warmed (if necessary) until the starting materials were completely 
dissolved. The solutions were then filtered to avoid the inclusion of 
undissolved starting materials in the filtrate. The filtered solutions were mixed 
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and left on the bench for crystallisation at room temperature. The materials 
obtained from crystallisation were then filtered and dried under suction. This 
experimental method was repeated using the different solvents and 
stoichiometric starting ratios (1:1, 1:2 and 2:1). The preparation details for 
this are presented below in Table 2.2.  
Similarly, this experimental method was also repeated using DL-malic acid: 
nicotinamide, the preparation details for which are presented in Table 2.3. 
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Table 2.2: Crystallisation studies of DL-malic acid with isonicotinamide 
Sample ID Quantities 
DL-Malic Acid: 
Isonicotinamide 
Solvent Yield & 
Appearance 
PXRD 
2 / 
TA-I-17-2a 1 mmol : 1 mmol Methanol 0.26 g white ppt  10.1, 13.4, 16.1, 16.5, 17.3, 18.2, 18.7, 19.9, 20.3, 21.3, 24.2, 24.8, 26.3, 27.1, 
27.7, 28.7, 30.1, 31.0, 32.6, 36.3, 37.1, 38.1 
TA-I-17-2b 1 mmol : 2 mmol Methanol 0.36 g white ppt 16.5, 16.9, 18.7, 18.9, 23.1, 24.7, 25.3, 26.8, 27.1, 29.7, 31.3, 32.4, 33.3 
TA-I-17-2c 2 mmol : 1 mmol Methanol 0.38 g white ppt 8.6, 10.5, 13.8, 16.3, 17.0, 17.7, 18.6, 19.1, 20.3, 21.6, 23.7, 24.5, 25.0,  25.2, 
26.6, 27.4, 28.1, 29.1, 30.4, 31.4, 32.2, 33.4, 33.8 
TA-I-18-1a 1 mmol : 1 mmol Acetone 0.63 g white crystals 13.9, 16.5, 17.7, 18.7,19.1, 20.8, 21.2, 21.7, 24.7, 25.3, 25.5, 26.7, 26.9, 27.6, 
28.1, 28.3, 29.1, 30.5, 38.3, 39.5 
TA-I-18-1b 1 mmol : 2 mmol Acetone 0.89 g white crystals 7.3, 8.8, 14.6, 16.4,17.6, 18.5, 18.9, 21.4, 22.3, 22.9, 23.8, 24.3, 24.9, 25.2, 25.7, 
26.6, 28.0, 28.5, 29.8, 33.2, 35.4, 37.4, 38.3, 39.3 
TA-I-18-1c 2 mmol : 1 mmol Acetone 0.70 g white crystals 10.5,13.8, 16.4, 16.8, 17.6, 19.1, 20.7, 21.1, 21.6, 24.6,25.4, 27.5, 28.1, 29.0, 
30.4, 34.1, 36.0, 36.6, 38.2, 39.1, 39.3, 41.9 
TA-I-18-3a 1 mmol : 1 mmol Acetonitrile 0.57 g white crystals 10.4, 13.8, 16.4, 16.9,17.6, 19.1, 20.6, 21.1, 21.6, 22.5, 23.4, 23.9, 24.5, 24.6, 
25.4, 27.4, 28.1,28.5, 29.0, 30.4, 31.5, 33.8, 34.1, 36.0, 36.6, 36.6, 38.1, 38.4, 
39.2 
TA-I-18-3b 1 mmol : 2 mmol Acetonitrile 0.86 g white crystals 6.8, 13.5, 15.1, 16.9, 18.0, 20.3, 22.0, 22.5, 23.9, 24.2, 24.7, 25.5, 28.1, 28.4, 
32.1, 32.7, 34.1,36.2, 37.1, 37.7, 38.3, 38.9 
TA-I-18-3c 2 mmol : 1 mmol Acetonitrile 0.70 g white crystals 10.4, 13.7, 16.4, 16.9, 7.5, 19.1, 20.6, 21.6, 22.5, 23.4, 24.5, 26.0, 27.4, 28.1, 
29.0, 30.4, 31.2, 33.8, 34.0, 35.9, 36.6, 38.1, 38.4, 39.3 
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Table 2.3: Crystallisation studies of DL-malic acid with nicotinamide 
Sample ID Quantities 
DL-Malic Acid: 
Nicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-17-3a 1 mmol : 1 mmol Methanol 0.71 g white ppt 7.7, 15.4, 18.0, 18.5, 21.7, 22.1, 23.2, 27.8 
TA-I-17-3b 1 mmol : 2 mmol Methanol 0.92 g white ppt 7.8, 14.9, 15.5, 17.8, 18.2, 18.5, 19.6, 22.3, 22.7, 23.3, 24.0, 24.6, 25.4, 25.9, , 27.3, 27.9, , , , , 31.1, , , 33.6, 34.7, 37.1, 39.1 
TA-I-17-3c 2 mmol : 1 mmol Methanol 0.64 g white crystals 7.6, 14.9, 15.3, 17.3, 18.1, 19.3, 20.0, 20.8, 22.2, 23.2, 23.5, 24.5, 25.3, 27.9, 
28.8, 31.4, 32.5, 33.4, 37.5 
TA-I-18-2a 1 mmol : 1 mmol Acetone 0.79 g white crystals 7.9, 15.1, 15.6, 18.2, 19.4, 21.0, 21.6, 22.4, 23.3, 24.6, 25.4, 25.8, 26.6, 27.2, 
28.0, 28.9, 31.5, 33.2, 33.5, 37.7 
TA-I-18-2b 1 mmol : 2 mmol Acetone 0.86 g white crystals 7.8, 15.0, 15.5, 18.2,19.4, 20.9, 21.6, 22.3, 23.3, 24.6, 25.5, 26.6, 27.2, 28.0, 
28.8, 31.5, 33.4 
TA-I-18-2c 2 mmol : 1 mmol Acetone 0.78 g white crystals 7.7, 14.9, 15.4, 18.0, 19.3, 20.8, 21.5, 22.2, 23.2, 24.4, 25.3, 26.5, 27.0, 7.8, 
10.3, 15.0, 15.5, 18.2, 19.1, 19.4, 20.9, 21.6, 22.4, 23.3, 24.6, 25.4, 26.6, 28.0, 
28.9, 30.2, 31.5, 32.2, 33.4, 34.3, 34.8, 37.7, 38.5, 40.2, 43.9, 28.7, 33.2 
TA-I-18-4a 1 mmol : 1 mmol Acetonitrile 0.59 g white crystals 7.7, 14.9, 15.4, 16.7, 17.4, 18.1, 19.0, 19.3, 20.9, 21.5, 22.3, 22.8, 23.3, 24.5, 
25.3, 25.6, 26.5, 27.9, 28.8, 29.1, 30.1, 31.4, 33.2, 33.4, 34.2, 34.6 
TA-I-18-4b 1 mmol : 2 mmol Acetonitrile 0.72 g white crystals 7.7, 14.9, 15.4, 16.7, 17.4, 18.1, 19.0, 19.3, 20.9, 21.5, 22.3, 22.8, 23.276, 
24.484, 25.335, 25.61, 26.5, 27.9, 28.8, 29.1, 30.1, 31.4, 33.2, 33.4, 34.2, 34.6 
TA-I-18-4c 2 mmol : 1 mmol Acetonitrile 0.62 g white crystals 7.8, 15.0, 15.5, 16.8, 17.4, 18.2, 19.0, 19.4, 20.9, 21.6, 22.3, 22.8, 23.3, 24.6, 
25.4, 25.7, 26.6, 27.1, 28.0, 28.9, 29.2, 30.2, 31.5, 32.1, 33.2, 33.5, 34.2, 34.7, 
36.9, 37.6, 38.5, 39.4, 40.2, 43.9, 47.5 
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2.3.2  Crystallisation Studies of L-Malic Acid with Pyridinecarboxamides  
Generally the following method was used, L-malic acid and isonicotinamide 
or nicotinamide were dissolved in the minimum amount of solvent (methanol, 
acetone, acetonitrile or ethyl acetate) with three stoichiometric starting ratios 
(1:1, 1:2 and 2:1). The same procedure was followed as above (see the start 
of Section 2.3). The preparation details for the L-malic acid are given in Table 
2.4.  
Similarly, this experimental method was repeated using DL-malic acid: 
nicotinamide. The preparation details for which are given in Table 2.5. 
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Table 2.4: Crystallisation studies of L-malic acid with isonicotinamide 
Sample ID Quantities 
L-Malic Acid: 
Isonicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-22-2a 1 mmol : 1 mmol Methanol 0.68 g white crystals Oil no value  
TA-I-22-2b 1 mmol : 2 mmol Methanol 0.85 g white crystals 15.1, 16.8, 17.9, 21.9, 22.4, 23.8, 24.2, 24.6, 25.5, 28.0, 28.4, 32.8, 34.0, 37.6, 38.8 
TA-I-22-2c 2 mmol : 1 mmol Methanol 0. 67 g white crystals 16.9, 21.2, 23.9, 25.5, 31.5, 35.0, 36.1, 37.2, 38.3, 39.4, 12.0 
TA-I-22-3a 1 mmol : 1 mmol Acetone 0.72 g white crystals 6.7, 15.2, 16.8, 17.9, 20.1, 21.9, 22.4, 23.8, 24. 24.6, 25.5, 28.0, 28.4, 32.1, 34.0, 37.6, 
38.9, 39.2 
TA-I-22-3b 1 mmol : 2 mmol Acetone 0.86 g white crystals 6.7, 13.4, 15.1, 16.8, 17.9, 20.1, 21.9, 22.4, 23.8, 24.2, 24.6, 25.5, 28.0, 28.4, 32.1, 32.8, 
33.9, 37.5, 38.8, 39.2 
TA-I-22-3c 2 mmol : 1 mmol Acetone 0.90 g  oil  
TA-I-22-4a 1 mmol : 1 mmol Acetonitrile 0.72 g beige crystals 6.6, 9.2, 10.6, 12.4, 13.1, 13.6, 15.2, 16.4, 17.2, 17.4, 18.3, 18.6, 19.1, 19.6, 20.3, 1.2, 21.9, 
23.2, 24.3, 24.9, 26.3, 27.5, 29.6 
TA-I-22-4b 1 mmol : 2 mmol Acetonitrile 0.74 g beige crystals 11.7, 16.7, 21.0, 22.0, 23.6, 25.2, 26.7, 27.5, 29.4, 30.3, 31.2, 34.0, 34.7, 35.6, 36.2, 37.1, 
38.0, 39.0 
TA-I-22-4c 2 mmol : 1 mmol Acetonitrile 0.68 g beige crystals 15.1, 16.7, 17.8, 20.9, 21.8, 22.4, 23.8, 24.3, 24.5, 25.3, 25.5, 26.9, 28.0, 28.3, 34.0, 34.9, 
35.8, 37.0, 37.5, 38.9, 39.2, 40.8 
TA-I-23-1a 1 mmol : 1 mmol Ethyl acetate 0.63 g white crystals 11.7, 16.8, 17.2, 18.9, 21.0, 22.1, 23.7, 25.3, 26.7, 27.7, 28.0, 30.5, 31.4, 34.0, 34.9, 35.9, 
36.3, 37.1, 38.1, 39.3, 46.3 
TA-I-23-1b 1 mmol : 2 mmol Ethyl acetate 0.86 g white crystals 15.3, 16.9, 18.1, 20.3, 21.2, 22.0, 22.7, 23.1, 24.0, 24.7, 25.6, 28.2, 28.5, 34.1, 37.6, 39.0 
TA-I-23-1c 2 mmol : 1 mmol Ethyl acetate 0.74 g white crystals 11.8, 16.8, 17.3, 18.9, 21.0, 22.2, 23.7, 25.3, 26.8, 27.7, 28.0, 29.6, 30.5, 31.4, 34.9, 35.9, 
36.4, 37.1, 38.1, 39.3, 46.4 
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Table 2.5: Crystallisation studies of L-malic acid with nicotinamide 
  
Sample ID Quantities 
L-Malic Acid: Nicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-23-3a 1 mmol : 1 mmol Methanol 0.72 g white crystals 7.5, 17.6, 18.3, 19.3, 20.0, 20.9, 21.3, 22.4, 22.8, 23.9, 24.7, 25.7, 26.8, 
27.1, 28.0, 29.0, 29.6, 30.2, 31.0, 31.6, 33.5, 34.1, 35.1, 36.1, 36.8 , 37.3, 
37.7, 38.3, 39.0, 39.4 
TA-I-23-3b 1 mmol : 2 mmol Methanol 0.96 g white crystals 6.7, 12.5, 14.7, 18.6, 19.6, 21.4, 24.5, 25.0, 25.4, 25.5, 26.1, 26.4, 29.2, 
32.7, 34.1, 37.4, 38.0, 39.7 
TA-I-23-3c 2 mmol : 1 mmol Methanol 0.86 g white crystals 19.3, 20.9, 21.3, 22.7, 23.8, 25.7, 28.0, 28.9 
TA-I-23-2a 1 mmol : 1 mmol Acetone 0.75 g white crystals 14.4, 19.0, 21.1, 25.2, 26.0, 27.7, 28.9 
TA-I-23-2b 1 mmol : 2 mmol Acetone 0.98 g white crystals 8.6, 14.6, 18.5, 19.7, 21.4, 24.4, 24.0, 24.9, 25.4, 26.2, 27.9, 29.1, 31.6, 
32.6 
TA-I-23-2c 2 mmol : 1 mmol Acetone 0.69 g white crystals  19.4, 21.0, 21.4, 22.9, 24.0, 25.8, 28.2, 29.1, 35.2 
TA-I-24-1a 1 mmol : 1 mmol Acetonitrile 0.62 g white crystals 17.3, 17.9, 18.9, 20.1, 20.6, 21.0, 22.2, 22.5, 23.5, 25.4, 26.4, 27.7, 28.6, 
29.2, 31.2, 33.2, 34.8, 36.0, 37.0, 40.2 
TA-I-24-1b 1 mmol : 2 mmol Acetonitrile 0.57 g white crystals 12.2, 14.3, 17.3, 18.9, 19.4, 20.1, 20.6, 21.0, 22.1, 22.5, 23.5, 24.6, 
25.2, 25.9, 26.4, 27.7, 28.7, 28.8, 29.3, 30.1, 31.2, 33.2, 33.8, 34.8, 
35.9, 37.1, 37.9, 38.6, 40.2 
TA-I-24-1c 2 mmol : 1 mmol Acetonitrile 0.57 g white crystals 18.9, 20.5, 21.0, 22.2, 22.5, 23.5, 25.3, 26.4, 27.6, 28.5, 29.2, 31.2, 33.1, 
34.7, 36.9 
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2.3.3  Crystallisation Studies of DL-3-Phenyllactic Acid with 
Pyridinecarboxamides 
DL-3-phenyllactic acid and the corresponding molar ratio of isonicotinamide 
or nicotinamide were dissolved individually in the minimum amount of solvent 
(methanol, acetone and acetonitrile). The samples were heated when 
acetone and acetonitrile were used; but, the samples dissolved in methanol 
at room temperature. The preparation details for this are given in Table 2.6 
Likewise, this experimental method was repeated using DL-3-phenyllactic: 
nicotinamide, the preparation details for which are given in Table 2.7. 
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Table 2.6: Crystallisation studies of DL-3-phenyllactic acid with isonicotinamide 
Sample ID Quantities 
DL-3-Phenyllactic Acid: 
Isonicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-31-2a 1 mmol : 1 mmol Methanol 0.56 g white crystals 8.1, 10.2, 16.0, 17.8, 18.9, 23.9, 24.6, 25.5, 26.3, 28.8, 30.6, 31.4, 
32.0, 33.6, 38.2 
TA-I-31-2b 1 mmol : 2 mmol Methanol 0.45 g white crystals 8.1, 16.0, 17.8, 18.9, 23.2, 23.6, 23.8, 24.6, 25.6, 26.6, 28.8, 31.5, 
36.6, 38.8 
TA-I-31-2c 2 mmol : 1 mmol Methanol 0.61 g white crystals 8.1, 12.2, 15.1, 15.9, 17.0, 17.8, 19.4, 20.7, 21.6, 22.8, 23.9, 24.6, 
25.6, 28.8, 32.6, 34.7, 39.4 
TA-I-31-1a 1 mmol : 1 mmol Acetone 0.53 g white crystals 8.1, 15.9, 17.8, 18.8, 23.7, 23.9, 24.6, 25.5, 28.7, 30.4, 31.5, 37.9, 
39.1 
TA-I-31-1b 1 mmol : 2 mmol Acetone 0.27 g white solid 8.0, 10.2, 17.8, 23.0, 23.7, 24.4, 25.3, 28.5, 31.4 
TA-I-31-1c 2 mmol : 1 mmol Acetone 0.32 g white solid 8.0, 15.7, 17.7, 18.7, 19.3, 20.4, 23.5, 23.7, 24.5, 25.4, 26.1, 28.7, 
30.6, 31.3, 34.4 
TA-I-31-3a 1 mmol : 1 mmol Acetonitrile 0.62 g  white crystals 17.5, 22.8, 23.3, 25.2, 28.3  
TA-I-31-3b 1 mmol : 2 mmol Acetonitrile 0.57 g  white crystals 11.2, 17.4, 22.0, 22.8, 23.3, 24.2, 25.1, 28.3, 34.6, 36.5 
TA-I-31-3c 2 mmol : 1 mmol Acetonitrile 0.4 g white crystals 17.5, 22.9, 23.3, 25.1, 28.4 
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Table 2.7: Crystallisation studies of DL-3-phenyllactic acid with nicotinamide  
Sample ID Quantities 
DL-3-Phenyllactic Acid: 
Nicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-32-3a 1 mmol : 1 mmol Methanol 0.42 g white crystals 8.3, 10.2, 12.5, 16.8, 17.8, 18.5, 20.1, 22.0, 22.8, 23.4, 25.1, 25.3, 
28.3, 30.4, 31.5 , 33.9, 37.2, 37.8 
TA-I-32-3b 1 mmol : 2 mmol Methanol 0.16 g white crystals 9.7, 12.0, 16.3, 17.3, 18.1, 19.6, 21.6, 22.3, 22.9, 24.8, 27.8, 36.7 
TA-I-32-3c 2 mmol : 1 mmol Methanol 0. 62 g white crystals 11.6, 15.0, 19.2, 19.7, 20.0, 22.3, 22.4, 24.9, 25.9, 27.5, 28.6, 30.4, 
33.8, 34.7, 37.1, 38.9 
TA-I-32-2a 1 mmol : 1 mmol Acetone 0.52 g white solid 8.1, 9.7, 14.4, 16.3, 16.8, 18.1, 18.7, 19.7, 21.0, 21.6, 22.3, 22.9, 
23.4, 23.8, 24.8, 28.0, 28.8, 31.0, 33.1, 33.3  
TA-I-32-2b 1 mmol : 2 mmol Acetone 0.69 g white crystals 8.0, 9.0, 9.8, 12.1, 13.3, 14.7, 16.4, 17.4, 18.1, 18.5, 18.9, 19.7, 21.6, 
22.4, 23.0, 24.9, 26.7, 27.9, 30.0, 31.1, 33.6, 36.7, 37.4 
TA-I-32-2c 2 mmol : 1 mmol Acetone 0.73 g white crystals 5.9, 8.3, 9.9, 12.9, 16.4, 17.0, 17.8, 18.5, 18.7, 19.8, 20.9, 21.1, 23.2, 
24.0, 24.9, 26.5, 28.2, 37.6 
TA-I-32-4° 1 mmol : 1 mmol Acetonitrile 0.60 g white solid 6.0, 9.9, 16.5, 17.1, 17.8, 18.6, 19.8, 21.1, 22.6, 23.5, 25.1, 26.9, 
28.3 
TA-I-32-4b 1 mmol : 2 mmol Acetonitrile 0.79 g white crystals 8.5, 10.3, 12.6, 16.9, 17.8,18.6, 20.1, 22.1, 22.8, 23.4, 25.3, 28.3, 
34.0, 37.2, 37.8 
TA-I-32-4c 2 mmol : 1 mmol Acetonitrile 0.88 g white solid 6.3, 10.2, 9.2 10.2, 11.9, 13.3, 13.7, 16.8, 17.4, 18.2, 19.0, 20.1, 
21.4, 21.6, 23.7, 24.6, 26.9, 27.1, 28.6, 33.3 
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2.3.4   Crystallisation Studies of L-3-Phenyllactic Acid with 
Pyridinecarboxamides 
L-3-phenyllactic acid and the corresponding molar ratio of the 
isonicotinamide were dissolved individually in the minimum amount of solvent 
(methanol, acetone, acetonitrile or ethyl acetate) at room temperature. This 
experimental method was repeated using the different solvents and 
stoichiometric starting ratios (1:1, 1:2 and 2:1). The preparation details for 
which are given in Table 2.8. 
Similarly, this experimental method was repeated using L-3-phenyllactic: 
nicotinamide, the preparation details for which are given in Table 2.9. 
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Table 2.8: Crystallisation studies of L-3-phenyllactic acid with isonicotinamide 
Sample ID Quantities 
L-3-Phenyllactic 
Acid: Isonicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-52-2a 1 mmol : 1 mmol Methanol 0.72 g white crystals 7.2, 8.6, 9.7, 11.3, 15.3, 17.4, 18.1, 19.9, 22.3, 22.6, 23.6, 
24.8, 25.6, 28.4, 30.2, 30.4, 35.6, 37.1, 37.2 
TA-I-52-2b 1 mmol : 2 mmol Methanol 0.57 g white crystals 7.1, 9.5, 11.3, 14.1, 14.7, 15.2, 17.3, 18.1, 19.6, 21.8, 22.6, 
23.0, 23.9, 24.8, 28.2, 30.1, 35.5, 37.0 
TA-I-52-2c 2 mmol : 1 mmol Methanol 0. 70 g white crystals 7.4, 8.1, 8.7, 9.7, 11.5, 14.5, 15.0, 15.5, 16.4, 17.5, 18.0, 18.2, 
18.4, 19.9, 20.4 , 20.8, 21.4, 22.8, 23.6, 24.2, 25.0, 26.0, 28.4, 
30.4, 33.2, 35.7, 37.2, 39.3 
TA-I-52-1a 1 mmol : 1 mmol Acetone 0.75 g white crystals 7.6, 10.1, 11.8, 15.2, 15.7, 17.7, 18.5, 20.2, 23.0, 24.0, 25.3, 
28.7, 30.6, 36.0 
TA-I-52-1b 1 mmol : 2 mmol Acetone 0.98 g white crystals 7.8, 10.2, 15.3, 17.9, 18.2, 18.7, 20.3, 23.0, 23.2, 24.2, 25.4, 
28.8, 30.2, 30.8, 37.7 
TA-I-52-1c 2 mmol : 1 mmol Acetone 0.69 g oil  
TA-I-52-3° 1 mmol : 1 mmol Acetonitrile 0.62 g oil  
TA-I-52-3b 1 mmol : 2 mmol Acetonitrile 0.57 g oil  
TA-I-52-3c 2 mmol : 1 mmol Acetonitrile 0.57 g oil  
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Table 2.9: Crystallisation studies of L-3-phenyllactic acid with nicotinamide 
Sample ID Quantities 
L-3-Phenyllactic Acid: 
Nicotinamide 
Solvent Yield & Appearance PXRD 
 
TA-I-53-2a 1 mmol : 1 mmol Acetone oil  
TA-I-53-2b 1 mmol : 2 mmol Acetone oil  
TA-I-53-2c 2 mmol : 1 mmol Acetone oil  
TA-I-53-3a 1 mmol : 1 mmol Methanol white crystals 18.0, 20.2, 25.5, 27.2 
TA-I-53-3b 1 mmol : 2 mmol Methanol white crystals 5.2, 14.9, 17.6, 19.9, 22.3, 25.2, 25.8, 27.3, 37.0, 38.7 
TA-I-53-3c 2 mmol : 1 mmol Methanol oil  
TA-I-53-4° 1 mmol : 1 mmol Acetonitrile 0.62 g  white crystals 14.8, 15.4, 22.2, 22.8, 27.7, 37.0, 39.1 
TA-I-53-4b 1 mmol : 2 mmol Acetonitrile 0.57 g  white crystals 25.8, 25.0, 34.4, 30.3 
TA-I-52-4c 2 mmol : 1 mmol Acetonitrile 0.57 g oil  
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2.4  Co-crystallisation Studies with Phenylboronic Acids  
2.4.1  Crystallisation Studies of Phenylboronic Acid with 
Pyridinecarboxamides 
Phenylboronic acid and the corresponding molar ratio of isonicotinamide or 
nicotinamide were dissolved individually in the minimum amount of solvent 
(methanol, acetone, acetonitrile or ethyl acetate) at room temperature. Again, 
the solutions were stirred and warmed (if necessary) until the starting 
materials were completely dissolved. This experimental method was 
repeated using the different solvents and stoichiometric starting ratios (1:1, 
1:2 and 2:1). The preparation details for this are shown in Table 2.10. 
This experimental method was repeated using phenylboronic acid: 
nicotinamide, Table 2.11 shows the preparation detail for this. 
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Table 2.10: Crystallisation studies of phenylboronic acid with isonicotinamide 
Sample ID Quantities 
Phenylboronic Acid:  
Isonicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-19-1a 1 mmol : 1 mmol Acetone 0.63 g white crystals 9.4, 15.5, 17.1, 17.8, 18.6, 19.5, 20.8, 21.5, 23.0, 23.5, 28.1, 28.6, 29.2, 
31.4, 34.6, 35.8, 37.9 
TA-I-19-1b 1 mmol : 2 mmol Acetone 0.9 g beige needles  9.4, 15.7, 17.1, 17.8, 18.7, 19.6, 20.7, 21.4, 23.1, 23.4, 23.6, 26.1, 26.5, 
28.2, 28.5, 29.0, 29.2, 31.8, 36.0, 37.9, 48.7 
TA-I-19-1c 2 mmol : 1 mmol Acetone 0.62g brown solid 7.4, 14.4, 15.6, 17.9, 18.9, 20.7, 22.8, 23.4, 28.4, 29.1, 31.7, 35.9, 48.4 
TA-I-19-2a 1 mmol : 1 mmol Acetonitrile 0.61g brown crystals 15.9, 17.2, 17.8, 18.2, 21.4, 21.6,23.1, 23.4, 23.6, 24.1, 28.3, 28.9, 29.4, 
31.9, 35.0, 36.0, 38.1, 39.9, 41.3, 45.4, 47.5 
TA-I-19-2b 1 mmol : 2 mmol Acetonitrile 0.92 g orange-yellow 
crystals 
9.5, 15.9, 17.3, 17.8, 18.8, 19.4, 19.8, 20.9, 21.7, 23.5, 23.7, 26.0, 28.2, 
29.1, 29.4, 30.0, 31.0, 31.4, 31.9, 34.8, 36.1, 38.1 
TA-I-19-2c 2 mmol : 1 mmol Acetonitrile 0.58 g orange-yellow 
crystals 
9.4, 9.7, 10.8, 11.5, 12.1, 12.5, 17.0, 18.9, 20.8, 22.1, 23.6, 24.1, 24.8, 25.1, 
28.4, 29.3, 29.8 
TA-I-19-3a 1 mmol : 1 mmol Methanol 0.67 g brown needle 9.2, 15.4, 16.8, 17.5, 18.4, 19.4, 20.6, 21.1, 22.2, 23.0, 23.3, 25.8, 27.4, 
27.7, 27.9, 28.5, 28.7, 29.1, 34.3, 35.4, 37.5, 37.9 
TA-I-19-3b 1 mmol : 2 mmol Methanol 0.97 g brown crystals 9.2, 9.5, 10.4, 10.8, 11.3, 11.9, 12.9, 13.9, 14.4, 15.3, 16.4, 16.8, 17.7, 18.6, 
19.3, 19.9, 20.1, 20.7, 21.5, 22.2, 23.1, 23.4, 23.7, 24.5, 24.9, 25.4, 26.2, 
27.7, 28.1, 28.8, 29.2, 29.7, 36.0, 40.5 
TA-I-19-3c 2 mmol : 1 mmol Methanol 0.92 g brown-orange 
crystals  
7.9, 9.4, 11.5, 14.5, 15.7, 17.1, 17.5, 17.8, 18.7, 19.7, 21.4, 21.6, 22.2, 22.6, 
23.1, 23.4, 23.5, 24.9, 25.4, 25.7, 26.1, 27.7, 28.2, 28.7, 29.1, 31.7, 35.1, 
35.6, 36.1, 36.7, 38.1, 39.7, 41.1, 42.1, 45.0, 45.7, 47.3, 48.5 
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Table 2.11: Crystallisation studies of phenylboronic acid with nicotinamide 
Sample ID Quantities 
Phenylboronic 
Acid: Nicotinamide 
Solvent Yield & Appearance PXRD 
2 / 
TA-I-20-2a 1 mmol : 1 mmol Acetone 0.55 g beige solid 7.8, 9.2, 12.2, 14.5, 15.4, 15.9, 17.7, 18.7, 19.9, 20.8, 22.0, 23.2, 25.6, 26.3, 
26.7, 27.9, 30.0 
TA-I-20-2b 1 mmol : 2 mmol Acetone 0.72 g beige solid 7.7, 9.2, 14.5, 16.0, 18.7, 20.0, 20.9, 21.9, 23.3, 25.1, 25.6, 26.9, 27.9, 30.1, 
36.3 
TA-I-20-2c 2 mmol : 1 mmol Acetone 0.9 g beige solid 5.1, 6.5, 7.1, 8.1, 8.5, 8.9, 9.5, 9.9, 10.4, 11.5, 12.4, 13.0, 13.7, 14.5, 15.8, 16.3, 
16.5, 17.1, 18.1, 19.0, 19.5, 19.8, 20.2, 21.1, 21.8, 23.2, 23.6, 24.3, 24.8, 26.1, 
26.6, 27.1, 28.1, 28.3, 29.5 
TA-I-20-3a 1 mmol : 1 mmol Methanol 0.57g white solid 7.4, 9.2, 10.9, 14.2, 16.0, 18.0, 18.7, 19.2, 20.7, 20.9, 22.1, 22.7, 23.3, 25.2, 
26.6, 27.4, 28.0, 29.6, 30.1, 32.5, 33.7, 38.2, 41.6 
TA-I-20-3b 1 mmol : 2 mmol Methanol 0.83 g creamy white solid 9.5, 11.3, 14.9, 16.3, 19.1, 19.5, 21.2, 22.3, 23.6, 24.7, 25.5, 25.9, 27.4, 28.3, 
29.9, 30.4, 32.9, 34.0, 38.5 
TA-I-20-3c 2 mmol : 1 mmol Methanol 0.9 g creamy white solid  6.5, 9.1, 10.4, 12.1, 12.3, 13.0, 13.5, 15.1, 16.2, 17.1, 17.3, 18.2, 18.5, 19.5, 
20.1, 21.1, 21.7, 23.1, 24.2, 24.7, 26.1, 27.4, 28.9 
TA-I-20-4a 1 mmol : 1 mmol Acetonitrile 0.57 beige oily No value  
TA-I-20-4b 1 mmol : 2 mmol Acetonitrile 0.86 g beige solid 8.2, 8.4, 11.9, 14.8, 16.2, 18.5, 20.5, 23.4, 24.4, 25.4, 26.1, 26.7, 27.0, 27.3 
TA-I-20-4c 2 mmol : 1 mmol Acetonitrile 0.74 g beige solid 7.8, 9.6, 11.1, 12.2, 13.4, 14.5, 15.6, 16.3, 17.8,19.3, 19.4, 20.0, 21.9, 23.0, 
24.0, 25.1, 25.6, 26.3, 27.0, 27.9, 29.8, 32.3, 36.6, 38.4, 40.5 
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2.4.2  Crystallisation Studies of Phenylboronic Acid with 4,4’-Bipyridine 
and 4-Phenylpyridine  
Phenylboronic acid and the corresponding molar ratio of the 4,4-dipyridyl or 
4-phenylpyridine were dissolved individually in the minimum amount of 
solvent (methanol, acetone or acetonitrile) at room temperature. This 
experimental method was repeated again using the different solvents and 
stoichiometric starting ratios (1:1, 1:2 and 2:1). Once the solutions were 
mixed they turned a bright yellow, they were then left to crystallise. The 
preparation details for which are shown in Table 2.12.  
Likewise, this experimental method was repeated using phenylboronic acid: 
4-phenylpyridine, Table 2.13 shows the preparation details for this. 
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Table 2.12: Crystallisation studies of phenylboronic acid with 4,4’-bipyridine 
Sample ID Quantities 
Phenylboronic Acid:  
4,4’-Bipyridine 
Solvent Yield & Appearance PXRD 
TA-I-54-1a 1 mmol : 1 mmol Acetone 0.55 g yellow solid 12.0, 13.2, 19.7, 20.2, 24.2, 25.5, 26.5, 27.3, 29.4, 33.5, 37.1 
TA-I-54-1b 1 mmol : 2 mmol Acetone 0.72 g yellow solid 11.3, 12.0, 13.2, 18.1, 19.6, 20.1, 21.3,  24.2, 25.4, 26.2, 26.4, 27.2, 28.7, 29.3, 
31.1, 33.4, 36.0, 37.1, 38.3, 38.5 
TA-I-54-1c 2 mmol : 1 mmol Acetone 0.80 g yellow solid   9.3, 10.0, 15.5, 16.1, 16.9, 18.5, 20.0, 21.2, 22.8, 23.6, 25.5, 26.5, 29.3 
TA-I-54-2a 1 mmol : 1 mmol Methanol 0.76 g yellow solid 5.7, 7.4, 10.3, 10.8, 11.3, 12.1, 12.4, 13.0, 14.3, 14.6, 15.1, 16.1, 16.5, 17.5, 18.2, 
18.7, 19.2, 19.7, 20.2, 21.5, 22.2, 22.9, 23.6, 24.1, 24.6, 25.5, 26.5, 27.3, 27.8, 
28.3, 29.3, 29.7, 30.3, 30.8, 31.0, 31.7, 32.6, 33.5, 34.6, 35.9, 36.4, 37.1, 38.3, 38.5 
TA-I-54-2b 1 mmol : 2 mmol Methanol 0.98 g yellow solid 5.7, 8.2, 9.4, 10.1, 11.3, 12.0, 12.6, 13.3, 14.0, 14.7, 15.6, 16.6, 17.1, 17.4, 18.2, 
18.8, 19.0, 19.8, 20.1, 21.5, 22.3, 22.7, 23.5, 24.0, 24.2, 25.6, 26.3, 26.6, 27.2, 
29.4, 30.9, 31.2, 32.6, 33.6, 34.2, 37.2, 38.2, 38.6 
TA-I-54-2c 2 mmol : 1 mmol Methanol 0.69 g yellow solid 5.7, 8.2, 9.4, 10.1, 11.3, 12.0, 12.6, 13.3, 14.0, 14.7, 15.6, 16.6, 17.1, 17.4, 18.2, 
18.8, 19.0, 19.8, 20.1, 21.5, 22.3, 22.7, 23.5, 24.0, 24.2, 25.6, 26.3, 26.6, 27.2, 
29.4, 30.9, 31.2, 32.6, 33.6, 34.2, 37.2, 38.2, 38.6 
TA-I-55-1a 1 mmol : 1 mmol Acetonitrile 0.71g yellow solid 11.3, 12.1, 13.3, 18.2, 19.7, 20.2, 21.6, 23.3, 25.6, 26.5, 27.3, 29.4, 31.2, 32.8, 
37.2, 38.4 
TA-I-55-1b 1 mmol : 2 mmol Acetonitrile 0.92 g yellow solid 11.4, 12.2, 13.4, 14.7, 18.3, 19.8, 20.3, 21.7, 23.3, 24.4, 25.7, 26.5, 27.3, 29.4, 
31.3, 32.9, 33.6, 37.2, 38.4, 38.8 
TA-I-55-1c 2 mmol : 1 mmol Acetonitrile 0.64 g yellow solid 5.6, 9.1, 10.4, 11.11, 11.64, 12.3, 12.9, 14.0, 14.6, 15.4, 16.4, 17.1, 17.3, 18.7, 
19.2, 20.2, 20.6, 21.3, 21.7, 23.04, 23.5, 24.4, 25.2, 26.3, 26.6, 26.8, 27.5, 28.6, 
29.1, 29.8, 30.8, 31.9, 32.4, 33.2, 39.3 
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Table 2.13: Crystallisation studies of phenylboronic acid with 4-phenylpyridine 
Sample ID Quantities 
Phenylboronic Acid:  
4-Phenylpyridine 
Solvent Yield & 
Appearance 
PXRD 
TA-I-56-2a 1 mmol : 1 mmol Acetone 0.62 g yellow solid 5.8, 6.9, 7.8, 8.0, 9.1, 10.1, 12.0, 12.8, 13.3, 14.0, 14.6, 15.3, 15.9, 16.9, 17.5, 
18.0, 18.2, 18.5, 19.4, 19.6, 20.9, 21.2, 22.1, 22.3, 22.7, 23.2, 23.9, 24.6, 24.9, 
25.4, 25.6, 26.2, 27.3, 27.8, 28.6, 29.5, 33.0, 33.7, 34.8, 35.1, 35.8 
TA-I-56-2b 1 mmol : 2 mmol Acetone 0.43 g yellow solid 9.8, 10.6, 12.7, 16.7, 17.8, 18.7, 18.9, 19.7, 20.0, 20.7, 21.5, 22.0, 22.3, 23.0, 
23.5, 23.8, 25.1, 25.8, 26.2, 26.3, 27.8, 29.3, 29.9, 30.6, 32.4, 33.1, 35.8 
TA-I-56-2c 2 mmol : 1 mmol Acetone 0.70 g yellow solid 7.8, 8.0, 8.8, 9.5, 9.9, 11.5, 11.8, 13.1, 14.3, 15.6, 16.4, 16.9, 17.5, 17.8, 18.1, 
18.6, 19.0, 19.5, 20.6, 20.7, 21.2, 21.9, 22.6, 23.2, 23.8, 24.6, 24.9, 25.4, 26.2, 
27.2, 27.7, 28.6, 29.7,30.0, 31.2, 31.6, 32.8, 33.6, 35.1, 35.9, 37.2, 38.7 
TA-I-56-1a 1 mmol : 1 mmol Methanol 0.69 g yellow solid 8.0, 8.9, 10.1, 11.9, 13.4, 15.8, 16.5, 17.0, 17.5, 17.8, 18.2, 18.5, 18.7, 19.1, 
19.8, 20.1, 20.7, 21.1, 21.2, 22.0, 23.3, 23.8, 24.5, 24.7, 27.8, 28.7, 29.5, 29.9, 
30.1, 30.7, 31.6, 33.6, 34.7, 35.1, 35.7, 35.9 
TA-I-56-1b 1 mmol : 2 mmol Methanol 0.76 g yellow solid 7.9, 8.1, 8.9, 9.7, 12.0, 13.4, 14.8, 15.5, 17.0, 17.6, 18.1, 18.4, 18.8, 19.2, 19.7, 
20.0, 20.7, 21.4, 22.1, 22.7, 23.2, 23.7, 24.1, 27.3, 27.7, 28.7, 29.5, 34.1, 34.9, 
39.2 
TA-I-56-1c 2 mmol : 1 mmol Methanol 0.93 g yellow solid 8.0, 8.2, 10.1, 11.1, 11.9, 11.5, 13.3, 14.2, 15.4, 15.9, 16.6, 16.9, 17.5, 18.1, 
18.5, 19.6, 19.9, 20.1, 20.6, 21.1, 22.0, 22.5, 22.8, 23.3, 23.9, 24.8, 26.4, 27.7, 
28.5, 30.3, 31.1, 32.1, 33.5, 36.0, 37.9, 39.3 
TA-I-56-3a 1 mmol : 1 mmol Acetonitrile 0.70 g yellow solid 8.0, 9.1, 9.7, 10.1, 11.9, 12.9, 13.4, 15.5, 17.0, 17.5, 17.8, 18.2, 18.7, 19.0, 19.3, 
19.8, 20.7, 21.2, 21.4, 22.1, 22.9, 23.3, 23.8, 25.1, 26.4, 27.8, 28.2, 28.6, 29.4, 
29.8, 39.1 
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Sample ID Quantities 
Phenylboronic Acid:  
4-Phenylpyridine 
Solvent Yield & 
Appearance 
PXRD 
TA-I-56-3b 1 mmol : 2 mmol Acetonitrile 0.71 g yellow solid 8.2, 9.2, 9.7, 9.9, 12.1, 15.0, 17.1, 17.8, 18.4, 19.3, 19.5, 19.9, 20.9, 21.5, 22.1, 
22.6, 23.4, 23.9, 25.1, 26.4, 26.7, 28.0, 28.7, 28.4, 29.6, 30.9, 35.1, 36.1 
TA-I-56-3c 2 mmol : 1 mmol Acetonitrile 0.61 g yellow solid 8.1, 9.1, 9.7, 10.1, 12.1, 13.0, 13.5, 14.3, 15.8, 16.6, 17.1, 17.8, 18.2, 18.6, 19.2, 
19.7, 19.9, 20.1, 20.8, 21.2, 22.1, 22.7, 23.3, 23.9, 24.7, 25.8, 26.6, 27.7, 28.8, 
29.6, 30.0, 30.8, 33.4, 36.1 
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2.6  Single Crystal X-Ray Studies 
Single crystal x-ray diffraction studies were undertaken with a Bruker X8 
diffractometer. Single crystals were selected from either mother liquors or 
they were separated from solids, they were then coated with perfluoroalkane 
oil and mounted into the diffractometer’s nitrogen cryostream. From the 
resulting diffraction data, structure solution and refinement were carried out 
with the Bruker APEX2 v2011.4-1 software. Data collection and the initial 
structure solution and refinement were carried out by Professor Ian Scowen 
at the University of Bradford. 
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Table 2.14: Crystal data and structure refinement for TA-1-17-3b (DL-malic acid: 
nicotinamide) 
Identification code  tai_17_3b_t 
Empirical formula  C20 H24 N4 O12 
Formula weight  512.43 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  Pca2(1) 
Unit cell dimensions a = 18.629(3) Å α= 90°. 
 b = 5.2842(8) Å β= 90°. 
 c = 22.841(4) Å Ɣ = 90°. 
Volume 2248.5(6) Å3 
Z 4 
Density (calculated) 1.514 Mg/m3 
Absorption coefficient 0.127 mm-1 
F(000) 1072 
Crystal size 0.754 x 0.348 x 0.226 mm3 
Theta range for data collection 2.19 to 24.66°. 
Index ranges -18<=h<=21, -5<=k<=5, -25<=l<=23 
Reflections collected 16447 
Independent reflections 3047 [R(int) = 0.0537] 
Completeness to theta = 24.66° 86.4 %  
Absorption correction Multi-scan (Bruker SAINT) 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3047 / 1 / 335 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0477, wR2 = 0.1130 
R indices (all data) R1 = 0.0631, wR2 = 0.1197 
Absolute structure parameter -1.2(17) 
Largest diff. peak and hole 0.263 and -0.284 e.Å-3 
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Table 2.15: Crystal data and structure refinement for TA-1-23-3b (L-malic acid: 
nicotinamide) 
Identification code  tai_23_3b_2_0m 
Empirical formula  C16 H18 N4 O7 
Formula weight  378.34 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 4.7631(2) Å α= 96.829(3)°. 
 b = 8.8253(4) Å β= 95.279(3)°. 
 c = 10.6620(5) Å Ɣ = 105.603(3)°. 
Volume 424.99(3) Å3 
Z 1 
Density (calculated) 1.478 Mg/m3 
Absorption coefficient 0.118 mm-1 
F(000) 198 
Crystal size 0.234 x 0.320 x 0.489 mm3 
Theta range for data collection 2.87 to 32.00°. 
Index ranges -6<=h<=6, -12<=k<=13, -15<=l<=15 
Reflections collected 7290 
Independent reflections 4822 [R(int) = 0.0135] 
Completeness to theta = 32.00° 93.0 %  
Absorption correction Multi-scan (Bruker SAINT) 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4822 / 3 / 312 
Goodness-of-fit on F2 1.021 
Final R indices [I>2sigma(I)] R1 = 0.0370, wR2 = 0.0845 
R indices (all data) R1 = 0.0516, wR2 = 0.0919 
Absolute structure parameter 0.8(8) 
Largest diff. peak and hole 0.295 and -0.191 e.Å-3 
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Table 2.16: Crystal data and structure refinement for TA-1-31-3c (DL-3-phenyllactic 
acid: isonicotinamide) 
Identification code  tai_31_3c_0m 
Empirical formula  C15 H16 N2 O4 
Formula weight  288.30 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.3395(5) Å α= 78.849(9)°. 
 b = 11.3914(15) Å β= 82.062(8)°. 
 c = 11.6131(13) Å Ɣ = 81.076(9)°. 
Volume 680.36(13) Å3 
Z 2 
Density (calculated) 1.407 Mg/m3 
Absorption coefficient 0.103 mm-1 
F(000) 304 
Crystal size 0.126 x 0.318 x 0.460 mm3 
Theta range for data collection 2.79 to 27.50°. 
Index ranges -6<=h<=6, -14<=k<=14, -15<=l<=15 
Reflections collected 17283 
Independent reflections 3114 [R(int) = 0.0822] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Multi-scan (Bruker SAINT) 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3114 / 0 / 206 
Goodness-of-fit on F2 0.790 
Final R indices [I>2sigma(I)] R1 = 0.0531, wR2 = 0.1298 
R indices (all data) R1 = 0.1038, wR2 = 0.1567 
Largest diff. peak and hole 0.316 and -0.296 e.Å-3 
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Table 2.17: Crystal data and structure refinement for TA-1-52-1a (L-3-phenyllactic acid: 
isonicotinamide) 
Identification code  tai_52_1a_0m 
Empirical formula  C15 H16 N2 O4 
Formula weight  288.30 
Temperature  173(2) K 
Wavelength  1.54178 Å 
Crystal system  Triclinic 
Space group  P1 
Unit cell dimensions a = 5.3040(2) Å α= 80.398(3)°. 
 b = 11.4994(4) Å β= 81.767(3)°. 
 c = 11.7480(5) Å Ɣ= 82.135(3)°. 
Volume 694.52(5) Å3 
Z 2 
Density (calculated) 1.379 Mg/m3 
Absorption coefficient 0.841 mm-1 
F(000) 304 
Crystal size 0.3 x 0.3 x 0.4 mm3 
Theta range for data collection 3.85 to 66.62°. 
Index ranges -6<=h<=6, -13<=k<=13, -13<=l<=13 
Reflections collected 14779 
Independent reflections 3555 [R(int) = 0.0722] 
Completeness to theta = 66.62° 97.2 %  
Absorption correction Multi-scan (Bruker SAINT) 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3555 / 3 / 411 
Goodness-of-fit on F2 1.071 
Final R indices [I>2sigma(I)] R1 = 0.0528, wR2 = 0.1276 
R indices (all data) R1 = 0.0689, wR2 = 0.1415 
Absolute structure parameter -0.1(3) 
Largest diff. peak and hole 0.208 and -0.308 e.Å-3 
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Table 2.18: Crystal data and structure refinement for TA-1-20-3a (phenylboronic acid: 
isonicotinamide) 
Identification code  tai_20_3a_0m 
Empirical formula  C12 H13 B N2 O3 
Formula weight  244.05 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.4403(3) Å α= 95.815(4)°. 
 b = 9.4941(5) Å β= 96.296(4)°. 
 c = 12.4001(6) Å Ɣ = 102.275(4)°. 
Volume 616.91(6) Å3 
Z 2 
Density (calculated) 1.314 Mg/m3 
Absorption coefficient 0.094 mm-1 
F(000) 256 
Crystal size 0.50 x 0.41 x 0.12 mm3 
Theta range for data collection 2.59 to 32.19°. 
Index ranges -8<=h<=7, -14<=k<=14, -17<=l<=18 
Reflections collected 24707 
Independent reflections 4168 [R(int) = 0.0698] 
Completeness to theta = 32.19° 95.7 %  
Absorption correction Multi-scan (Bruker SAINT) 
Max. and min. transmission 0.9887 and 0.9543 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4168 / 0 / 179 
Goodness-of-fit on F2 1.003 
Final R indices [I>2sigma(I)] R1 = 0.0532, wR2 = 0.0947 
R indices (all data) R1 = 0.1275, wR2 = 0.1182 
Largest diff. peak and hole 0.267 and -0.227 e.Å-3 
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 Table 2.19: Crystal data and structure refinement for RBi_1_0m (phenylboronic acid: 
isonicotinamide) 
Identification code  rbi_1_0m 
Empirical formula  C12 H13 B N2 O3 
Formula weight  244.05 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 12.0598(8) Å α= 90°. 
 b = 5.1459(2) Å β= 101.963(2)°. 
 c = 19.2537(11) Å Ɣ = 90°. 
Volume 1168.91(11) Å3 
Z 4 
Density (calculated) 1.387 Mg/m3 
Absorption coefficient 0.099 mm-1 
F(000) 512 
Crystal size 0.120 x 0.177 x 0.470 mm3 
Theta range for data collection 3.34 to 23.70°. 
Index ranges -13<=h<=9, -4<=k<=5, -17<=l<=16 
Reflections collected 4848 
Independent reflections 1142 [R(int) = 0.0248] 
Completeness to theta = 23.70° 64.9 %  
Absorption correction Multi-scan (Bruker SAINT) 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1142 / 0 / 215 
Goodness-of-fit on F2 0.932 
Final R indices [I>2sigma(I)] R1 = 0.0344, wR2 = 0.0743 
R indices (all data) R1 = 0.0463, wR2 = 0.0833 
Largest diff. peak and hole 0.113 and -0.170 e.Å-3 
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Table 2.20: Crystal data and structure refinement for TA-1-61-3a (3-nitrophenylboronic 
acid: isonicotinamide) 
Identification code  tai_61_3a_0m_a 
Empirical formula  C12 H12 B N3 O5 
Formula weight  289.06 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 5.0091(5) Å α= 65.845(6)°. 
 b = 11.6769(11) Å β= 79.684(7)°. 
 c = 12.6083(13) Å Ɣ = 80.152(6)°. 
Volume 658.08(11) Å3 
Z 2 
Density (calculated) 1.459 Mg/m3 
Absorption coefficient 0.113 mm-1 
F(000) 300 
Crystal size 0.11 x 0.14 x 0.35 mm3 
Theta range for data collection 2.05 to 25.00°. 
Index ranges -5<=h<=5, -13<=k<=13, -14<=l<=14 
Reflections collected 11617 
Independent reflections 2289 [R(int) = 0.0711] 
Completeness to theta = 25.00° 99.3 %  
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2289 / 0 / 192 
Goodness-of-fit on F2 0.909 
Final R indices [I>2sigma(I)] R1 = 0.0550, wR2 = 0.1217 
R indices (all data) R1 = 0.0950, wR2 = 0.1387 
Largest diff. peak and hole 0.210 and -0.241 e.Å-3 
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Table 2.21 Crystal data and structure refinement for TA-1-56-2c ([PhBO]3[4-Phpy]4[4-
Phpy]) 
Identification code  tai_56_2c_0m 
Empirical formula  C63.50 H52.50 B6 N2.50 O6 
Formula weight  1011.44 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 47.2140(10) Å α= 90°. 
 b = 13.4209(3) Å   β= 108.5010(10)°. 
 c = 18.7318(3) Å   Ɣ = 90°. 
Volume 11256.0(4) Å3 
Z 8 
Density (calculated) 1.194 Mg/m3 
Absorption coefficient 0.074 mm-1 
F(000) 4232 
Crystal size 0.322 x 0.528 x 0.681 mm3 
Theta range for data collection 2.54 to 29.76°. 
Index ranges -54<=h<=59, -15<=k<=17, -25<=l<=25 
Reflections collected 66823 
Independent reflections 12798 [R(int) = 0.0627] 
Completeness to theta = 29.76° 79.6 %  
Absorption correction None 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12798 / 0 / 705 
Goodness-of-fit on F2 0.983 
Final R indices [I>2sigma(I)] R1 = 0.0525, wR2 = 0.1016 
R indices (all data) R1 = 0.1448, wR2 = 0.1316 
Largest diff. peak and hole 0.194 and -0.227 e.Å-3 
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Table 2.22: Crystal data and structure refinement for TA-1-54-1c ([PhB(OH)2][4,4’-bipy]) 
Identification code  twin4 
Empirical formula C20H20BN2O6 
Temperature                                                            173 
Space group                                                            C2  
Volume 2183.67 (16) Å
3
 
a, b, c (Å) 9.2670 (4), 17.6376 (7), 14.1413 (6) 
α, β, γ (°) 90, 109.134 (2), 90 
Z 4 
Radiation type Mo Kα 
µ (mm−1) 0.09 
Data collection 
No. of measured, independent and observed [I > 2σ(I)] reflections 1382, 1382, 1335 
Rint 0.0000 
θmax (°) 22.0 
(sin θ/λ)max (Å−1) 0.526 
Refinement 
R[F2 > 2σ(F2)], wR(F2), S 0.078, 0.225, 1.14 
No. of reflections 1382 
No. of parameters 302 
No. of restraints 1 
H-atom treatment H atoms treated by a mixture of independent 
and constrained refinement 
 w = 1/[σ2(Fo2) + (0.1004P)2 + 19.9417P]  
 Where P = (Fo2 + 2Fc2)/3 
(Δ/σ)max 0.267 
Δρmax, Δρmin (e Å−3) 0.44, −0.30 
Absolute structure Flack H D (1983), Acta Cryst. A39, 876-881 
Absolute structure parameter −5 (7) 
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Table 2.23: Crystal data for TA-1-54-2a ([(PhBO)3(4,4’-bipy)][PhB(OH)2]) 
Identification code  t_a 
Chemical formula C16H15BN2O2 
Mr 278.11 
space group P21/c 
Temperature (K) 173 
a, b, c (Å) 22.417 (9), 14.497 (5), 10.223 (4) 
α, β, γ (°) 90, 99.157 (11), 90 
V (Å3) 3280 (2) 
Z 8 
Radiation type Mo Kα 
µ (mm−1) 0.07 
Crystal size (mm) 0.25 × 0.24 × 0.05 
Data collection 
No. of measured, independent and 
observed [I> 2σ(I)] reflections 40735, 3325, 1996  
Rint 0.215 
θmax (°) 20.6 
(sin θ/λ)max (Å−1) 0.495 
Refinement 
R[F2> 2σ(F2)], wR(F2), S 0.080, 0.201, 1.09 
No. of reflections 3325 
No. of parameters 414 
H-atom treatment H atoms treated by a mixture of independent 
and constrained refinement 
(Δ/σ)max 0.357 
Δρmax, Δρmin (e Å−3) 0.29, −0.25 
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3.0 An Investigation into the Preparation of Crystalline 
Multicomponent Systems from Chiral Formers: Malic Acid 
3.1  Introduction and Aims of the Study 
In this study, an attempt has been made to evaluate the influence of a chiral 
centre that is adjacent to molecular synthons, in order to identify the potential 
translation of information into the solid form. The co-crystallisation of 
pyridinecarboxamides has been compared in terms of both the racemic 
mixture of malic acid and the enantiomerically pure form of the acid (L-malic 
acid).  
 
 
        a)              b)   c)       d) 
Figure 3.1: The co-crystallisation of: a) nicotinamide; b) isonicotinamide; c) L-malic 
acid (R-form); and, d) D-malic acid (S-form) 
With regards to Figure 3.1 above, nicotinamide and isonicotinamide were 
used in the co-crystallisation process with the acid co-formers. The two 
molecules are structurally similar but differ in position of the N atom in the 
pyridine rings. The formers have been selected to promote acid-amide 
interactions as primary motifs for the assembly of multicomponent products. 
This study is designed to provide some insight into the role of the chiral 
centres that are adjacent to the primary hydrogen bonding motif. 
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Malic acid was crystallised independently with both nicotinamide and 
isonicotinamide. Crystallisation studies were performed in a range of different 
solvents (methanol, acetone and acetonitrile) with different molar ratios of the 
starting material (1:1, 1:2 and 2:1). The products were isolated as white 
crystalline powders after slow evaporation of the solvent occurred at room 
temperature (Table 2.2 and 2.3 Chapter 2). 
This section will now focus on explaining the phenomena of transformation of 
chiral information based on the preparation of solid state multicomponent 
systems from mixtures of chiral and achiral formers. In addition, an 
understanding of the competition between the homodimers of carboxamides 
and acid-amide dimers in rings should also be gained.  The alternative hetero 
interaction between the pyridine N to acid provides a single point attachment 
between the formers which may be structurally analogous to the interaction 
with 4,4’-bipyridine (isonicotinamide) or 3,3’-bipyridine (nicotinamide). Only 
two structures of -hydroxy acids with isonicotinamide are known: D-tartaric 
acid (JAWUZ)83 and DL-mandelic acid (LUNPAL)84, with nicotinamide with 
citric acid (CUYXUG)85; and racemic and enantiopure mandelic acid 
(JILZOU1 and JILZOU, respectively)83.   
The key stages in this study are:  
Co-crystallisation from different starting stoichiometric ratios and a range of 
solvents with different polarities. 
Characterisation using powder x-ray diffraction data to confirm the formation 
of new material. 
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Characterisation of new materials using NMR (to identify stoichiometries) and 
IR techniques (co-crystal formation).  
3.2  Phase Chemistry 
3.2.1  Crystallisation Studies of DL-Malic Acid with Pyridinecarboxamides  
3.2.1.1 Isonicotinamide 
Solutions of DL-malic acid and isonicotinamide were prepared in ratios of 1:1, 
1:2 and 2:1 in methanol, acetonitrile and acetone. After slow evaporation of 
the solvent, at room temperature, white crystalline solids were isolated. The 
resulting products were analysed with powder x-ray diffraction and solid state 
infrared spectroscopy. In addition, stoichiometric ratios of the crystalline 
products were established using a solution nuclear magnetic resonance 
spectroscopy (1HNMR). 
Comparison of the PXRD patterns of the starting materials (DL-malic acid 
and isonicotinamide), against the multicomponent system, allows for 
evaluation and the drawing of initial conclusions as to whether the 
complexation reactions were successful. The PXRD were compared to the 
isolated polymorphs (EHOWIH, EHOWIH01, EHOWIH02) of isonicotinamide 
from the database86.  
The sample TA-I-17-2a showed a presence of new peaks at 13.9, 19.9, 21.8, 
22.8 and 24.2 (see Figure 3.2). Similarly, the non-stoichiometric product of 
TA-I-17-2b showed unique peaks at 17.6, 19.7, 22.9, 24.5, 27.8 and 47.5. In 
addition, TA-I-17-2c showed distinctive peaks at 16.7 and 17.3, indicating 
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that a new phase was present. Detailed analysis of the PXRD is provided to 
support this chapter, this can be found in Appendix A.    
Both stoichiometric and non-stoichiometric products showed no significant 
peak appearances that were in the region of 39 to 40. The data obtained by 
analysis can be used to depict the conclusion that the starting materials have 
formed a new phase (TA-I-17-2a, TA-I-17-2b, TA-I-17-2c). The non-
stoichiometric products (2:1) showed the presence of peaks that 
corresponded with the starting materials, specifically DL-malic acid in the 
following regions of 19.0, 26.6 and 33.3. 
The multicomponent formation of DL-malic acid/isonicotinamide was also 
investigated using acetone (TA-I-18-1a, 1b and 1c) and acetonitrile (TA-I-18-
3a, 3b and 3c) as the solvent. The use of x-ray powder diffraction is likely to 
be very useful in demonstrating the important aspects with regards to the 
nature of the interactions and the effect of the solvent within the formation of 
a multicomponent system.  The XRD powder patterns for the materials 
formed, provides confirmation that TA-I-18-1a showed peaks at 21.4, 21.9 
and 25.5 which was similar to the results identified for TA-I-17-2a and TA-I-
18-3a.  
Analysis of non-stoichiometric products, through the use of acetone and 
acetonitrile, also agree well with the results of the multicomponents by 
methanol; as such, TA-I-18-3b showed a peak at 28.41 and TA-I-18-3c 
showed a peak at 28.88, along a 2 scale. When reviewing the PXRD 
patterns, it is interesting to notice that the molar ratio 1:1 and 2:1 products 
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show somewhat similar traces of peaks on the new phase. However, the ratio 
1:2 products (specifically at 2: 15.1, 25.5 and 24.7) showed a mixture of 
multicomponent systems and starting materials, specifically isonicotinamide 
and its polymorphic form (EAOWIH01) which do not appear in the other 
ratios. 
To summarise, the samples in methanol (2:1, 1:1 and 1:2) all produced a 
new phase. The 2:1 and 1:1 had the same new phase, and the 1:2 ratio also 
produced a new phase; additionally, the 2:1 ratio also had some excess DL-
malic acid. In acetonitrile, all of the ratios produced the same new phase; 
however, the 1:1 ratio showed two new phases with some traces of 
isonicotinamide and the 1:2 ratio produced a new phase with the excess of 
isonicotinamide polymorphic form (EAOWIH02). In acetone the same new 
phase was present for all three ratios. Hence, the solvents and the ratios of 
starting material used seem to have had an effect on the phase that is 
produced (Figure  3.2 and 3.3). 
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TA-1-18-1c 2:1 Me2CO
TA-1-18-1b 1:2 Me2CO
TA-1-18-1a 1:1 Me2CO
TA-1-18-3c 2:1 MeCN
TA-1-18-3b 1:2 MeCN
TA-1-18-3a 1:1 MeCN
TA-1-17-2c 2:1 MeOH
TA-1-17-2b 1:2 MeOH
TA-1-17-2a 1:1 MeOH
DL-malic acid : isonicotinamide
Dl-malic acid (DLMALIC)
Dl-malic acid (DLMALIC11)
Isonicotinamide (EHOWIH02)
Dl-malic acid (EHOWIH01)
 
Figure 3.2: X-ray powder diffraction patterns of isonicotinamide and DL-malic acid, and products of crystallisation with a range of solvents  
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Figure 3.3: Representation of crystalline phases identified from the co-crystalisations of DL-malic acid: isonicotinamide 
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In order of establish whether DL-malic acid is present in the product (by 
implication that the product contains a co-crystal phase), the 1HNMR 
experiment was undertaken. From the integral values of different peak 
intensities for protons in different environments on DL-malic acid and 
isonicotinamide, it is evident that this new material contains the starting 
components. Thus, indicating that both the DL-malic acid and 
isonicotinamide are present in the co-crystal (see Table 3.1). 
The different systems were dissolved (CD3)2OD as a solvent. A peak at 
2.08ppm represents the residual proton in the deuterated-acetone, and the 
peak at 4.0ppm represents the water in the system.  The structures used in 
the assignments of the 1HNMR spectra are detailed below in Figure 3.4. 
O
O
O
O O
Ha
He
Hf
Hb Hc
Hd
                
N
O N
Hh
Hg
Hh
Hg
Hi
Hi
 
                 a)         b) 
Figure 3.4: Structures used in the assignment of the 
1
HNMR spectra of sample: a) 
malic acid; and, b) isonicotinamide  
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Table 3.1: 
1
HNMR spectral data of sample and its starting materials for: DL-malic acid and isonicotinamide (Appendix AA 3.1) 
Sample TA-I-17-2b DL-Malic Acid Isonicotinamide 
Shift 
(ppm) 
Multiplicity, 
Integration 
Assignment 
Shift 
(ppm) 
Multiplicity, 
Integration 
Assignment Shift (ppm) 
Multiplicity, 
Integration 
Assignment 
2.08 S Acetone-d6 2.10 bs, 1H  He -- -- -- 
2.60 dd, 0.5H Hb 
Hc 
2.53 dd, 1H 
Hb, Hc 
-- -- -- 
2.81 dd, 0.5H 2.78 dd, 1H -- -- -- 
4.30 S water -- -- -- -- -- -- 
4.51 dd, 0.5H Hd 4.42  dd, 1H Hd -- -- -- 
-- -- -- -- -- -- 6.05 s, 2H NH2 
7.77 d, 2H Hh -- -- -- 7.96 d, 2H Hh 
8.70 d, 2H Hg -- -- -- 9.06 d, 2H Hg 
   11.00 bs, 2H Ha, Hf    
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The 1HNMR spectrum of isonicotinamide exhibited two doublets for the 
aromatic protons in the range of 7.96 to 9.06ppm. The structure of 
isonicotinamide was confirmed in the 1HNMR spectrum of sample TA-I-17-
2b, where a doublet was observed in the deshielded region of 8.70ppm for 
two Hg protons corresponding to CH protons in the neighbourhood of the 
heteroatom – nitrogen in this case. The other set of two aromatic protons (Hh) 
resonated in the region 7.77ppm, again as a doublet.   
The structure of malic acid was also confirmed in the 1HNMR spectrum of 
sample TA-I-17-2b, whereby a doublet of doublets in the region of 2.60 and 
2.81ppm for each of two diastereotopic protons Hb and Hc, were observed. 
The methine proton of the chiral centre appeared as a doublet of doublets in 
the region of 4.50ppm, it also appeared to be deshielded due to the fact that 
this proton is in the neighbourhood of a highly electronegative oxygen atom. 
All the signals of the protons of malic acid appeared to be deshielded with a 
slight change in their chemical shift values – this was evidenced by the 
comparison of chemical shift values of neat malic acid and that of sample TA-
I-17-2b, as can be seen in Table 3.1. It is worth noting that this might be the 
result of complexation. 
The 1HNMR spectrum obtained for sample TA-I-17-2b shows similarities to 
the isonicotinamide between 7.77 and 9.10ppm, as well as similarities to the 
DL-malic acid between 2.60 and 4.51ppm, thus indicating that a 
multicomponent system is formed successfully from malic acid and 
isonicotinamide. 
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The 1HNMR spectrum of the multicomponent system sample shows common 
peaks/shifts in both of the starting materials; thus, suggesting that some 
complexation between the two has occurred.  Similar behaviours were 
observed for multicomponent systems TA-I-18-1a and TA-I-18-3a, they 
utilised the same starting materials but different solvents (acetone and 
acetonitrile) in the multicomponent preparation. 
These conclusions are supported by the data obtained using FT-IR 
spectroscopy, an overlay of the sample TA-I-17-2a and non-stoichiometric 
TA-I-17-2b. In addition, the TA-I-17-2c product, along with both starting 
materials of DL-malic acid and isonicotinamide are shown in Table 3.2; the 
formation of a new complex when compared with the starting materials can 
be clearly observed. 
Table 3.2: FT-IR assignment of TA-I-17-2 (a) (b) and (c) for DL-malic acid and 
isonicotinamide, and products of crystallisation (1:1) (1:2) and (2:1) in MeOH 
Assignment is made using the literature
87,69
 
Iso-
nicotinamide 
DL-Malic 
Acid 
TA-I-17-2a  TA-I-17-2b  TA-I-17-
2c 
Assignment 
(cm
-1
)  (cm
-1
) (cm
-1
) (cm
-1
)  (cm
-1
) 
  3445 s  3490   3490 s _(OH) of CHOH 
3370, 3186   3384, 3205 3389,  
3295,3228 
3384s, 
3204 
ύ NH2 ύ NH2  
3076, 3064, 
3053, 3041 
  3095   3091 w ύ CH , ύ CH  
  3030 s, br 292,628, 
952,773 
298,929, 
282,839 
2898 w _(OH) of COOH 
hydrogen bond mode 
_s(CH2_ 
  2911 sh       ύ CH2 
  2624 m, br       Combinations H2 bond 
mode, dimer 
    2465 2407 2557 w   
      1958     
  1739 vvs, 
1716 vs 
1716, 1684 1685 1725 s (C= O) of dimeric 
COOH out-of-phase 
    1609 1611     
1667         ύ CO  
1624, 1596         δNH2 , ύ ring +δCCH , ύ 
ring 
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1552   1548 1554 1548 ύ ring 
1496         δCCH +ύ ring  
1410   1414 1411 1415 δCCH +ύ ring 
  1442 s-m       _(C–O) Cυ(OH) of 
COOH, (acid II) 
  1410 s-m       υ(CH2_scis) 
1395         ύ CN + δCC , 
δCCH+δCCO 
  1385 w       υ(CH) of CHOH 
  1359 m.-w       δ(CH2) SCIS, δ(CH2)wag 
  1290 s, d   1292   υ(OH) C_(C–O) of 
COOH(acid III) 
  1277 sh       υ(CH2)twist,(OH), (C–O) 
  1267 sh 1262   1268 δ(CH) of CHOD 
1265         ῡ ring 
1228   1221 1229 1221 δCCH (74)+ύ ring (14) 
  1219 m       δ(CH2) 
  1185 s 1182 1169   δ(CH2) twist, δ(CH2)scis 
1148         ring+CCH+CN+CC 
1122         CCH+ ring 
  1103 s 1107 1098 1104 (CH2)SCIS,        ῡ(C-
O),δ(OH) 
1085     1060   δ CCH +ύ ring  
1063         NH2 rock  +ύCN 
  1033 w 1027 1026 1029 ύ(C–C), (CH) 
969         CH 
  968 m   962 965 (C–C), υ(C-O)tors (acid 
IV) 
955   959     ῡ CH 
  951m       δ(OD)+ υ(C-O)of 
COOD(acidIII) 
  885m,  891 884 890 δ(C-O), (C-CH2), (C-H) 
875         ᵞCH 
853   855   859 ᵞCH+ᵞ CC +ᵞCO 
  825vvw       δ(C-O), (C-CH2), (C-H) 
  790 vw       δ(CH2) 
778         γring +γco 
755         δ ring + ύcc + ύring 
  750 vw        O-C=O def.coupled 
with OH 
  724 vvw       Def 
708         ring  + CO  
  667 m       υ(C–H), υ(C–CH2), 
669     695   ring+ring 
629         δ CCO  + ύ ring  
542         NH2 twist  + ring + CC 
S=strong, v=very, m=medium, w=week, sh=shoulder, as=anti,symmetric, sym,symmetric, i.p=in-plane 
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In order to achieve an experimental assignment of the molecular vibrations of 
racemic and enantiomeric forms of malic acids and isonicotinamide, and to 
explain the observed differences, the three different ratios have been 
examined and compared against the literature reviewed88,80. 
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TA-I-17-2b
TA-I-17-2c
 
Figure 3.5: IR spectra of DL-malic acid, isonicotinamide and multicomponent in 
methanol solvent, in different ratios 
Inspection of the solid state FT-IR data for the products obtained from 
crystallisation were compared to those obtained from the starting materials. 
The FT-IR clearly shows that the infrared trace of the 1:1 and 2:1 ratios are 
fairly similar; however, the trace for the 1:2 ratio clearly shows some 
differences (see Figure 3.5). 
Baranska et al. studied, in detail, the vibrational spectra of both the racemic 
and enantiomeric forms of malic acid. With regards to measuring the 
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vibrational spectra of the racemic (DL), and the enantiomeric forms of malic 
acid in the range of 4000 to 450 cm-1, this allowed for a comparative study of 
the current results to be made with the literature89. 
Baranska et al. reported significant distinctions in the spectra of the racemic 
and enantiomeric forms; but, it should be noted that no differences were 
observed between the spectra of L- and D-malic acid89. In the 3500 to 
3000cm-1 region, a sharp band was observed at 3445cm-1. According to Van 
Loock et al.90, this suggests that the OH of the CHOH group in DL-malic acid 
might not be involved in hydrogen bonding. In comparison to the 
multicomponent complexes, a peak at 3445cm-1, in the starting material, was 
shifted to 3490cm-1 for both of the multicomponent ratios of 1:1 and 2:1 (TA-I-
17-2a and TA-I-17-2c). Whereas, for ratio 1:2 (TA-I-17-2b), it was absent 
(see Figure 3.6a). 
The spectrum of isonicotinamide is dominated by two stretching modes at 
3370 and 3186cm-1, and they have been assigned to the hydrogen bonded 
NH2 group. In contrast, the multicomponent compounds showed 
characteristic peaks at 3384 and 3205cm-1 in TA-I-17-2a (1:1), with peaks at 
3389cm-1, 3228cm-1 for TA-I-17-2b (1:2), and peaks at 3384 and 3204cm-1 for 
TA-I-17-2c, this could be assigned to NH2. 
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Figure: 3.6a: IR spectra of DL-malic acid, Isonicotinamide, and TA-I-17-2a, 2b and 2c in 
methanol for the region of 3500 to 3000cm
-1
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Figure 3.6b: IR spectra of DL-malic acid, isonicotinamide, and TA-I-17-2a, 2b and 2c in 
methanol for the region of 2000 to 1000 cm
-1
  
In the 3000 to 2000cm-1 region no significant peaks were observed. 
Whereas, for the vibrational spectra of the multicomponent system for the 
region of 2000 to 1000cm-1 (see Figure 3.6b), several important observations 
can be made. According to Baranska et al., the IR spectrum of the racemate 
DL-malic acid has a multiplet structure with two prominent bands of C=O at 
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1739 and 1716cm-1. In contrast, the multicomponent complex of TA-I-17-2a 
(1:1)  had peaks at 1716cm-1, and TA-I-17-2b (2:1) had a peak at 1725cm-1  –
this can be assigned to the C=O group. For isonicotinamide, due to the H-
bonding effect, the NH2 bending mode is expected to be higher; in contrast, 
the C=O stretching mode is lower in frequency value than the corresponding 
values of the free molecule. Thus, no signs of these peaks were observed in 
the multicomponent systems.  
3.2.1.2 Nicotinamide 
The equimolar solution of DL-malic acid and nicotinamide were dissolved in 
methanol, acetone and acetonitrile for the different stoichiometric ratios, they 
were then left to re-crystallise at room temperature. Once crystallised, white 
crystalline solids were obtained which could then be analysed.  The PXRD 
analysis of the starting materials for each of the samples of: TA-I-17-3a, TA-I-
17 3b and TA-I-17-3c, were compared in order to demonstrate whether 
complexation had been successful.  
The PXRD patterns clearly showed that the multicomponent system of TA-I-
17-3a showed new peaks at 7.7, 17.9, 19.3, 21.40 and 21.7, these peaks 
are not as a result of the starting material or the polymorphs of the starting 
material. Similarly, the non-stoichiometric product of TA-I-17-3b also showed 
peaks at 7.7, 17.8, 18.1, 18.4, 31.1 and 39.1, along the 2 scale; finally, TA-
I-17-3c showed peaks at 7.8,14.9, 20.8, 27.9 and 33.7 (Figure 3.7).   
The PXRD pattern of the 1:1 nicotinamide: DL-malic acid mole ratio mixture 
was somewhat the same as that obtained for the 1:2 mixture, although an 
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increase in intensity of the 15.3, 2θ peak, was observed. In the pattern of 
the stoichiometric multicomponent system, TA-I-17-3a had scattering peaks 
which ranged between 30 and 37 (2θ) and were therefore effectively of 
negligible intensity. 
The same analysis was performed for each of the different solvents (acetone 
and acetonitrile). Multicomponents TA-I-18-2a, 2b and 2c (all used acetone 
as the solvent) and TA-I-18-4a, 4b, 4c (used acetonitrile as the solvent) all 
showed new characteristic peaks for both the stoichiometric and non-
stoichiometric products at 7.7 to 7.81, along the 2θ scale – this is in 
agreement with the results of TA-I-17-3a, 3b, 3c (which used methanol as the 
solvent). An interesting observation is that the peak appearance decreases 
when the polarity of the solvent increases (thus, peak appearance for 
methanol ˂ acetone ˂ acetonitrile). The PXRD data clearly shows that the 
starting materials have been converted into the same new phase with all of 
the solvents. However, when methanol was used in the 1:2 and 1:1 ratio, the 
starting material nicotinamide was present, and in the 2:1 ratio DL-malic acid 
was present (see Figure 3.7 and 3.8).  
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DL-malic acid : nicotinamide
TA-1-18-2c 2:1 Me2CO
TA-1-18-2b 1:2 Me2CO
TA-1-18-2a 1:1 Me2CO
TA-1-18-4c 2:1 MeCN
TA-1-18-4b 1:2 MeCN
TA-1-18-4a 1:1 MeCN
TA-1-17-3c 2:1 MeOH
TA-1-17-3b 1:2 MeOH
TA-1-17-3a 1:1 MeOH
Nicotinamide (NICOAM01)
DL-malic acid (DLMALC11
Single Crystal (tai_17_3b_t)
 
Figure 3.7: X-ray powder diffraction patterns of nicotinamide and DL-malic acid and products of crystallisation 
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0.50
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0.50
0.67
0.00
1.00
MeOH MeCN Me2O
XDL-malic acid Xnicotinamide
DL-malic acid (DLMALC01)
Nicotinamide (NICOAM01)
{DL-malic acid)(nicotinamide)}
(TA-1-17-3b) new phase 
Graphical representation of crystalline phases identified from co-crystallisations
DL-malic acid : nicotinamide
 
Figure 3.8: Representation of crystalline phases identified from co-crystallisations of DL-malic acid: nicotinamide  
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Table 3.3: FT-IR assignment of TA-I-17-3(a) (b) and (c) for DL-malic acid and 
nicotinamide and products of crystallisation (1:1) (1:2) and (2:1) in MeOH 
Nic- 
otinamide  
DL-Malic Acid TA-I-17-3a  TA-I-17-3b  TA-I-17-3c  
Assignment 
 (cm
-1
) (cm
-1
) (cm
-1
) (cm
-1
) (cm
-1
) 
  3445 s  3474,3405 3475 3474 _(OH) of CHOH 
3366, 
3167 
  3214, 3367 3344, 3218 ύ NH2 , ύ NH2  
2782, 
2316 
  2765, 2491 2779  ύ CH (99), ύ CH  
  3030 s, br 3076 3170  
_(OH) of COOH hydrogen 
bond mode _s(CH2) 
  2911 sh 2931  2976, 2932 ύ CH2 
  
2851  2853 
 
  2624 m, br    
Combinations H2 bond 
mode,dimer 
  
1739 vvs, 1716 
vvs, 1690 vvs 
1717  1719 
(C= O) of dimeric COOH out-
of-phase 
    1690     
1680   1670  1672 ύ CO  
1483, 
1618 
  
1614,1575,14
24 
1600,1616 1615, 1578 CN amide Stretch 
1341      CH ip bend 
1410     1428 δCCH +ύ ring  
  1442 s-m  1480  
_(C–O) Cυ(OH) of COOH, 
(acid II) 
  1410 s-m 1401  1400 υ(CH2_scis 
1395      ύ CN + δCC , δCCH+δCCO 
  1385 w  1398  υ(CH) of CHOH 
  1359 m.-w 1368, 1302 1344 1367, 1303 δ(CH2) SCIS, δ(CH2)wag 
  1290 s, d  1299  
υ(OH) C_(C–O) of COOH(acid 
III) 
  1277 sh    υ(CH2)twist,(OH), (C–O) 
  1267 sh    δ(CH) of CHOD 
1230   1239 1241 1247 CC stretch 
1200   1201  1201 CH ip bend 
  1219 m 1222 1224 1221 δ(CH2) 
  1185 s 1192 1198 1191 δ(CH2) twist, δ(CH2)scis 
1154   1150   CC stretch 
1122   1110 1110 1112 CH ip bend 
  1103 s    (CH2)SCIS, ῡ(C-O),δ(OH) 
1027    1029  NH2 rock 
1063   1044  1043 NH2 rock  +ύCN 
  1033 w   1005 ύ(C–C), (CH) 
972   994   CH op bend 
936    939  CH op bend 
  968 m   970 (C–C), υ(C-O)tors (acid IV) 
  951m 942   δ(OD)+υ(C-O)of COOD(acidIII) 
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907 902 901 
 
  885m,  886   δ(C-O), (C-CH2), (C-H) 
827    830 833 CH op bend 
853      Vvw 
  825vvw 834   δ(C-O), (C-CH2), (C-H) 
  790 vw 795 790 794 δ(CH2) 
777      γring + ring def 
  750 vw 750  751  O-C=O def.coupled with OH 
  724 vvw   713 Def 
702   705 703  Ring op. Bend γ ring 
  667 m 643   υ(C–H), υ(C–CH2), 
 
The FT-IR spectra of nicotinamide and DL-malic acid, as well as their 
multicomponent products, showed evidence of a number of differences in 
both the fingerprint region and the high frequency region. To identify the 
formation of successful complexes, classification of NH2, C-O and C-N amide 
stretching and ∂ NH2 vibrations are important as they present useful 
information on the intermolecular H-bonding interactions within the 
multicomponent system as well as for any nicotinamide molecules. 
The FT-IR spectra also showed that absorption bands (of around 1650cm-1) 
were observed in the carbonyl, CN amide stretch for the multicomponent 
system; thus, TA-I-18-4a consisted of a broadened and overlapping envelope 
that contains the out-of-plane deformation modes that can imitate the starting 
materials80.  However, careful examination of the outline of the band system 
of the stoichiometric and non-stoichiometric (TA-I-18-4b, TA-I-18-4c) 
multicomponent systems in this region (700 to 1400cm -1) identified that any 
contributions of the scarcely shifted bands are generally due to the initial 
starting material. As such, a lack of shift in the vibrational frequencies 
indicates that the patterns of molecular motion of the supramolecular synthon 
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are not significantly different and are therefore relative to those of the initial 
reactants. This point indicates that both homosupramolecular synthons (i.e., 
nicotinamide and malic acid) are not strongly changed upon formation of the 
heterosupramolecular synthon of the multicomponent system. 
3.2.2 Crystallisation Studies of L-Malic Acid with Pyridinecarboxamides  
L-malic acid was crystallised together with isonicotinamide. The 
crystallisation was performed using different solvents (methanol, acetone and 
acetonitrile) as well as the different starting molar ratios of 1:1, 1:2 and 2:1. 
The solid products were formed once the solutions containing the individual 
components were mixed; these products were isolated as white crystalline 
solids. 
The overlaid PXRD pattern of the starting materials were compared against 
the sample TA-I-22-2a, 2b and 2c in order to draw initial conclusions as to 
whether complexation had been successful.  The PXRD patterns obtained for 
L-malic acid and isonicotinamide, and their multicomponents are shown in 
Table (Figure 3.9). Interestingly, TA-I-22-2a and 2b showed new 
characteristic peaks at 15.1, 16.8, 23.8, 27.9, 28.4, 32.8, 33.9 and 37.6, 
none of these peaks resembled the L-malic acid, isonicotinamide or its 
polymorphic forms; thus, verifying the preposition that a new phase was 
present. 
In addition, an excess of L-malic acid in TA-I-22-2c also showed new 
characteristic peaks at 11.9, 16.9, 23.9, 35.0 and 37.1; thus, indicating that 
they have no correspondence in the diffraction pattern, as its starting material 
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and its polymorphic forms represent a new phase once the methanol was 
used as a solvent. 
Further investigation was then conducted using acetone and acetonitrile, as 
two other solvents. Although both starting materials exhibited a strong 
scattering peak at around 19.4 and 24.4, along the 2θ scale; the L-malic 
acid also showed evidence of characteristic scattering peaks at 15.3 and 
20.9 (2θ scale), and isonicotinamide showed a characteristic scattering peak 
of  25.9 along the 2θ scale. The 1:1 molar ratio of the starting materials 
which used acetone as a solvent gave rise to multicomponent system TA-I-
22-3a; this was nearly same as when methanol was used as the solvent. The 
PXRD pattern of TA-I-22-3a and 3b revealed different scattering peak at 
15.2, 16.8, 28.4 and 32.1; thus, illustrating that they produced the same 
phase. 
The XRD powder pattern for each of the isolated products that were prepared 
using acetonitrile as the solvent also shows evidence of a new phase by the 
appearance of a few new peaks that were not present in the multicomponent 
system – they were formed by the use of methanol and acetone. The 1:1 
molar ratio product, TA-I-22-4a showed very prominent characteristic peaks 
at 6.6, 9.2, 10.5, 12.4, 13.1, 13.6, 15.4, 17.2, 18.6 and 21.2, this strongly 
suggests that a new phase was formed which is very different from its 
starting materials and the polymorphic forms associated with it (Figure 3.9). 
On the other hand, the non-stoichiometric product for the 1:2 molar ratio,  TA-
I-22-4b, shows unique peaks at 11.7, 16.7, 22.9, 29.4, 30.4 and 31.4. The 
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2:1 molar ratio also presents peaks on the 2 scale of: 15.1, 16.7, 17.8, 23.8, 
24.5, 28.3 and 37.5. This suggests that all three ratios in acetonitrile 
produced a new phase.  
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TA-1-22-3c 2:1 Me2CO
TA-1-22-3b 1:2 Me2CO
TA-1-22-3a 1:1 Me2CO
TA-1-22-4c 2:1 MeCN
TA-1-22-4b 1:2 MeCN
TA-1-22-4a 1:1 MeCN
TA-1-22-2c 2:1 MeOH
TA-1-22-2b 1:2 MeOH
TA-1-22-2a 1:1 MeOH
L-malic acid : isonicotinamide
Isonicotinamide (EHOWIH01)
L-malic acid (COFRUK10)
 
Figure 3.9: X-ray powder diffraction patterns of isonicotinamide and L-malic acid and products of crystallisation with a range of solvents  
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Figure 3.10: Representation of crystalline phases identified from co-crystallisations of L-malic acid: 
isonicotinamide formatting 
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Further investigation using FT-IR analysis was carried on the samples above 
in order to confirm the presence of all of the important functional groups and 
to ensure that the differences in the sample occurred as a result of the 
starting material, in order to truly indicate whether complexation/hydrogen 
bond formation had occurred (see Table 3.4, below). 
Table 3.4: FT-IR assignment of TA-I-22-2(a) (b) and (c) for L-malic acid and 
isonicotinamide and products of crystallisation for (1:1) (1:2) and (2:1) in MeOH 
Iso 
nicotinamide 
L-Malic Acid TA-I-22-2a TA-I-22-2b TA-I-22-2c 
Assignment 
FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  3537 vs, br  3501     ᶹ(OH) of CHOH 
3370, 3186   
  3168   
ύ NH2 (100), ύ NH2 
(100) 
3076, 3064, 
3053, 3041 
  
3099     
ύ CH (99), ύ CH (100) 
  3393 sh 
3347, 3214 3380   
_(OH) of COOH 
hydrogen bond mode 
_s(CH2_ 
  2926 2978, 1917 
 
 
  2849 2784 
 
 
  2670 sh 2579     ύ (OD) of CHOD 
      1958     
            
  1721 vs 
1704     
(C= O) of dimeric 
COOH out-of-phase 
      
 
    
1667   1666 1635 1617 ύ CO  
1624, 1596   
      
δNH2 , ύ ring +δCCH , 
ύ ring 
1552   1553 1552, 1504 1505 ύ ring 
1496   1428     δCCH +ύ ring  
1410   1416   1414 δCCH +ύ ring 
  1413 s-m       υ(CH)2_scis 
1395   
1351,1332 1392, 1321 1354, 1333 
ύ CN + δCC , 
δCCH+δCCO 
  1288 m 
      
(OD)+(C-O)of COOD 
1265   1250 1242   ῡ ring 
1228   
1232   1231 
δCCH (74)+ύ ring (14) 
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  1224 m 1218     δ(CH2) 
  1186 m 
      
δ(CH2) twist, 
δ(CH2)scis 
1148   
1154 1156   
ring+CCH+CN+CC 
1122     1122   CCH+ ring 
  1107 s 
  1094 1104 
(CH2)SCIS,        ῡ(C-
O),δ(OH) 
1085         δ CCH +ύ ring  
1063   1063 1060   NH2 rock  +ύCN 
  1036 w       ύ(C–C), (CH) 
  1019 1026 1019, 1027  
994   980   981 Ring 
969   964 951 944 CH 
955   939     ῡ CH 
  907 
 
905  
  899 vw  
884   884 
δ(C-O), (C-CH2), (C-H) 
875         ᵞCH 
853   
861 860 861, 824 
ᵞCH+ᵞ CC +ᵞCO 
  757 vw     795 δ(CH2) 
778       776 γring +γco 
755   
  759   
δ ring (30)+ ύcc(17)+ 
ύring 
708         ring  + CO  
  660 m 
      
υ(C–H), υ(C–CH2), 
669     682   ring+ring 
629         δ CCO  + ύ ring  
542   
    563 
NH2 twist  + ring + CC 
The infrared absorption spectra of isonicotinamide, L-malic acid, and their 
1:1, 1:2 and 2:1 molar ratios, for the multicomponent products of TA-I-22-2a, 
2b and 2c, were found to exhibit a number of differences in both the 
fingerprint region as well as the high frequency region (see Table 3.4).  In 
order to appraise the trends, in the spectra of multicomponents more 
effectively, the origins of the major absorbance peaks of starting materials 
needed to be compared with the stoichiometric and non-stoichiometric 
products. The results shown above clearly show differences in the vibrational 
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modes observed in TA-I-22-2a, 2b, 2c, these could be as a result of structural 
differences and the binding fashion. The vibrations spectra of starting 
materials and products in the region of 3500 to 1300cm-1 is interesting, these 
regions are characteristic of  -OH vibrations, --CH and --C vibrations, as well 
as symmetric and asymmetric stretching vibrations of carboxylic groups 
forming dimeric rings as the CH deformation bands and coupled vibrations of 
the COOH group. The region below 1300 to 900cm-1 is less characteristic 
because a number of overlapping bands, such as the -CO and -CC bands 
and the CH and OH for the deformation vibrations.  
The IR spectrum in the region of 3500 to 3000cm-1 for L-malic acid shows 
vibration modes of OH of the CHOH bond, but only TA-I-22-2a shows this 
kind of bonding at 3501cm-1. Similarly, N stretching wavenumbers were 
contributed from isonicotinamide in this region; for example, amino 
hydrogens are involved in H-bonding interactions91. In solid isonicotinamides, 
due to the H-bonding effect, the N bending mode is expected to be higher; 
whereas, the multicomponents of TAI-22-2b and TA-I-22-2c showed 
stretching modes which were lower in value than the corresponding values of 
the starting materials. 
L-malic acid showed a well developed band that appeared at 2670cm-1, this 
may have been as a result of the shift in the broad band with the maximum at 
3537cm-1, which was assigned to ᶹ(OH) of CHOH. Similarly, the 
multicomponent system of TA-I-22-2a showed bands at 2926, 2849 and 
2579cm-1 and TA-I-22-2b showed just two bands which were observed at 
2978 and 2784cm-1. These bands may be ascribed only to the ᶹ(OH) 
 97 
 
vibration of the CHOH moiety.  In the region of 2000 to 1000cm-1, L-malic 
acid contributes only one -CO band at 1721cm-1, whereas the IR spectrum of 
the TA-I-22-2a was at 1706 cm-1, and TA-I-22-2b and TA-I-22-2c had two 
prominent bands of 1553 to 1540cm-1 (see Table 3.3). 
Similar investigation was carried out for the multicomponent system prepared 
using acetone as a solvent in order to determine whether the solvent 
participate in the bonding pattern or whether it was just a suitable medium for 
the preparation of multicomponents. 
Table 3.5: FT-IR assignment of TA-I-23-3 (a) (b) and (c) for L-malic acid and 
isonicotinamide, and products of crystallisation for (1:1) (1:2) and (2:1) in Me2CO 
Iso-
nicotinamide 
L-Malic 
Acid 
TA-I-23-3a TA-I-23-3b TA-I-23-3c 
Assignment 
FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  3537 vs, br  3493 3492   _(OH) of CHOH 
3370, 3186   3167 3167 3158 
ύ NH2 (100), ύ NH2 
(100) 
3076, 3064, 
3053, 3041 
      3098 ύ CH (99), ύ CH (100) 
  3393 sh 3381 3381 3323 
_(OH) of COOH 
hydrogen bond mode 
_s(CH2) 
  
2783 2783 
  
  
2483 2483 
  
  2670 sh       ύ (OD) of CHOD 
  
1956 1956 1958 
 
  1721 vs     1725 
(C= O) of dimeric 
COOH out-of-phase 
            
1667   1695 1694   ύ CO  
1624, 1596   1635 1685 1614, 1600 
δNH2 , ύ ring +δCCH , 
ύ ring 
1552   1548 1547 1503 ύ ring 
1496         δCCH +ύ ring  
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1410         δCCH +ύ ring 
  1413 s-m     1413 υ(CH)2_scis 
1395   1394     
ύ CN + δCC , 
δCCH+δCCO 
  
1322 1323 1333 
 
  1288 m       (OD)+(C-O)of COOD 
1265   1243 1242 1238 ῡ ring 
1228         δCCH ύ ring  
  1224 m       δ(CH2) 
  1186 m 1163 1163 1187 
δ(CH2) twist, 
δ(CH2)scis 
1148         ring+CCH+CN+CC 
1122   1124 1124   CCH+ ring 
  1107 s     1100 
(CH2)SCIS,        ῡ(C-
O),δ(OH) 
1085   1091 1091   δ CCH +ύ ring  
1063   1058 1058   NH2 rock  +ύCN 
  1036 w 1034   1028 ύ(C–C), (CH) 
994   995     Ring 
969         CH 
955     945 945 ῡ CH 
  899 vw      
 
δ(C-O), (C-CH2), (C-
H) 
875       885 ᵞCH 
853   859 859 821 ᵞCH+ᵞ CC +ᵞCO 
  757 vw       δ(CH2) 
778         γring +γco 
755   753 753 756 
δ ring (30)+ ύcc(17)+ 
ύring 
708       706 ring  + CO  
  660 m 676 686   υ(C–H), υ(C–CH2), 
669         ring+ring 
629         δ CCO  + ύ ring  
542   
   
NH2 twist  + ring + CC 
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To identify the formation of successful complexes, classification of NH2, C-O 
and C-N amide stretching and ∂NH2 vibrations were deemed to be very 
important as they can reveal useful information about the intermolecular H-
bonding interactions in a multicomponent system, as well as for the L-malic 
acid and isonicotinamide molecules. 
Similarly, in the case of L-malic acid, the υ(C=O) doublet band indicates the 
presence of two kinds of dimeric carboxyl rings which are responsible for 
shape and intensity in the IR spectrum. According to Wolfs and Desseyn’s   
formation of υ(C-O) ∂(OH), band combined vibration of the COOH group is 
an important aspect70,89. 
The FT-IR spectra (See Table 3.5) also showed that absorption bands (of 
around 1650cm-1) were observed in the carbonyl, CN amide for the 
multicomponent system of TA-I-23-3a, which consisted of a broadened and 
overlapped envelope that contained the out-of-plane deformation mode 
which were imitative from the starting materials89. The lack of movement 
within the vibrational frequencies in TA-I-23-3a, 3b and 3c indicates that the 
patterns of molecular motion of the supramolecular synthon are not 
significantly different or relative to those of the initial reactants.  
In order of establish whether L-malic acid is present in the product (by 
implication the product contains a co-crystal phase), the 1HNMR experiment 
was undertaken. From the integral values of different peak intensities for 
protons in the different environments on L-malic acid and isonicotinamide 
that were obtained from the NMR spectra, it is clearly evident that this new 
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material contains the starting components in the 1:1, 1:2 and 2:1 
stoichiometric ratio. Thus, indicating that both the DL-malic acid and 
isonicotinamide are present in the co-crystal. 
The structures used in the assignments of the 1HNMR spectra are detailed 
below in Figures 3.11a and 3.11b. 
O
O
O
O O
Ha
He
Hf
Hb Hc
Hd
                
N
O N
Hh
Hg
Hh
Hg
Hi
Hi
 
          a)      b)          
Figure 3.11: Structures used in the assignments of the 
1
HNMR spectra: a) L-malic 
acid; and, b) isonicotinamide 
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Table 3.6: 
1
HNMR spectral data of sample and its starting materials i.e. L-malic acid and isonicotinamide 
Sample TA-I-22-4b L-malic acid Isonicotinamide 
Shift 
(ppm) 
Multiplicity, 
Integration 
Assignment 
Shift 
(ppm) 
Multiplicity, 
Integration 
Assignment 
Shift 
(ppm) 
Multiplicity, 
Integration 
Assignment 
2.08 S Acetone-d6 2.10 bs, 1H  He -- -- -- 
2.60 dd, 0.5H Hb 
Hc 
2.53 dd, 1H 
Hb, Hc 
-- -- -- 
2.81 dd, 0.5H 2.78 dd, 1H -- -- -- 
4.30 S water -- -- -- -- -- -- 
4.51 dd, 0.5H Hd 4.42  dd, 1H Hd -- -- -- 
-- -- -- -- -- -- 6.05 s, 2H NH2 
7.77 d, 2H Hh -- -- -- 7.96 d, 2H Hh 
8.70 d, 2H Hg -- -- -- 9.06 d, 2H Hg 
   11.00 bs, 2H Ha, Hf    
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The 1HNMR spectrum of isonicotinamide, exhibited two doublets which are a 
mirror image of each other for aromatic protons in the range of 7.96 to 
9.06ppm. The structure of isonicotinamide was confirmed in the 1HNMR 
spectrum of sample TA-I-22-4b, where a doublet was observed in the 
deshielded region of 8.70ppm for two Hg protons corresponding to CH 
protons in the neighbourhood of the heteroatom, nitrogen in this case. The 
other set of two aromatic protons (Hh) resonated in the region of 7.77ppm as 
a doublet (see Table 3.6).   
The structure of malic acid was also confirmed in the 1H NMR spectrum of 
sample TA-I-22-4b, which showed a doublet of doublets in the region 2.60 
and 2.81ppm for each of the two diastereotopic protons Hb and Hc. The 
methine proton of the chiral centre appeared as a doublet of doublets in the 
region of 4.50ppm, it also appeared deshielded due to the fact that the proton 
was in the neighbourhood of a highly electronegative oxygen atom. All the 
signals of the protons of malic acid appeared deshielded with a slight change 
in the chemical shift values, as is evident by the comparison of the chemical 
shift values of the neat malic acid and that of sample TA-I-17-2b, as shown in 
(Table 3.1). This may well be the result of complexation. 
The 1HNMR spectrum obtained for sample TA-I-22-4b shows similarities to 
the isonicotinamide between 7.77 and 9.10ppm, with similarities to the L- 
malic acid, ranging between 2.60 and 4.51ppm; thus, indicating that a 
multicomponent system can be formed successfully from malic acid and 
isonicotinamide. 
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One important observation to share is that the integration values of malic acid 
are half those of the integration values of isonicotinamide. The protons Hb,  Hc 
and Hd of malic acid have integration values of 0.52, 0.52 and 0.54 for each 
of these protons, respectively. This clearly indicates that one molecule of 
malic acid might be coordinated with two molecules of isonicotinamide as 
shown below in terms of the expected structure of sample TA-I-22-4b in 
Figure 3.12.  
The 1HNMR spectrum obtained for sample TA-I-22-4a also shows similarities 
to the isonicotinamide, between 7.78 and 9.12ppm, with similarities to the L-
malic acid of between 2.61 and 4.52ppm; thus indicating that a 
multicomponent system can be formed successfully from malic acid and 
isonicotinamide. 
The 1HNMR spectrum obtained for sample TA-I-22-3c shows similarities to 
the isonicotinamide between 7.78 and 8.67ppm, as well as similarities to the 
L-malic acid of between 2.61 and 4.51ppm; thus indicating that a 
multicomponent system can be formed successfully from malic acid and 
isonicotinamide.  
Most importantly, the integration value of signals of malic acid and 
isonicotinamide clearly indicate that one molecule of malic acid might be best 
coordinated with two molecules of isonicotinamide, as shown below by the 
expected structure of the sample (see Figure 3.12).  
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Figure 3.12: Expected structure of SAMPLE of one molecule of malic acid with two 
molecules  of isonicotinamide 
3.2.2.1  Nicotinamide 
L-Malic acid was crystallised together with nicotinamide in various solvents. 
The crystallisation was performed using the same method used to crystallise 
the L-malic acid with isonicotinamide. Thus, PXRD, NMR and FT-IR were 
used to characterise whether a new phase had formed.   
The spectral PXRD data, shown below (see Figure 3.13) clearly shows that 
samples, TA-I 23-3a, 3b and, 3c, do not represent any of the starting 
materials of L-malic acid or nicotinamide, or its polymorphic forms. Sample 
TA-I-23-3a illustrated a presence of new peaks at 14.4, 18.9 and 25.9, along 
the 2θ scale. This sample also had fewer amorphous regions than the 
starting materials; thus indicating a more defined and stable structure.  
Similarly, the non-stoichiometric molar ratio product sample of TA-I-23-3b 
showed characteristic peaks at 8.6, 14.6, 18.5, 19.5, 21.5, 24.1, 29.1, 32.6, 
37.3 and 38.1. In addition, TA-I-23-3c also showed some new peaks at 
21.49, 22.97, 24.01, 28.2 and 35.28, along the 2θ scale. Nonetheless, these 
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results show that some form of new phase had been formed in both the 
stoichiometric and non-stoichiometric samples.  The different stoichiometries 
in methanol all produced a new phase, but in the 1:1 and 2:1 ratios an 
additional new phase was also present (see Figure 3.13 and 3.14). 
Further investigation was conducted using the same starting materials with 
different solvents for the preparation of the co-crystal in order to study the 
effect of the solvent in the co-crystallisation and bonding pattern. The PXRD 
pattern shows a new phase for each of the products; to illustrate, the 1:1 (TA-
I-24-1a, 1b and 1c) ratio shows some new unique peaks, but these new 
peaks were not present in either the starting material or its polymorphic form. 
The different stoichiometries in acetonitrile all produced the same new 
phases. (see Figure 3.13 and 3.14). 
The 1:1 ratio (TA-I-23-2a) in acetone shows unique peaks at 7.5, 17.6, 18.3, 
21.3, 26.7, 28.0, 28.9, 31.0, 37.0, 37.3, 38.3 and 39.3. Similarly, the ratio 2:1 
(TA-I-23-2c) shows smaller peaks that do not correspond with the starting 
materials at 21.3, 28.0 and 28.9 along the 2 scale. The different 
stoichiometric products formed using acetone all produced a new phase, but 
in 1:1 and 1:2 ratios an additional new phase was also exist. Thus, it is 
concluded that complexation occurred within the system bonded network 
(see Figure 3.13 and 3.14).  
However, it can also be concluded that new phases were formed through the 
use of all three solvents (acetone, acetonitrile and methanol). This conclusion 
was further supported by the FT-IR data obtained, which clearly shows 
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similarities and dissimilarities between both the starting materials and the 
multicomponent products.   
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L-malic acid : nicotinamide
TA-1-23-2c 2:1 Me2CO
TA-1-23-2b 1:2 Me2CO
TA-1-23-2a 1:1 Me2CO
TA-1-24-2c 2:1 MeCN
TA-1-24-2b 1:2 MeCN
TA-1-24-2a 1:1 MeCN
TA-1-23-3c 2:1 MeOH
TA-1-23-3b 1:2 MeOH
TA-1-23-3a 1:1 MeOH
TA-I-23-3b single crystal 
Nicotinamide (NICOAM01)
 
Figure 3.13: X-ray powder diffraction patterns of nicotinamide and L-malic acid, and products of crystallisation with a range of solvents  
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Figure 3.14: Representation of crystalline phases identified from co-crystallisations of L-malic acid 
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The FT-IR spectra of enantiomeric (L) forms of malic acid, nicotinamide and 
their multicomponent systems were accepted as having significant 
differences in the spectra between them.   
3.3  X-Ray Structure Analysis 
3.3.1  Single Crystal Analysis of DL-Malic Acid and Nicotinamide TA-1-17-3b 
The single crystal structure of nicotinamide and DL-malic acid was obtained 
from a colourless block in the orthorhombic space group of Pca21. The 
asymmetric unit of the crystal confirms the presence of a stoichiometric 
complex (1:1) co-crystal, where two molecules of malic acid form hydrogen 
bonding with two molecules of nicotinamide. The asymmetric unit essentially 
describes a hydrogen bonded dimer; this is a formed pseudosymmetric 
centred dimer that is formed by intermolecular hydrogen bonding between 
carboxylate oxygen and the secondary alcohol of malic acid. This is 
augmented by the hydrogen bonding to the isonicotinamide; the nicotinamide 
essentially bridges the two malic acids of the dimer which forms a 
carboxylate COH to pyridine nitrogen and amide nitrogen to the alcohol OH 
of the second malic acid (see Figure 3.15).  
The dimer assembly forms a type of planar unit within the crystal packing, the 
remaining carboxylate acids of the malic acid molecules lie above and below 
the plane linking the two further nicotinamide units through the acid COH 
group to the amide carboxyl groups. This further propagates the structure 
parallel to the a-axis.  These linked dimers are shown on the b-axis in Figure 
3.16; however, when viewed down the c-axis, the dimers are a complex 
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network of interconnected dimer units stabilised by aromatic - interactions 
between nicotinamide. This is in addition to the hydrogen bonded systems. 
 
a) 
 
 
b) 
Figure 3.15: The asymmetric unit of the DL-malic acid: nicotinamide co-crystal 
showing: a) the numbering scheme adopted; and, b) the hydrogen bonding of the 
pseudo-centrosymmetric dimer 
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a) 
 
b) 
Figure 3.16: The crystal packing of DL-malic acid: nicotinamide co-crystal showing: a) 
linked dimer units viewed down the b-axis of the unit cell; and, b) the crystal packing 
network viewed down the c-axis of the unit cell 
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3.3.2 Single Crystal Analysis of L-Malic Acid and Nicotinamide (TA-1-23-3b) 
The 1:2 co-crystal is crystallised in the P1 space group with two molecules of 
nicotinamide and a single molecule of the S-enantiomer of malic acid in the 
asymmetric unit. In this case, the generation of a non-centrosymmetric 
crystal lattice is consistent with the inclusion of the single malic acid 
enantiomer in the solid state structure. 
Again, the crystal packing in this system is the linkage of - stacked 
assemblies of nicotinamide through H-bonds to each acid unit of malic acid. 
In this case, however, no significant H-bonding is observed in the malic acid 
“bridges”; thus, the structural units repeat solely through translation of the 
unit cell (see Figure 3.17).  
 
a) 
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b) 
Figure 3.17: The asymmetric unit of the L-malic acid: nicotinamide co-crystal 
showing: a) the asymmetric unit; and, b) the crystal packing 
3.3 Discussion 
The initial results for these systems show that while the resulting co-crystal 
systems showed interesting and predictable hydrogen bonding patterns, the 
transmission of chiral information into chiral solid state was surprising and the 
resulting crystal structures can be described as being relatively unusual.  
It is apparent that recognition between enantiomeric molecular forms plays a 
significant role in the assembly of these systems. This mechanism can be 
considered independently from the H-bonding networks that support the 
heteromolecular interactions (e.g. acid-amide recognition). Discrimination 
and control of such interactions could therefore play a role in transmitting 
chiral molecular information into solid state multicomponent assemblies. 
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In both cases, the use of nicotinamide and isonicotinamide with DL-malic 
acid, usually carboxylic acid, to amide hydrogen bonding exists and is further 
stabilised by additional hydrogen bonding from the amide-amide and 
carboxylic-carboxylic acid. The analysis and data interpretation has shown 
that the newly formed multicomponents differed from their starting materials, 
specifically with regards to the single crystal analysis which revealed that 
supramolecular synthon motifs were formed. 
The study revealed that similar supramolecular synthons were observed by 
other complexes of carboxylic acid with isonicotinamide and nicotinamide.  
Although single crystal structure analysis was not performed – this could 
have provided confirmation of explicit supramolecular synthons within the 
system; nonetheless, the PXRD provided a good overview of the amorphous 
and crystalline phases. Use of the different solvents (acetone, acetonitrile 
and methanol) indicated slight changes in the PXRD patterns – this can be 
explained further by the preposition given by Seaton et al.18 with regards to 
considering the solvent, the solute interactions and the weaker discrete acid-
amide interactions which suggest that it could be a good source for solvent 
selectivity. Consequently, a more detailed study related to solubility would 
help to identify explicit solvents and their solute interactions could be 
identified to explain this difference further. These results also explain that 
solvents can play an important role in the selective growth of a desired 
molecular complex. Similarly, FT-IR data analysis of nicotinamide and 
isonicotinamide co-crystals has helped to support the literature by revealing 
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that it is the primary hydrogen bonded interaction that combines nicotinamide 
with the carboxylic acid molecule. 
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Chapter 4 
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4.0  An Investigation into Multicomponent Crystalline Systems from 
Chiral Co-Formers and Achiral Analogues: DL- 3-Phenyllactic Acid and 
L-phenyllactic acid.  
4.1  Introduction and Aims of the Study 
This chapter will provide a review of the investigation of DL-phenyllactic acid, 
L-phenyllactic acid, as potentials to form co-crystals with amides. The amide 
species includes nicotinamide and Isonicotinamide. By using these acids and 
compounds, crystallisation was carried out with different stoichiometric ratios; 
the co-crystals were then analysed using powder x-ray diffraction and solid 
state infrared spectroscopy. In addition, in order to confirm the stoichiometric 
ratios of the products produced, 1HNMR was used. Infrared spectroscopy 
was used to investigate the intermolecular bonds.  
The main concept to consider, when selecting compounds for co-
crystallisation, is whether they hold functional characteristics that will allow 
them to act as hydrogen bond donors and acceptors; in addition, it is also 
important that the general rules for hydrogen bonding, in terms of the design 
of hydrogen bonded solids are considered. Furthermore, the compounds that 
are polymorphic display structural flexibility which will ultimately increase the 
chances of co-crystallisation. Therefore, in order to achieve the overall aim of 
this project, it is imperative that the following aspects are considered and 
understood: the basis of crystal engineering, the intermolecular interactions 
involved in crystal packing, as well as how crystals are formed and an 
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understanding of the factors which affect crystals. Moreover, an 
understanding of the solvent and crystal relationship will also be useful. 
Therefore to investigate the preparation of solid state co-crystal systems from 
mixtures of chiral and achiral forms, in order to analyse how the 
transformations take place.  
4.2   Phase Chemistry 
4.2.1  Crystallisation Studies of DL-3-Phenyllactic Acid with 
Pyridinecarboxamides 
4.2.1.1  Isonicotinamide 
DL-3-phenyllactic acid was crystallised together with isonicotinamide. The 
crystallisations were performed using different solvents and different starting 
molar ratios. The solid products were left to re-crystallise in the form of white 
crystalline solids and oils.  
The spectral PXRD data (see Figure 4.1) clearly shows that the samples TA-
I-31-1a, 1b and 1c were very different from the starting materials of 
isonicotinamide and phenyllactic acid.  
Despite the fact that both starting materials exhibited a strong scattering peak 
at around 19.6 and 25.8, phenyllactic acid exhibited a characteristic 
scattering peak at 10.9, 15.0 and 25.6; similarly, isonicotinamide exhibited a 
characteristic scattering peak at 18.8, 20.9, 23.4 and 31.3  Interestingly the 
1:1, 1:2, 2:1 molar ratio of the products for TA-I-31-1a, 1b and 1c, all showed 
characteristic peaks in the same region at 17.5, 22.9, 23.3, 25.2 and 28.4; 
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thus indicating that a new phase had formed, however peak appeared for TA-
I-31-1b showed peak at 18.2, 31.1 which corresponds to isonicotinamide. 
Similarly TA-I-31-1c also showed few peaks that correspond to DL-
phenyllactic acid. The PXRD results of the samples prepared using methanol 
as the solvent also followed somewhat similar result patterns. A similar new 
phase was produced using acetonitrile as solvent however, 1:2 molar ratio 
product showed existence of isonicotinamide (see Figure 4.1 and 4.2). 
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DL-3-phenyllactic acid : isonicotinamide
TA-1-31-1c 2:1 Me2CO
TA-1-31-1b 1:2 Me2CO
TA-1-31-1a 1:1 Me2CO
TA-1-31-3c 2:1 MeCN
TA-1-31-3b 1:2 MeCN
TA-1-31-3a 1:1 MeCN
TA-1-31-2c 2:1 MeOH
TA-1-31-2b 1:2 MeOH
TA-1-31-2a 1:1 MeOH
Isonicotinamide (EHOWIH01)
DL-3- phenyllactic acid (AVIMEY)
Tai-31-3c (single crystal)
 
Figure 4.1: X-ray powder diffraction patterns of isonicotinamide and DL-phenyllactic acid, and products of crystallisation with a range of solvent 
 
 121 
 
 
0.67
0.50
0.33
1.00
0.00
0.33
0.50
0.67
0.00
1.00
MeOH MeCN Me2CO
XDL-3-phenyllactic acid Xisonicotinamide
DL-3-phenyllactic acid (AVIMEY)
Isonicotinamide (EHOWIH01)
{(DL-3-phenyllactic acid)
(isonicotinamide)} (TA-1-31-3c)
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Graphical representation of crystalline phases identified from co-crystallisations of  
DL-3-phenyllactic acid : isonicotinamide
 
Figure 4.2: Representation of crystalline phases identified from co-crystallisations of DL-3-phenyllactic acid: isonicotinamide  
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Further investigation using FT-IR analysis was performed on all of the 
samples above in order to confirm the presence of important functional 
groups, and to ensure that the differences in the samples (from the starting 
materials) were assessed to indicate whether complexation/hydrogen bond 
formation had occurred. 
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Figure 4.3: Comparative FT-IR spectra for TA-I-31-1a, 1b and 1c in ratios 1:1, 1:2 and 
2:1 in Me2CO 
The comparative FT-IR spectra for multicomponent systems of TA-I-31-1a, 
1b and 1c (Figure 4.3), explained several characteristic bands which were 
distinguishable between TA-I-32-3a, 3b and 3c; these results can be used to 
assess the relative strengths of the hydrogen bonding interactions in the solid 
state. Phenyllactic acid generally showed two different types of O-H..O 
interactions; these products also identified alcohol OH group as the donor 
and carboxylic acid O=C group as the acceptor. The O---O and H---O 
distances arising from these types of interactions are shorter, but they 
 123 
 
substantiated the finding that stronger O-H..O hydrogen bonds were 
observed from the IR data.  The multicomponent TA-I-31-1a provided a sharp 
band at 3517cm-1; interestingly, TA-I-31-1b and 1c also showed peaks at this 
position, but they were less intense then 1a which is a characteristic of OH 
stretching (Figure 4.3). A similarly sharp OH stretching band also appeared 
at 3442cm-1 for the IR spectrum of TA-I-31-2a. This absorption band 
corresponds to the stretching frequency of the alcohol O-H bond, which 
would be expected to shift to lower wavenumbers as the strength of an O-
H..O hydrogen bond increases.  
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Figure 4.4: Comparative FT-IR spectra TA-I-31-2a, 1b and 1c in ratios 1:1, 1:2 and 2:1 
in MeOH 
4.2.1.2 Nicotinamide  
DL-3-phenyllactic acid was also crystallised together with nicotinamide. The 
crystallisation was again performed using different solvents and different 
starting molar ratios. However, it should be noted that some products were 
oils and were not characterised with PXRD. 
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The PXRD patterns obtained for DL-phenyllactic acid, nicotinamide and its 
multicomponents are shown in Figure 4.5.  By looking at the result patterns, it 
is quite obvious that TA-I-32-2a and 2b were different from their starting 
materials. This was evidenced by the appearance of new characteristic 
peaks at 8.2, 9.8, 14.4, 16.3, 19.7, 21.1 and 22.9, none of these peaks 
resembled the DL-phenyllactic acid or nicotinamide, or its polymorphic form. 
This substantiates the preposition that multicomponent formation had 
occurred. 
The system with excesses of DL-phenyllactic acid in TA-I-32-2c also showed 
new characteristic peaks at 5.9, 8.3, 9.9, 12.9, 16.4, 17.8, 19.8, 20.9 and 
21.1. Thus, the 1:1 and 1:2 ratio in acetone produced the same new phase, 
but the 2:1 ratio in the same solvent different new phase was present with 
exist of DL-phenyllactic acid (Figure 4.6). Further investigation was 
performed using acetonitrile as the solvent. Samples of TA-I-32-4a and 4c 
showed somewhat similar peaks which indicated a new phase formation; in 
addition, TA-I-32-4a (1:1 ), in particular, showed that an additional new phase 
was also present. 
The PXRD analysis was performed on the samples prepared by DL-
phenyllactic acid and nicotinamide which used methanol for preparation. The 
multicomponent systems of TA-I-32-3a and 3b showed new peaks at 8.3, 
10.2, 12.5, 16.8, 22.0, 25.1 and 31.5. TA-I-32-3c also showed peaks at 19.3, 
24.9, 28.6 and 30.4. Therefore, the different stoichiometries in methanol all 
produced a new phase with excess  of nicotinamide in 2:1 ratio. 
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DL-3-phenyllactic acid :nicotinamide
TA-1-32-2c 2:1 Me2CO
TA-1-32-2b 1:2 Me2CO
TA-1-32-2a 1:1 Me2CO
TA-1-32-4c 2:1 MeCN
TA-1-32-4b 1:2 MeCN
TA-1-32-4a 1:1 MeCN
TA-1-32-3c 2:1 MeOH
TA-1-32-3b 1:2 MeOH
TA-1-32-3a 1:1 MeOH
Nicotinamide (NICOAM01)
DL-3- phenyllactic acid (AVIMEY)
 
Figure 4.5: X-ray powder diffraction patterns of nicotinamide and DL-phenyllactic acid, and products of crystallisation with a range of solvents  
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Figure 4.6: Representation of crystalline phases identified from co-crystallisations of DL-3-phenyllactic acid: nicotinamide 
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An extended FT-IR study of the multicomponent systems helped to indicate 
the presence of functional groups which were expected in the samples of 
successful co-crystallisation of the two starting materials. In this regard, 
Figure 4.7 shows an overlaid IR pattern of TA-I-32-2a, 2b and 2c.  The visual 
inspection of the FT-IR pattern illustrates that the region of 650 to 1800cm-1 
was very similar for all three multicomponent systems. 
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Figure 4.7: Comparative FT-IR spectra TA-I-32-2a, 2b and 2c in ratios 1:1, 1:2 and 2:1 
in Me2CO 
4.2.2  Crystallisation Studies of L-3-Phenyllactic Acid with 
Pyridinecarboxamides 
4.2.2.1 Isonicotinamide  
L-phenyllactic acid was crystallised together with isonicotinamide. This 
crystallisation was performed using different solvents and different starting 
molar ratios. The solid products were left to re-crystallise and form white 
crystalline solids.  
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The spectral PXRD data illustrates that the samples of TA-I-52-1a and 1b 
(see Figure 4.8), differed from the starting materials of isonicotinamide and L-
phenyllactic acid. TA-I-52-1c presented as oil and PXRD was therefore not 
possible on this sample. The PXRD patterns for TA-52-1a and 1b gave 
similar diffraction patterns which provided evidence of the same phase. The 
presence of new peaks at 7.6, 10.1, 15.2, 17.7, 25.3, 28.7, 30.6 and 35.9, 
along the 2θ scale supports this proposal.  The data obtained via analysis 
can be used to portray the initial conclusion that the starting materials 
efficiently reached complexation as they formed multicomponent systems for 
TA-I-52-1a and TA-I-52-1b.  
The multicomponent formation of L-phenyllactic acid and isonicotinamide 
was also investigated using methanol (TA-I-52-2a, 2b and 2c) as the solvent. 
X-ray powder diffraction was then used to identify the important aspects with 
regards to the nature of the interactions and the effect of solvents in 
multicomponent system formation. 
The PXRD patterns for the materials formed corroborates that TA-I-52-2a 
showed peaks at  7.2, 8.6, 9.7,11.3, 15.3, 17.4, 18.1, 19.9, 22.3, 23.6 and 
24.8; this showed the same phase as which was obtained with acetone. All 
three compounds showed very different diffraction pattern , indicating that 
new phases were produced with the different ratios; however the 
isonicotinamide was remaining in 1:1 ratio and the L-phenyllactic in 2:1 ratio 
(Figure 4.8 and 4.9). 
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In summary, three new phases were produced from the different ratios of the 
starting materials and solvents. Furthermore, the type of phase produced 
was not dependent on the solvent used or the ratio of the starting material.   
Further investigation was performed on the samples of TA-I-52-1a, 1b and 1c 
for the starting materials of L-phenyllactic acid and isonicotinamide, using FT-
IR spectral data for characterisation of the systems.  The results indicated 
that some complexation/co-ordination between the two occurred as the 
spectrum of the multicomponent system showed common peaks in both of 
the starting materials and products. 
The FT-IR spectra and literature confirm that O---O and H---O distances 
arising from these types of interactions are less when compared to stronger 
O-H---O hydrogen bonds92; in addition, a sharp band at 3492cm-1 was 
characteristic of OH stretching. This absorption band maintained 
correspondence with the stretching frequency of the alcohol O-H bond, it 
would therefore be expected that this would shift to lower wavenumbers as 
the strength of the O-H---O hydrogen bond increases80. Although the peak 
maxima of TA-I-52-1a signified bands which were more difficult to quantify, a 
qualitative comparison of the spectra shows that the O-H stretching bands in 
the spectrum shifted slightly to lower wavenumbers; thus corroborating that 
shorter O---O and H---O distances in the structure of TA-I-52-1a can be 
compared to the phenyllactic acid and isonicotinamide hydrogen bond. The 
spectra also indicated strong IR absorption bands for the carbonyl group at 
1726 and 1710cm_1, respectively. 
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L-3-phenyllactic acid : isonicotinamide
TA-1-52-1c 2:1 Me2CO - oil
TA-1-52-1b 1:2 Me2CO
TA-1-52-1a 1:1 Me2CO
TA-1-52-3c 2:1 MeCN - oil
TA-1-52-3b 1:2 MeCN
TA-1-52-3a 1:1 MeCN
TA-1-52-2c 2:1 MeOH
TA-1-52-2b 1:2 MeOH
TA-1-52-2a 1:1 MeOH
Isonicotinamide (EHOWIH01)
L-3-phenyllactic acid (PLACTA10)
Tai_52_1a (single crystal)
 
Figure 4.8: X-ray powder diffraction patterns of isonicotinamide and L-phenyllactic acid, and products of crystallisation with a range of solvents  
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Figure 4.9: Representation of crystalline phases identified from co-crystallisations of L-phenyllactic acid: isonicotinamide 
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4.2.2.2  Nicotinamide  
L-phenyllactic acid was crystallised together with nicotinamide. This 
crystallisation was performed using different solvents and different starting 
molar ratios. The solid products were left to re-crystallise and form white 
crystalline solids. The stoichiometric ratios for nicotinamide and L-
phenyllactic acid were isolated as white crystalline solids.  
The PXRD patterns obtained for L-phenyllactic acid and nicotinamide in the 
1:1 ratio for TA-I-53-3a are shown in Figure 4.10.  L-Phenyllactic acid 
exhibited a characteristic scattering peak at 14.9 and 20.6, and nicotinamide 
exhibited a characteristic scattering peak at 15.1 and 19.2. The 1:1 
stoichiometric multicomponent product of TA-I-53-3a and 3b exhibited 
different scattering peaks from their starting material, but the same peaks 
were observed at 18.1, 20.1 and 25.6 and thus exhibited the same phase. 
Additionally, TA-I-53-3b had additional peaks which correspond with the 
starting material of nicotinamide. TA-I-53-3c was oil and therefore was not 
characterised using the PXRD.  
Similar analysis was carried out using the solid products of TA-I-53-4a and 
4b with the 1:1 and 1:2 ratios in acetonitrile. Peaks appeared at positions that 
were compared with TA-I-53-3a and 3b. Although the products of TA-I-53-4a 
and 4b showed new peaks at 14.8 and 15.4, which indicate a new phase, in 
TA-I-53-4a, the peaks recorded at 22.84 corresponded with 22.15 and 27.7 
which corresponded directed with the starting material of nicotinamide. In 
general it was observed that the L-3-phenyllactic acid/nicotinamide system 
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showed no new phase for the 1:2 product, with any three solvents (MeOH, 
MeCN, and Me2CO). The 1:1 multicomponent system product showed new 
phase 1 with MeOH, new phase 2 and some traces of nicotinamide with 
MeCN and no multicomponent formation when Me2CO was used. Similarly, 
the 1:2 product showed a new phase 1 and some traces of nicotinamide with 
MeOH and new phase 2 with acetonitrile; however, no new phase with 
Me2CO. 
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L-3-phenyllactic acid :nicotinamide
TA-1-53-4b 1:2 MeCN
TA-1-53-4a 1:1 MeCN
TA-1-53-3b 1:2 MeOH
TA-1-53-3a 1:1 MeOH
Nicotinamide (NICOAM01)
L-3-phenyllactic acid
 
Figure 4.10: X-ray powder diffraction patterns of nicotinamide and L-phenyllactic acid, and products of crystallisation with a range of solvents 
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Figure 4.11: Representation of crystalline phases identified from co-crystallisations of L-phenyllactic acid: nicotinamide  
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4.3  X-Ray Structure Analysis 
4.3.1  Single Crystal Analysis of DL-3-Phenyllactic Acid and Isonicotinamide 
(TA-1-31-3c) in MeCN 
The crystal structure of DL-3-phenyllactic acid and isonicotinamide displayed 
the geometry of the crystal as triclinic. It shows the dimeric nature of the 
isonicotinamide molecules which are linked with DL-3-phenyllactic acid, 
along with a network of hydrogen bonds among the assemblage of 
appropriate functional groups. 
The co-crystal TA-I-31-3c was crystallised in the triclinic P1 space group with 
a= 5.3395 (5) Å, b = 11.3914 (15) Å, c = 11.6131 (13) Å, and α = 78.849 (9)°, 
β= 82.062 (8)°, γ = 81.076 (9)° which shows a single molecule of DL-3- 
phenyllactic acid and isonicotinamide in each of the asymmetric units. The 
phenyllactic acid molecule adopts a V-shape conformation in that the two 
molecules are twisted (see Figure 4.12). 
 
Figure 4.12: The asymmetric unit of the DL-3-phenyllactic acid: isonicotinamide co-
crystal  
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Crystal structure analysis was also performed to rationalise the hydrogen 
bonding preferences of acceptors and donors in the presence of other 
competing functional groups.  Isonicotinamide has one type of donor (amine 
NH2) as it has two acidic protons, but there is only one type of acceptor, 
namely, the carbonyl O atom which is capable of forming hydrogen bonds in 
the co-crystal. Phenyllactic acid has two types of donors, namely: the 
carboxylic hydroxyl group (OHcarboxylic) and the alcoholic hydroxyl group 
(OHhydroxyl), which, in total, bear two acidic protons. In addition, there are 
three types of acceptors, namely, the carbonyl O atom and the O atom of 
(OHcarboxylic), as well as the O atom of the alcoholic hydroxyl group (OH 
alcohlic), all of which are capable of forming hydrogen bonds in the 
multicomponent complex.  
The DL-phenyllactic acid molecule possesses two strong hydrogen bonding 
functional groups: a carboxylic acid and a hydroxyl group. The hydrogen 
bonded unit in the co-crystal possesses two molecules of isonicotinamide 
and one molecule of phenyllactic acid as shown in Figure 4.13. In this 
structure, the robust synthon holds the heteroaryl ring and phenyl ring within 
the same plane.  
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Figure 4.13: The hydrogen bonded unit in the co-crystal of two molecules of 
isonicotinamide and one molecule of DL-3- phenyllactic acid 
In Figure 4.13, it can be seen that the amine group of isonicotinamide uses 
its hydrogens to form N-H- - - Ocarbonyl of isonicotinamide hydrogen bonds; 
furthermore, the oxygen atom of carbonyl functionality is the hydrogen bond 
accepter which forms C=O---N-H hydrogen bonds with the adjacent 
isonicotinamide molecule which eventually leads to the formation of a dimer. 
                  
Figure 4.14: The structure crystal showing the primary intermolecular interaction 
between the acid and the N-heterocyclic nitrogen atom as well as the amide-amide 
dimer 
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In Figure 4.14, it can be seen that the primary intermolecular interaction is 
the O-H---N hydrogen bond between the acid and the N-heterocyclic nitrogen 
atom as well as the amide-amide dimer.  The presence of the COOH 
functional group, within the compound, promotes the intermolecular O−H···O 
hydrogen bonds, this further links the molecules through intermolecular 
C−H···O and C−H··· interactions. 
 
Figure 4.15: Formation of amide-amide dimmer in TA-I-31-3c 
The alcoholic OH of DL-phenyllactic acid protrudes almost perpendicularly 
from either side of the chain, hence this hydroxyl functionality is not involved 
in the hydrogen bonding. 
Each of the hydrogen bonded units of DL-3- phenyllactic acid consists of DL-
phenyllactic acid, one distinct molecule of isonicotinamide which is bound 
through hydrogen bonds. The DL-phenyllactic acid molecule is bound to the 
isonicotinamide molecule through the O–H---N(pyridyl ring).  
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Each hydrogen bonded unit of isonicotinamide consists of two distinct 
molecules of isonicotinamide and one DL-phenyllactic acid molecule, which 
is bound through the hydrogen bond.  The isonicotinamide molecule is bound 
to the other molecule of isonicotinamide through C=O(Isonicotinamide)---N–
H(isonicotinamide ′) and N–H---- C=O. The isonicotinamide molecule is bound to one 
molecule of DL-3-phenyllactic acid through the N(pyridine ring )---O–Hcarboxyl 
hydrogen bonds. The nicotinamide molecule also shows interactions to 
another molecule of DL-phenyllactic acid through a pair of N(pyridine ring) with 
the ring carbons  
 
Figure 4.16: Labelling scheme adopted to show extended hydrogen network with co-
crystal 
Isonicotinamide was found to co-crystallise with the DL-3-phenyllactic acid 
supramolecular assemblies which involve hydrogen bonds between the 
nicotinamide pyridyl nitrogen and carboxylic hydrogen of DL-3-phenyllactic 
acid which also assembled the nicotinamide nitrogens and carboxamides 
group of adjacent isonicotinamide molecules.  An extended network of H-
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bonds among the assemblage of appropriate functional groups supports this 
crystal structure. These findings are noteworthy, because they indicate the 
co-crystal properties.  Furthermore, the crystal structure, displayed in Figure 
4.15, also indicates that OH was not primarily involved in the intramolecular 
O-H- - -O(carbonyl) hydrogen bond interactions. 
These crystal structures also agree with the IR spectral analysis. This 
vibrational analysis showed that the N-H stretching vibration displayed a shift 
in wavenumbers, around 3310cm-1, which is indicative of complexation. 
Similarly, the OH stretching band also appeared with a shift below 3442cm-1, 
in the IR spectrum. This absorption band corresponds to the stretching 
frequency of the alcohol O-H bond, which can be expected to shift to lower 
wavenumbers as the strength of an O-H- - -O hydrogen bond increases93. 
Aryl and heteroaryl rings, and the chain of phenyllactic acid, are packed in an 
antiparallel manner over the other similar pairs from adjacent 2D sheets to 
interdigitate the structure via --- interactions. 
This supramolecular heterosynthon is a two-point recognition event as there 
are two ranges corresponding to O−H···N (heteroaryl) and N−H···O=C 
interactions. In this case, the supramolecular synthons are entirely different. 
The DL-phenyllactic acid-pyridine OHacid ···N pyridine supramolecular 
heterosynthon is formed and the primary amide is hydrogen bonded to the 
other carboxamides group. The lone pair interaction of the carbonyl of 
carboxamide is shown with the NH2 group of other carboxamide groups 
which exhibit a hydrogen bond. 
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Figure 4.17: 2D sheets indicating --- interaction within TA-I-31-3c 
4.3.2 Single Crystal Analysis of L-3-Phenyllactic Acid and Isonicotinamide  
(TA-1-52-1a) 
The crystal structure of the multicomponent complex of L-phenyllactic acid 
and isonicotinamide displayed the geometry of the crystal as triclinic. It 
shows the dimeric nature of the isonicotinamide molecules which are linked 
with L-3-phenyllactic acid along with a network of hydrogen bonds that are 
among the assemblage of appropriate functional groups (Figure 4.18). 
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Figure 4.18: Asymmetric unit of L-3- phenyllactic acid:isonicotinamide 
The co-crystal TA-I-52-1a_0m crystallises in the triclinic P1 space group with 
a = 5.3040 (2) Å, b = 11.4994 (4) Å, c = 11.7480 (5) Å, and α = 80.398 (3)°, β 
= 81.767 (3)°, γ = 82.135 (3)° which shows two molecules of each of L-3-
phenyllactic acid and isonicotinamide within the asymmetric unit. The L-3-
phenyllactic acid molecule adopts a zigzag conformation. The crystal 
structure analysis was also performed to rationalise the hydrogen bonding 
preferences of acceptors and donors in the presence of other competing 
functional groups.  
As previously discussed, isonicotinamide has one type of donor (amine NH2) 
that in total bears two acidic protons; in addition, there is one type of 
acceptor, namely, the carbonyl O atom that is capable of forming hydrogen 
bonds in the co-crystal. Phenyllactic acid has two types of donors, namely, 
the carboxylic hydroxyl group (OHcarboxylic) and the alcoholic hydroxyl group 
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(OHhydroxyl) which in total bear two acidic protons with three types of 
acceptors, namely, the carbonyl O atom and the O atom of (OHcarboxylic) as 
well as the O atom of the alcoholic hydroxyl group (OH alcohlic) – these are 
capable of forming hydrogen bonds in the co-crystal (see Figure 4.20).  
 
Figure 4.19: Basic unit showing hydrogen bonds in the co-crystal 
The L-3-phenyllactic acid molecule possesses two strong hydrogen bonding 
functional groups: a carboxylic acid and a hydroxyl group. The hydrogen 
bonded unit in the co-crystal possess two molecules of isonicotinamide and 
two molecules of phenyllactic acid, as shown in the packing diagram within 
the structure. This robust synthon holds the heteroaryl ring and phenyl ring in 
the same plane (see Figure 4.20). 
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Figure 4.20: Formation of dimer in L-3- phenyllactic`acid: isonicotinamide co-crystal 
In Figure 4.20 (the packing diagram), the amino group of isonicotinamide 
uses its hydrogens to form N-H- - - Ocarbonyl of isonicotinamide hydrogen bonds with 
the oxygen atom of carbonyl functionality, here the hydrogen bond accepter 
forms C=O- - - N-H hydrogen bonds with the adjacent isonicotinamide 
molecule – this eventually leads to the formation of a dimer.  
This diagram reveals that the primary intermolecular interaction is the O-H---
N hydrogen bond between the acid and the N-heterocyclic nitrogen atom as 
well as the amide-amide dimer and the OH- - -OH interaction. Further linking 
of the molecules through intermolecular C−H···O and C−H··· interactions 
occurs, but alcoholic OH of L-3-phenyllactic acid protrudes almost 
perpendicularly from either side of the chain hence this hydroxyl functionality 
is not involved in the hydrogen bonding. 
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Each hydrogen bonded unit of L-3-phenyllactic acid consists of two 
molecules of L-phenyllactic acid and one distinct molecule of isonicotinamide 
which are bound through hydrogen bonds. The L-phenyllactic acid molecule 
is bound to the molecule of isonicotinamide through O–H---N(pyridyl ring) as well 
as bound to another molecule of L-phenyllactic acid.  
Each hydrogen bonded unit of isonicotinamide consists of two distinct 
molecules of isonicotinamide and one L-phenyllactic acid molecule, bound 
through hydrogen bonds. The isonicotinamide molecule is  bound to the other  
molecule of isonicotinamide through C=O(Isonicotinamide)---N–H(isonicotinamide′)  and 
N–H---C=O. The isonicotinamide molecule is bound to one molecule of L-3-
phenyllactic acid through N(pyridine ring)---O–Hcarboxyl hydrogen bonds. The 
isonicotinamide molecule also demonstrates interactions with another 
molecule of L-phenyllactic acid through a pair of N(pyridine ring), with the ring 
carbons. 
The crystal structure also displays that OH of L-3- phenyllactic acid was not 
primarily involved in intramolecular O-H---O(carbonyl) hydrogen bond 
interactions. Instead O-H was involved in intermolecular hydrogen bonding 
with another molecule of L-phenyllactic acid via the O-H----O-H hydrogen 
bond – such interactions were not observed in cases of co-crystals that were 
formed by DL-3-phenyllactic acid. 
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Figure 4.21: Labelling scheme adopted to show extended hydrogen bonded network 
The crystal structure is also in agreement with the IR spectral analysis. The 
vibrational analysis showed that the N-H stretching vibration displaying a shift 
in wavenumbers, around 3310cm-1, which is indicative of complexation. 
Similarly, the OH stretching band also appeared with a shift that was below 
3442 cm-1, within the IR spectrum. This absorption band corresponds with 
the stretching frequency of the alcohol O-H bond, which would be expected 
to shift to lower wavenumbers as the strength of an O-H- - -O hydrogen bond 
increases. 
Aryl and heteroaryl rings, and chains of phenyllactic acid, are packed 
antiparallel with the other similar pairs from adjacent 2D sheets to 
interdigitate the structure via --- interactions. 
This supramolecular heterosynthon is a three-point recognition event as 
there are three ranges which correspond to O−H···N(heteroaryl) and 
N−H···O=C interactions, and O-H- - -O-H interactions. In this case, the 
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supramolecular synthons are entirely different. The L-3-phenyllactic acid-
pyridine OHacid ···N pyridine supramolecular heterosynthon is formed and the 
primary amide is hydrogen bonded to the other carboxamide group. The lone 
pair interaction of the carbonyl of carboxamide is shown with the NH2 group 
of the other carboxamide group which exhibits a hydrogen bond. 
4.4  Discussion  
A comparative study of the multicomponent systems, using both 
homochirality and racemic of the 3PLA with amide (isonicotinamide and 
nicotinamide), using the different molar ratios for each of the starting 
materials and different solvent (acetone, acetonitrile and methanol), was 
provided in this part of the research. This study has revealed crystal 
structures of co-crystals of DL-phenyllactic acid and isonicotinamide; as 
such, both of the compounds crystallised in the triclinic space group, thus 
showing the dimeric nature of nicotinamide molecules that were linked with 
phenyllactic acid along with a network of hydrogen bonds that were among 
the assemblage of appropriate functional groups. 
The DL-phenyllactic acid molecule possesses two strong hydrogen bonding 
functional groups: a carboxylic acid and a hydroxyl group. In addition, the 
hydrogen bonded unit, in the co-crystal, possessed the two molecules of 
isonicotinamide and nicotinamide, and one molecule of phenyllactic acid, as 
shown in the packing diagram (see Figure 4.21).  In the structure, the robust 
synthon held the heteroaryl ring and the phenyl ring in the same plane.   
Each hydrogen bonded unit of DL-3-phenyllactic acid consists of DL-
phenyllactic acid and one distinct molecule of isonicotinamide bound through 
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hydrogen bonds. The DL-3-phenyllactic acid molecule was bound to the 
molecule of isonicotinamide through O–H---N(pyridyl ring). Furthermore, 
homochiral crystals were grown using an aprotic, and a less polar solvent 
system. The research considered the use of an ideal racemic system to 
investigate homochiral versus heterochiral nucleation, as a means for 
resolving enantiomers.  
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Chapter 5 
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5. 0 An Investigation into Multicomponent Crystalline Systems from 
Phenylboronic Acids and Pyridinecarboxamides 
5.1  Introduction and the Aims of the Study 
Hydrogen bonding, - stacking, and N-H--- and C-H--- interactions play a 
considerable role in governing the specific functional structures of important 
biomolecules13,94,15. These non-covalent interactions are also the basis of 
crystal engineering, supramolecular chemistry, self-assembly, molecular 
recognition and DNA intercalation17,18,95. Although the foundation of hydrogen 
bonding and stacking, or -hydrogen bonding interactions, are different from 
these, hydrogen bonding arises from electrostatic interaction, while 
dispersion forces dominate the --- stacking and -hydrogen bonding 
interactions18. 
The aspiration of this current part of the research is to investigate the 
potential for modification of the hydrogen bonding environment that has 
originated from the interaction of boronic acids and amides. These 
modifications of the hydrogen bonding regime, from benzoic acids where the 
carboxylic acid provides an O, OH donor-acceptor system and the 
phenylboronic acid unit which provides an OH, OH donor-donor system, aim 
to: 
Prepare and characterise co-crystal systems of boronic acid. 
Investigate and confirm that a boroxine ring forming reaction is a dynamic 
covalent process. 
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Investigate the thermodynamic equilibriums that exist between boronic acid 
monomers and boroxinestrimers. 
Identify how the use of different solvents (acetone, acetonitrile and methanol) 
effect the formation of a multicomponent system. 
Study the effect of changing the molar ratio of isonicotinamide and 
nicotinamide to phenylboronic acid for the final products. 
Where possible, characterise the system by single crystal analyses. 
Perform a comparative study of selected multicomponent systems by both 
the single crystal and by its PXRD pattern. 
Characterise the systems with FT-IR, PXRD and single crystal analyses. 
5.2  Phase Chemistry 
5.2.1  Crystallisation Studies of Phenylboronic Acid and 
Pyridinecarboxamides  
5.2.1.1  Isonicotinamide 
The phenylboronic acid and isonicotinamide multicomponent systems were 
prepared through the use of slow evaporation of the saturated equimolar 
(ratio 1:1) and non-equimolar (ratios 1:2 and 2:1) solutions within the different 
solvents of methanol, acetone and acetonitrile. The products (white 
crystalline solid) were then analysed using PXRD, FT-IR and single crystal 
analysis. 
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The PXRD patterns obtained for isonicotinamide, phenylboronic acid, as 
stoichiometric (TA-I-19-1a) and non-stoichiometric products (TA-I-19-1b and 
TA-I-19-1c), are shown in Figure 5.1.  While both solids exhibited a strong 
scattering peak at around 20.8 and 25.8º (on the 2θ scale), phenylboronic 
acid exhibited a characteristic scattering peak at 15.27º and isonicotinamide 
exhibited a characteristic scattering peak at 23.44º.  The 1:1 stoichiometric  
product of TA-I-19-1a evidenced peaks at 15.4, 17.1, 20.8, 21.5, 23.5, 28.6, 
34.6, 35.8 and 37.91º; similarly, the non-stoichiometric product of TA-I-19-2b 
also exhibited strong scattering peaks at 15.69, 17.7, 21.3, 23.6, 26.5, 28.4, 
29.1 and 48.6º, similarly TA-I-19-1c which showed new peaks at 7.4, 14.4, 
15.6, 18.9, 22.8, 23.4, 28.4, 29.1 and 35.9º. All different stoichiometries in 
acetone produced the same new phase with excess  of the starting material , 
thus indicating that complexation had occurred (Figure 5.1 and 5.2 ) 
The comparative XPRD patterns obtained for phenylboronic acid, 
isonicotinamide, its polymorphic forms and the multicomponent products 
prepared using acetonitrile are shown in Figure 5.1. The 1:1 stoichiometric 
product of TA-I-19-2a exhibited altered scattering peak at 15.9, 21.5, 23.7, 
29.4, 31.9, 39.9 and 47.5º along the 2θ scale with excess of isonicotinamide. 
Similarly, the non-stoichiometric molar ratio products of TA-I-19-2b also 
showed new characteristic peak appearances at 9.6, 19.4, 19.9 and 29.16º 
which is different from the new phase was present in 1:1 ratio. In addition, 
TA-I-19-2c also showed the appearance of new peaks similar to the new 
phase was produced in 1:1 ratio, which is indicative of the formation of a 
multicomponent system; however, the peaks at 12.1, 18.9, 20.9, 22.1, 24.2, 
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29.4 and 29.9º, along the same 2θ scale, showed similarities with the starting 
material isonicotinamide. Thus representing that some of the excess of the 
starting material remained in the mixture in its solid form (see Figure 5.1 and 
5.2). 
The comparative study of the PXRD pattern shows that the starting material 
and the multicomponent systems using methanol as solvent revealed the 
appearance of new peaks. TA-I-19-3a (the 1:1 molar ratio product of the 
starting material) showed not much difference from the starting materials. 
The pattern of 1:1 more corresponding with isonicotinamide. On the other 
hand, TA-1-19-3b presented new significant peaks at 9.3, 10.9, 11.4, 11.9, 
14.5, 16.5, 17.8, 19.3, 19.9, 20.2, 28.88 and 29.22º, along the 2θ scale. 
Correspondingly, TA-I-19-3c showed new peaks at 7.9, 9.4, 11.5, 14.6, 15.8, 
17.0, 17.6, 19.7, 21.4, 21.7, 22.7, 23.1, 24.9 and 35.1, along the 2θ scale. In 
addition isonicotinamide also existed in this ratio. Thus indicating that 
hydrogen bonded multicomponent system formation occurred within all of the 
samples.  
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phenylboronic acid :isonicotinamide
TA-1-19-3a 1:1 MeOH
TA-1-19-3b 1:2 MeOH
TA-1-19-2a 1:1 MeCN
TA-1-19-1a 1:2 Me2CO
TA-1-19-3c 2:1 MeOH
TA-1-19-2b 1:1 MeCN
TA-1-19-2c 1:1 MeCN
TA-1-19-1b 1:2 Me2CO
TA-1-19-1c 1:2 Me2CO
Isonicotinamide (EHOWIH01)
Phenylboronic acid (PBORA)
RB1_1 single crystal 
 
Figure 5.1: X-ray powder diffraction patterns of isonicotinamide and phenylboronic acid, and products of crystallisation with a range of solvents 
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phenylboronic acid (PBORA)
isonicotinamide (EHOWIH01)
{{phenylboronic acid)
(isonicotinamide)} (RB1_1) 
[ new phase 1]
Graphical representation of crystalline phases identified from co-crystallisations of  
phenylboronic acid : isonicotinamide
New Phase 2
 
Figure 5.2: Representation of crystalline phases identified from co-crystallisations of phenylboronic acid and isonicotinamide 
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In  a research study conducted by Seaton et al., the use of isonicotinamide 
and benzoic acid [1:1] co-crystallisation revealed that solvent selectivity could 
be streamlined in a supramolecular manner by reflecting the interactions and 
the varying solvent volumes which also effect it (Figure 5.3)18,96. 
 
Figure 5.3: Comparison of the main intermolecular interactions between: a) 1:1; and, 
b) 2:1 benzoic acid: isonicotinamide molecular complees
18 
 
The literature also indicated that the isonicotinamide, benzoic acid co-crystal 
showed a C=O---HO hydrogen bond which was in competition with the 
discrete amide-acid interaction. Generally, sensitivity to a particular solvent 
would vary the packing volume of the –NH2 vs –CO2 H moieties which would 
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also have an effect on the functional groups on the solvents for both the acid-
amide and the amide-amide associations18. 
The crystal structure can be further stabilised by various C-H---O and --- 
stacking interactions. Due to the presence of phenylboronic acid and its 
ability to form tetrameric motifs which consist of acid-acid homosynthons, 
such motifs are generally composed of hydrogen bonded complexes, with 
obvious (B)O-H---N, (B)O-H---O, C-H---O, C-H---N, C-H---, C-H---B and 
very strong --- stacking interactions97. 
Further investigation was also carried out using the FT-IR technique, see 
Figure 5.4.   
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Figure 5.4: Comparative FT-IR spectra for TA-I-19-1a, 1b and 1c in ratios 1:1, 1:2 and 
2:1 in Me2CO 
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Table 5.1: FT-IR assignments for samples TA-I-19-1a, TA-I-19-1b and TA-I-19-1c in 
Me2CO 
Iso-
nicotinamide 
Phenylboronic 
Acid 
TA-I-19-1a TA-I-19-1b TA-I-19-1c 
Assignment  
FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  
3482 3482 3480 
 
3370, 3186   
3309 
3186  
 3388 
3186 
3388  
ύ NH2 (100), ύ NH2 
(100) 
  
3273, 3081, 
3024 
3079 
2568 
3079 
3097 
3023 
OH and VOD 
3076, 3064, 
3053, 3041 
    
3055 
3042 
3023  
  
ύ CH (99), ύ CH 
(100) 
1624, 1596, 
1667 
        
δNH2 , ύ ring 
+δCCH , ύ ring ,ύ 
CO  
  
2568 2567 
  
  2419    2465     
  1964 1958   1959     
  1894    1891     
    
1713 
 
  
1666 1666 1667 C=O 
  
1621   1626 1621 
 
  1604 
 
1601 1603  C=C stretch 
  1572  1554  1553 1554  C=C stretch 
1552         ύ ring 
  1499 1497  1497   1498 C=C stretch 
1496         δCCH +ύ ring  
  
1444 1441 1441 
 
1410         δCCH +ύ ring 
1395   1397      ύ CN + δCC , 
  1350 1366  1366   1357   
  1275, 1191  1275 1275   1275 C-O  stretch 
1265         ῡ ring 
1228   
 1234 
1219 
1233  
1219 
 
  
δCCH (74)+ύ ring 
(14) 
  1161       C-O  stretch 
1148   1146   1146   ring+CCH+CN+CC 
1122    1119 1119    CCH+ ring 
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  1095   1107  1106  C-O  stretch 
  1072   1076  1073  C-O  stretch 
1085         δ CCH +ύ ring  
1063    1063    1064 NH2 rock  +ύCN 
  1029 1027  1027  1028  B-C stretch 
  1007    1008 1008    
994     993    Ring 
  972       B-O sym. Stretch 
969         CH 
955         ῡ CH 
  923 
      
Csp2- H bending 
      
875         ᵞCH 
853    851     ᵞCH+ᵞ CC +ᵞCO 
  803       B-O sym. Stretch 
  697, 857   846  846 BO2 out- of –Plane 
778         γring +γco 
  764  761 766   760 Boroxole ring 
755         
δ ring (30)+ 
ύcc(17)+ ύring 
708       724  ring  + CO  
  697, 857       BO2 out- of –Plane 
669         ring+ring 
629         δ CCO  + ύ ring  
542         
NH2 twist  + ring + 
CC 
Many strong and clear stretching modes appeared in the FT-IR spectra for 
the phenylboronic acid, isonicotinamide and their respective multicomponent 
systems of TA-I-19-1a, 1b and 1c (Table 5.1). These stretching modes reflect 
the arrangement of phenylboronic acid and isonicotinamide after the 
formation of co-crystals.  The C=O stretching mode appeared at 1666cm-1 for 
TA-I-19-1a, 1667cm-1 for TA-I-19-1b and 1666cm-1 for TA-I-19-1c, while the 
C-N stretching mode appeared at 1397cm-1 for TA-I-19-1a. Similarly, the 
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symmetric and asymmetric CH2 stretching modes were assigned at 3065 to 
2568cm-1 for TA-I-19-1a, and 2901 to 2922cm-1 for TA-I-19-1b.  On the basis 
of these results, it can be assumed that the TA-I-19-1a and TA-I-19-1b 
multicomponent systems had relatively well-ordered constructions when 
compared to TA-I-19-1c (see Figure 5.4).  
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Figure 5.5: Comparative FT-IR spectra for TA-I-19-2a, 2b and 2c in ratios 1:1, 1:2 and 
2:1 in MeCN 
The comparative plots of the FT-IR spectra for TA-I-19-2a, 2b and 2c all had 
the characteristics expected of hydrogen bonded complexes, including the 
presence of both N-H stretching (~3481cm-1 shown by both TA-I-19-2a and 
TA-I-19-2b, and at ~3451cm-1 bending [~1495cm-1] modes), see Figure 5.5. 
Consequently, the proposed multicomponent systems of TA-I-19-2a, 2b and 
2c agree well with the results obtained from the PXRD pattern which is 
indicative that  hydrogen bonded multicomponent system formation occurred.  
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The results obtained are similar to the results of TA-I-19-1a, 1b and 1c which 
were attained by using acetone as the solvent.  
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Figure 5.6: Comparative FT-IR spectra for TA-I-19-3a, 3b and 3c, in ratios 1:1, 1:2 and 
2:1 MeOH 
The TA-I-19-3a sample showed correspondence with phenylboronic acid, 
with peaks at 991cm-1 (ring deformation), 1604cm-1 (C=C stretch) and 3083 
(ᶹOH), as well as consistencies with isonicotinamide which were fairly 
obvious at 755cm-1 (C-H wag), 1218cm-1 (C-N stretch), 1297cm-1 (ring 
deformation) and 3185cm-1 (ᶹNH2) (O-C-H stretch). However, the 
multicomponent systems of TA-I-19-3a, 3b and 3c showed slightly different 
patterns at 2959, 2568, 1823 and 1624cm-1 which is representative that 
multicomponent formation occurred within these systems98,99.  These results 
were similar to those obtained by the different solvents in TA-I-19-1a and TA-
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I-19-2a, this is indicative that the solvent was not directly involved in the 
hydrogen bonding pattern.  
5.2.1.2 Nicotinamide 
The PXRD pattern shows the comparative study of the starting materials with 
the polymorphic forms. The resulting  patterns showed that TA-I-20-2a had 
new peaks at 7.81, 9.22, 15.99, 17.77 and 26.77º, along the 2θ scale which 
indicates a new phase . The non- stoichiometric product of TA-I-20-2b 
showed peaks similar to the peaks present in the sample made from a 1:1 
ratio. These peaks were showed at 7.79, 9.23, 14.51, 26.99 and 36.31º,along 
the 2θ scale. The different ratios 1:1 and 1:2 both show same new phase 
with excess of nicotinamide. However, TA-I-20-2c showed a few new peaks 
at 5.28 to 8.92, 10.39, 12.44, 13.01,14.50, 1585, 24.83, 26.66, 27.06, 28.08, 
28.30 and 29.56º, along the 2θ  scale which is different from the phase that 
was presented in 1:1 and 1:2. This is indicative that multicomponent 
formation occurred within these systems (Figure 5.7 and 5.8). 
Further analysis was performed using the same system of phenylboronic acid 
and nicotinamide with methanol as the solvent. The product obtained was 
analysed with both PXRD and single crystal analyses. The PXRD pattern 
showed that the multicomponent system of TA-I-20-3a showed new peaks at 
7.41, 9.28, 10.95, 4.22, 16.08, 18.05, 19.23, 20.70, 20.93, 26.63, 38.24 and 
41.61º, along the 2θ scale. The non-stoichiometric product of TA-I-20-3b 
showed peaks that corresponded with nicotinamide, but new peaks were also 
identified at 9.50, 11.29, 14.90, 16.37 and 28.43º, along the 2θ scale. Finally, 
TA-I-20-3c showed new peaks at 6.54, 9.12, 10.46, 12.34, 13.02, 13.52, 
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17.08, 21.79 and 26.18º, along the 2θ scale, but a few peaks were identified 
at 15.17, 17.35, 18.24, 20.16, 21.17 and 28.92º which corresponds with the 
starting materials or the polymorphic forms (Figure 5.7 and 5.8). The same 
system of phenylboronic acid and nicotinamide with acetonitrile as the 
solvent was used. The non-stoichiometric product 1:2 and 2:1 ratios all 
produced different phase with excess  of nicotinamide at 2:1 ratio (Figure 5.7 
and 5.8). 
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TA-1-20-2c 2:1 Me2CO
TA-1-20-2b 1:2 Me2CO
TA-1-20-2a 1:1 Me2CO
TA-1-20-4c 2:1 MeCN
TA-1-20-4b 1:2 MeCN
TA-1-20-4a 1:1 MeCN
TA-1-20-3c 2:1 MeOH
TA-1-20-3b 1:2 MeOH
TA-1-20-3a 1:1 MeOH
Nicotinamide (NICOAM01)
Phenylboronic acid (PHBORA)
TA-1-20-2a (Single crystal)
phenylboronic acid :nicotinamide
 
Figure 5.7: X-ray powder diffraction patterns of nicotinamide and phenylboronic acid, and products of crystallisation with a range of solvents 
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Figure 5.8: Representation of crystalline phases identified from co-crystallisations of phenylboronic acid and nicotinamide 
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Similar results were also observed for the PXRD pattern of these same 
systems when they used acetonitrile was used as the solvent. 
Further investigation was then carried out using the FT-IR analysis for the 
ranges of 600 to 4000cm-1 (Figure 5.9). 
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Figure 5.9: Comparative FT-IR spectra for TA-I-20-2a, 2b and 2c, in ratios 1:1, 1:2 and 
2:1 in Me2CO 
The results indicate that nicotinamide (NH2) presented symmetric and 
asymmetric stretching wavenumbers at 3366 and 3161cm-1, for TA-I-20-2a at 
3392, 3257 and 3314cm-1, for TA-I-20-2b at 3371 and 3172cm-1, and for TA-
I-20-2c at 3383cm-1. There was clearly an increase in hydrogen bonding 
through the NH2 hydrogens which affected the NH2 bending mode on the 
formation of the multicomponent systems63.  Analogous wavenumber shifts 
were also obtained in aniline and phenylenediamine complexes96,100. The C-
O stretching wavenumber was observed at 1693cm-1 in nicotinamide and at 
1693, 1689 and 1678 cm-1, respectively for TA-I-20-2a, 2b and 2c (Figure 
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5.8). Similar stretching and bending mode were also observed for TA-I-20-3a, 
3b and 3c, as well as for TA-I-20-4a, 4b and 4c for the different solvents. 
5.3   X-Ray Structure Analysis 
5.3.2   Single Crystal Analysis of Polymorphic Forms of Phenylboronic Acid 
and Nicotinamide (TA-1-20-3a and RBi_1) 
 
Figure 5.10: Triclinic crystal packing of the co-crystal of phenylboronic acid: 
nicotinamide 
The crystal structure of the co-crystal of phenylboronic acid and nicotinamide 
displays the geometry of the crystal as triclinic. It shows that the dimeric 
nature of phenylboronic acid is linked with the nicotinamide molecules along 
with an extended network of H-bonds that are among the assemblage of 
appropriate functional groups. 
The boronic acid group has a trigonal geometry and is fairly coplanar with the 
benzene ring. The CBO2 plane is quite coplanar with the benzene ring, with 
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a respective twist around the C–B bond for the two molecules of PhB (OH)2.  
Each dimeric phenylboronic acid ensemble is also linked with hydrogen 
bonds to four other nicotinamide molecules in order to give an infinite array of 
layers. 
Each hydrogen bonded unit of phenylboronic acid consists of phenylboronic 
acid, two distinct molecules of nicotinamide and other phenylboronic acid 
molecules which are bound through hydrogen bonds. The phenylboronic acid 
molecule is bound to the two distinct molecules of nicotinamide through O–H-
--N–H(Nicotinamide).  The phenylboronic acid molecule is bound to the other 
molecule of phenylboronic acid through a pair of O–H---O hydrogen bonds. 
Furthermore, each hydrogen bonded unit of nicotinamide consists of two 
distinct molecules of nicotinamide and one phenylboronic acid molecule, 
bound through hydrogen bonds. The nicotinamide molecule is  bound to the 
other  molecule of nicotinamide  through C=O(Nicotinamide)---N–H(Nicotinamide′)  and 
N–H(Nicotinamide)--- C=O(Nicotinamide′). The nicotinamide molecule is bound to one 
molecule of phenylboronic acid through N(pyridine ring of nicotinamide)---O–H 
hydrogen bonds. The nicotinamide molecule also demonstrated interactions 
with another molecule of phenylboronic acid through a pair of N(pyridine ring of 
nicotinamide) with the ring carbons. 
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Figure 5.11: Extended hydrogen bonding network within co-crystal 
Due to the behaviour of phenylboronic acid and its property which allows it to 
form hydrogen bonded dimers, phenylboronic acid and nicotinamide were 
found to co-crystallize with nicotinamide to form supramolecular assemblies. 
These assemblies involved hydrogen bonds that were between the B(OH)2 
groups and the nicotinamide nitrogens and the carboxamide group. 
Furthermore, an extended network of H-bonds, found among the assemblage 
of the appropriate functional groups, supports the crystal structure. 
Consequently, these findings indicate noteworthy co-crystal properties. 
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Figure 5.12: Formation of supramolecular hetrosynthon in TA-I-20-3a 
The nicotinamide molecules look like a novel ribbon-shaped conformation. 
The catenated dimer, sometimes referred to as an amide tape or ribbon, is a 
chain of translational related dimers linked along a 5.1 Å short axis by N−H---
O bonds. This supramolecular heterosynthon is a two-point recognition event 
as there are two ranges which correspond to the O−H---O and N−H---O 
interactions.  
In this case, the supramolecular synthons are entirely different. The 
phenylboronic acid-pyridine OHacid ---Npyridine supramolecular heterosynthon is 
formed and the primary amide is hydrogen which is bonded to the 
carboxamide group. The lone pair interaction of the carbonyl of carboxamide 
is shown with the NH2 group of the other carboxamide group which is 
exhibiting a hydrogen bond. 
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a) 
 
 
b) 
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c) 
Figure 5.13: The crystal packing of the phenylboronic acid: nicotinamide co-crystal 
showing: a) and b) Formation of ladder like structure by hetrosynthon, and c) The 
hydrogen bonding network 
5.4  Discussion 
The study of the multicomponent system of phenylboronic acid and 
nicotinamide was investigated by stoichiometric and non-stoichiometric 
mixtures, through the use of the PXRD, IR and single crystal analyses. The 
infrared absorption spectroscopy explains about the nature of interactions in 
the multicomponent system, specifically for identifying strong O-H stretching 
interactions which were involved in the specified formation of hydrogen 
bonding networks.  All of the systems, whether stoichiometric or non-
stoichiometric, produced multicomponent formations. 
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Single crystal analysis proved to be significantly helpful to the study as it 
detailed the hydrogen bonding network in the multicomponent system. The 
structure displayed the equivalent supramolecular synthons as expected for 
the boronic acid with isonicotinamide.  The study also revealed that solvents 
only act as a medium of multicomponent formation as they did not take direct 
involvement in the bonding process. Consequently, consideration of the 
competition of the solvent- solute interactions and the weaker, more discrete, 
acid-amide interactions suggests that solvent selectivity is of value; however, 
further studies into explicit solvent-solute interactions are needed in order to 
explain this difference further. These results therefore highlight how the 
choice of solvent can play an important role in the selective growth of a 
desired molecular complex18. 
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Chapter 6 
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6.0   An Investigation into Multicomponent Crystalline Systems from 
Phenylboronic Acids and Pyridine Co-Formers 
Exploiting the dynamic covalent chemistry of the boroxine ring construction 
(see Figure 6.1), in the development of multicomponent systems, is based on 
the proliferation of hydrogen bonded networks as a means for assembly. This 
current research study focused on the binary systems of phenylboronic acid, 
with regards to 4,4’-bipyridine and 4-phenylpyridine. This research study also 
focused on determining the effect of different solvents and different molar 
ratios of starting materials on the multicomponent system. 
Acidic Donor Basic Acceptor Proposed Structure of Boroxine 
Phenylboronic 
Aacid 
4,4’-Bipyridine/ 
4 Phenylpyridine 
Boroxine 
( L is representation of legand) 
 
 
 
 
 
 
 
 
 
Figure 6.1: The binary systems of phenylboronic acid, with regards to 4,4’-bipyridine 
and 4-phenylpyridine   
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6.1  Introduction and Aims of the Study 
The main aim of this study was to investigate the potential for modification of 
the hydrogen bonding environment, within the hydrogen bonded 
multicomponent system of boroxines. This study also aimed to determine 
how the use of different solvents (acetone, acetonitrile and methanol) and the 
use of different molar ratios (1:1, 1:2 and 2:1), of the starting materials, could 
be used to drive the systems between the boronic acid co-crystal and the 
boroxine adduct; as such, it aimed to: 
Prepare and characterise co-crystal systems of boronic acid. 
Investigate and confirm that the boroxine ring forming reaction is a dynamic 
covalent process. 
Investigate the thermodynamic equilibrium that exist between boronic acid 
monomer and boroxinestrimers. 
Characterise the obtained multicomponent system in terms of the FT-IR, the 
PXRD and 1HNMR. 
6.2  Phase Chemistry 
6.2.1 Crystallisation Studies of Phenylboronic Acids with Pyridines 
6.2.1.1  4,4’-Bipyridine 
Phenylboronic acid and 4,4’-bipyridine were dissolved in acetone in ratios of 
1:1, 1:2 and 2:1.  An analysis of the starting materials, against the samples of 
 178 
 
TA-I-54-1a, TA-I-54-1b and TA-I-54-1c allowed for comparison and the 
drawing of initial conclusions as to whether a new phase was isolated. 
The powder x-ray diffraction (PXRD) obtained for the multicomponent system 
were formed in 1:1, 1:2 and 2:1 ratios of phenylboronic acid and 4,4’-
bipyridine, they also used acetone as the solvent for their formation.  
The PXRD patterns obtained for phenylboronic acid, 4,4‘-bipyridine and the 
1:1 co-crystal product of TA-I-54-1a indicated that phenylboronic acid 
exhibited a characteristic scattering peak at 15.3 and 20.9, and 4,4’-
bipyridine exhibited a characteristic scattering peak at 22.4 and 25.0 .The 
1:1 stoichiometric co-crystal products exhibited different scattering peaks at 
20.2 and 25.5, which is indicative that they did not correspond to  the 
diffraction patterns of the starting materials; thus indicative that a new phase 
was formed. 
The current research result patterns of phenylboronic acid with 4,4’-bipyridine  
can be compared to the research by Rodriguez-Cuamatzi et al.; the findings 
suggest that similar behaviours occurred when boric acid and 4,4‘-bipyridine 
formed a co-crystal synthesis [(ba)(bpy)(H2O)] using the stoichiometric, 1:1 
ratio (Figure 6.2)97.  Similarly, the current study also used acetone as the 
solvent which was not dried prior to use; interestingly, the moisture from the 
solvent also showed its effect on the bonding pattern. 
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Figure 6.2: Hydrogen bonding motifs found in the crystal structures of 
[(ba)(bpy)(H2O)] 
The XRPD pattern of the non-stoichiometric multicomponent system was 
barely distinguishable from its starting material of phenylboronic acid and 
4,4’-bipyridine, or from TA-I-54-1a. The pattern of 1:2 molar ratio of 
phenylboronic acid demonstrated similar peak appearances at 26.4, with 
respect to phenylboronic acid; although, one peak had a scattering angle of 
20.1 along the 2θ scale. This appeared to double in relative intensity. The 
XRPD pattern of the multicomponent system of the 2:1 phenylboronic acid 
molar ratio produced a major scattering peak that shifted slightly to 27.2 on 
the 2θ scale. Thus, strong new peaks were observed at the scattering angles 
of 26.4, along the 2θ scale (Figure 6.3). 
The XRPD pattern of a phenylboronic acid-rich multicomponent signifies 
more of a progression in the physical phases than the 4,4‘-bipyridine did in 
terms of its rich molar ratio fraction. To illustrate, TA-I-54-1b showed more 
regular peak appearances then the TA-I-54-1c sample (which identified very 
few peaks). These insignificant peak appearances, in the region of 30 to 46, 
were identified along the 2θ scale. 
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phenylboronic acid :4,4’-bipyridine
TA-1-54-1c 2:1 Me2CO
TA-1-54-1b 1:2 Me2CO
TA-1-54-1a 1:2Me2CO
TA-1-55-1c 2:1 MeCN
TA-1-55-1b 1:2 MeCN
TA-1-55-1a 1:1 MeCN
TA-1-54-2c 2:1 MeOH
TA-1-54-2b 1:2 MeOH
TA-1-54-2a 1:1 MeOH
TA-1-54-1c (Single crystal)
TA-1-54-2a (Single crystal)
 
Figure 6.3: X-ray powder diffraction patterns of 4,4’ bipyridine and phenylboronic acid, and products of crystallisation with a range of solvents 
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New Phase 3
Figure 6.4: Representation of crystalline phases identified from co-crystallisations of 4,4’ bipyridine and phenylboronic acid 
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The study conducted by Rodriguez-Cuamatzi et al. demonstrated similar 
interactions for multicomponent complexes. During their study, they 
concluded that the supramolecular structures that were outlined by [(1,4-
bdba)(bpy)2] (1) and [(3-apba)(bpy)2] (2), for boronic acid and 4,4’-bipyridine 
concluded that the molecules interacted with each other through a hydrogen 
bonding motif [where each dihydroxyboryl group is connected to two bpy 
molecules through O-H---N hydrogen bonds. This was similar to that found 
for the 1:2 adduct between phenylboronic acid and bpy ([(pba)(bpy)2] (see 
Figure 6.5). This conclusion will be helpful for the prediction of structures of 
supra-molecular synthons101. 
 
 
Figure 6.5: Hydrogen bonding motifs found in the crystal structures of: (a) [(1,4-
bdba)(bpy)2] (1); and, (b) [(3-apba)(bpy)(2) 
The samples of TA-I-54-1b were also analysed using single crystal analysis 
(provided by Professor Scowen, University of Bradford); the results of which 
clearly illustrate that the primary hydrogen bonding motif, comprised  of 
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hydrogen bonded networks with significant (B)O-H---N, (B)O-H---O, C-H---O, 
C-H---N, C-H---, --- and C-H---B interactions. 
 
Figure 6.6: Primary hydrogen bond motif of TA-I-54-1b 
The secondary hydrogen bonding motif for sample TA-I-54-1b (as provided 
by Professor Scowen) also demonstrates the outcome in the hydrogen 
bonding network by the intervention of the water molecule (see Figure 6.6). 
The motif clearly showed linkage of the parallel strands of N-H--- hydrogen 
bonding. The imperative facet of this motif is the emergence of the centroid 
(signified by the pink sphere in Figure 6.7). It is worth noting that the centroid 
is in the vicinity of the electron density which is positioned in the centre of this 
aromatic system.  The strong N-H bonds are generally formed in areas where 
centroid  electron density lies within the neighbouring phenylboronic acid. 
 
Figure 6.7: The secondary hydrogen bonding motif for sample TA-I-54-1b 
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The secondary hydrogen bonding motifs, as depicted by Rodriguez-Cuamatzi 
et al. explained four types of secondary interactions that occurred between 
the C-H acid hydrogen atoms of the pyridyl moieties and the neighbouring 
boronic acid molecules149 as the following interactions: (i)  C-H---O, (ii) C-H---
N, (iii)C-H--- and (iv) C-H---B.  All of the C-H---O, C-H---N and C-H--- 
interactions were within the previously established limits102,103.  However, in 
this case the boron atoms were involved in p---p-interactions with the 
oxygen atoms, this provides them with electron density. Interestingly, a 
search of the CSD database104 revealed 27 entries for boronic acids, eight of 
which showed intermolecular C-H---B interactions in their crystal.  Therefore, 
it can be suggested that C-H---B interactions play a non-negligible role in the 
structures of supramoleculars. 
As in most of the known crystal structures of boronic acids97, the hydroxyl 
groups that are attached to the boron atoms have syn-configuration.  In the 
hydrogen bonded macrocycles, the pyridine rings of opposite bpy molecules 
have slightly displaced parallel-sandwich geometries105 which are almost 
coplanar to each other, thus they form centroids. According to Rodriguez-
Cuamatzi et al., within each bpy molecule, the pyridine rings are twisted 
around the central C-C bonds, by angles ranging from 28.6 to 37.5° 97.  Thus, 
based on these progress result patterns, and by observing the behaviour of 
boronic acid and 4,4’-bipyridine, the predicted macromolecule structures will 
resemble the structures presented in Figure 6.8. 
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Figure 6.8: Predicted macromolecule structures of boronic acid with 4,4’-bipyridine  
An interesting aspect of this analysis “the formation of boroxines ring”, is that 
not much is observed in the 1:1 ratio multicomponent adduct – this is 
supported by the work presented by Kua et al.106. They noted that the 
trimerisation of phenylboronic acids to form arylboroxine rings (step 1), is 
enthalpically unfavourable. In contrast, the formation of stable 1:1 adducts 
(step 2), was highly favourable, thermodynamically; in fact, it was sufficiently 
favourable to drive the two-step reaction forward toward formation of the 
products. The main reason for this reaction is substitution of the -electron-
withdrawing groups, in the para position of the phenyl ring, which was 
disfavoured in step 1; whereas, the -electron-donors behaved in total 
opposition to this.  Conversely, the substituents that were overall electron-
withdrawing tended to favour step 2, whereas electron donors disfavoured it 
(Figure 6.9)106. 
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Figure 6.9: Two-step reaction sequence of boroxine construction followed by adduct 
formation 
Further investigation was performed on the data collected from TA-I-54-1a, 
TA-I-54-1b and TA-I-54-1c, and its starting materials in order to verify the 
initial conclusions (see Table 6.1). FT-IR analysis was also performed to 
determine whether or not the anticipated hydrogen bonded multicomponent 
structure had been formed (Figure 6.10). 
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Figure 6.10: Comparative FT-IR spectra of TA-I-54-1a, 1b and 1c, in ratios 1:1, 1:2 and 
2:1 in Me2CO 
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Table 6.1: FT-IR assignments for samples TA-I-54-1a, TA-I-54-1b and TA-I-54-1c in 
Me2CO 
Phenyl 
boronic acid 
cm
-1
 
4,4’-
bipyridine 
cm
-1
 
TAI-54-1a 
cm
-1
 
TAI-54-1B 
cm
-1
 
TAI-54-1c 
cm
-1
 
Assignment  
  (cm
-1
) 
 3429 3860, 3721 
3637 
3446 3436 O-H, stretch 
3273 
3081 
3024 
3025 2927 
2895 
  3020,3050 OH and VOD 
2419 2362 2342,2361 2360,2342 2340  
1964 1942   1956  
1894 1868     
  1722,1710    
 1654 1692,1665 
1620 
 1626 C=N stretch 
1604 1592 1594 1594 1601 C=C stretch 
1572  1572,1567   C=C stretch 
 1540 
1532 
1548,1530 1532 1543 C=C stretch 
1499 1488 1480  1493 C=C stretch 
1439 1406 1440, 1447 1442,1417  
B-O asym. stretch 
 1409 1401 1400 1390 
1350  1377,1341 1374,1341 1340,1326 
1275, 
1191 
1218  1211 1280,1212 
1199 
C-O  stretch 
1161 1123   1176,1122 C-O  stretch 
1095   1066 1085 C-O  stretch 
1072 1075 1023 1042  C-O  stretch 
B-C stretch 
 
1029 1038  1023 1069 
1007  1001 1001 1019 
1001 
972 988 990 990 980 B-O sym. stretch 
923 850  845 826 Csp2- H bending 
803 803 801 801 811 B-O sym. stretch 
764 733 781,781  769 Boroxole ring 
697, 857  715, 
668 
688,651 746, 
707,672 
BO2 out- of -Plane 
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The FT-IR spectra of the starting materials and corresponding 
multicomponent systems of TA-I-54-1a, TA-I-54-1b and TA-I-54-1c showed 
many strong and clear stretching modes (Figure 6.9). These stretching 
modes reflected the arrangement of phenylboronic acid with 4,4’-bipyridine 
utilising hydrogen bonded network assemblies.  As shown in Table 6.1, some 
stretching modes were confirmed, such as an O-H stretching mode (in the 
region of 3637cm-1 in TA-I-54-1a, and approx ~3446cm-1 in both TA-I-54-1b 
and TA-I-54-1c) which supported the proposition that formation of 
multicomponent systems was successful. In contrast, the C=N stretching 
mode appeared at ~1620cm-1 (for TA-I-54-1a and TA-I-54-1c) and the C=C 
stretching mode, for all three multicomponents, occurred in the region of 
~1600cm-1.  In particular, the symmetric and asymmetric B-O stretching 
modes of phenylboronic acid, and three multicomponent adducts, were 
assigned at ~1430cm-1 and ~850cm-1, respectively. 
The B-O-H deformation (ȢBOH) can be easily recognised in the spectrum of 
phenylboronic acid; however, in multicomponent systems, its frequency is 
lowered slightly.  A strong band at 1007cm-1 in the spectrum of phenylboronic 
acid, which shifts to 990cm-1 upon multicomponent formation, is identified 
with this vibration. The bands located at 1197 and 929cm-1, and at 1183 and 
914cm-1, have been assigned to Ȣ BOH in the phenylboronic acid and 
multicomponent system. 
On the basis of these results, it is possible to assume that the 
multicomponent systems of TA-I-54-1a, TA-I-54-1b and TA-I-54-1c have 
relatively well-ordered constructions. 
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Figure 6.11: Predicted macromolecule structures showing N-H bonding pattern 
between phenylboronic acid and 4,4’dipyridyl 
 
 
The crystal structure of the co-crystal of phenylboronic acid and 4,4’-dipyridyl 
was shown as belonging to space group C2. It showed phenylboronic acid 
linked with 4,4’-dipyridyl molecules through hydrogen bonds which provided 
an infinite array of layers which contained discrete termolecular coordinating 
structures. The boronic acid group has a trigonal geometry and is fairly 
coplanar with the benzene ring, and the CBO2 plane is quite coplanar with 
the benzene ring.  
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Figure 6.12: Crystal structure showing basic unit of phenylboronic acid and 4,4’-
dipyridyl molecule 
Each hydrogen bonded unit of phenylboronic acid consists of phenylboronic 
acid and two distinct molecules of 4,4’-dipyridyl which are bound through 
hydrogen bonds. The phenylboronic acid molecule is bound to the two 
distinct molecules of 4,4’-dipyridyl through O–H---N. 
In packing each hydrogen bonded unit of 4,4’-dipyridyl, one molecule of 4,4’-
dipyridyl and half a molecule of phenylboronic acid were bound through N---
O–H hydrogen bonds. The 4,4’-dipyridyl molecule was bound to one 
molecule of phenylboronic acid; the 4,4’-dipyridyl molecule also showed 
weak interactions with another molecule of phenylboronic acid through a pair 
of N with the ring carbons. 
The crystal structure also supported the IR spectral data, as discussed 
previously.  A strong band of B-O-H deformation at 1002 and 929cm-1, that 
was easily recognised in the IR spectrum indicated the complexation of 
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phenylboronic acid, while also ruling out the possibility of triphenylboroxine 
formation. 
As no peaks were observed in the IR spectrum, in the region of 1080 to 
1090cm-1, which corresponds to the B-C stretching vibrations of 
phenylboronic acid, again this ruled out the possibility of phenylboronic 
anhydride formation. 
The crystal structure therefore clearly indicates the conformation of BOH in 
boronic acid, being syn-syn. Each 4,4’-dipyridyl ring is stacked parallel to the 
other 4,4’-dipyridyl ring, this could be as a result of the - interactions of the 
two aromatic rings.  
 
Figure 6.13: Crystal structure indicating the - interactions of the two aromatic rings 
As shown in the packing diagram, the hydrogen bonded dimers of 
phenylboronic acid did not appeared in the crystal structure due to the fact 
that the concentration of phenylboronic acid is half of the concentration of 
 192 
 
4,4’-dipyridyl. An extended network of H-bonds, among the assemblage of 
appropriate functional groups, supports the crystal structure. These findings 
are noteworthy as they are indicative of co-crystal properties. In this case, 
phenylboronic acid-pyridine OH---N supramolecular heterosynthon is formed. 
 
Figure 6.14: Supramolecular heterosynthon is formed within Twin4 TA-I-54-1b 
The co-crystal is a multiple component crystal in which all components are 
solid under ambient conditions, when used in their pure form; thus, in order to 
study the phenomena in more detail, different solvents were used 
(acetonitrile and methanol) during the multicomponent system formation 
(Figure 6.3 and 6.4). The solid products (TA-I-54-2a and TA-I-55-1a) were 
analysed using powder x-ray diffraction (PXRD) and infrared (IR) analysis. 
Peaks appeared at positions within the multicomponent system for TA-I-54-
1a (when acetone was used as the solvent – see Figure 6.3.), the results 
were similar to the multicomponent system of TA-55-1a (where acetonitrile 
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was used as the solvent) at angles 12.11, 13.25, 19.71, 20.23, 25.59, 26.53, 
29.41 and 37.14º, along the 2θ scale; however, new peaks also appeared at 
31.18 and 32.80º, along the 2θ scale. 
When comparing the multicomponent systems of TA-54-1a and TA-55-1a 
with the system of TA-I-54-2a (using methanol as the solvent), somewhat 
different PXRD patterns were shown (see Figure 6.3) and totally new peaks 
appeared in the region of 5.74, 7.43, 10.26, 14.33, 27.84, 30.81, 34.61, 
35.90, 36.40 and 37.05º, along the 2θ scale. These peaks were not linked to 
either the starting materials (phenylboronic acid, 4,4’-bipyridine) or the other 
multicomponent systems which had been formed using acetone and 
acetonitrile as solvents.  Thus, indicating that sample TA-I-54-2a had formed 
a multicomponent complex while also being indicative that hydrogen bonding 
is stronger. In addition, it is well known that methanol is a very polar solvent 
which also enhances the hydrogen bonding network. 
Wakabayashi et al. discuss solvent behaviour for these boroylpyridines as 
being dependent on their dipole moment; thus, greater polar solvents provide 
better stabilisation, due to greater solvation which favours the cyclic 
trimers107. 
Table 6.2: FT-IR assignments for samples TA-I-54-2a, TA-I-54-2b and TA-I-54-2c in 
MeOH 
Phenyl-
boronic 
acid 
cm
-1
 
4,4’-
bipyridine 
cm
-1
 
TAI-54-2a 
cm
-1
 
TAI-54-2B 
cm
-1
 
TAI-54-2c 
cm
-1
 
Assignment  
  (cm
-1
) 
[36] 
 3429 3436 3430 3436 O-H, stretch 
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3273, 
3081 
3024 
3025 
2927 
2895 
2919 3044 
2921 
3043, 
2921 
2852 
Csp2-H  stretch 
2419 2362 2361,2342 2360,2342 2361,2342  
1964 1942 1954 1932   
1894 1868     
 1654 1629 1619 1630 C=N stretch 
1604 1592 1601  1602 C=C stretch 
1572  1540 1531  C=C stretch 
 1540 
1532 
 1532 1540 C=C stretch 
1499 1488  1483  C=C stretch 
1439  1442 1447 1442,  
B-O asym. stretch 
 1409 1413 1400 1414 
1350  1396,1341 1376,1313 1394,1325 
1275, 
1191 
1218 1283,1211 
1193 
1211 1283,1211 
1196 
C-O  stretch 
1161 1123  1116 1149 C-O  stretch 
1095   1098 1085 C-O  stretch 
1072 1075 1069 1065,1041  C-O  stretch 
B-C stretch 
 
1029 1038 1023 1023 1069 
1007  1003  1030 
972 988 989 990  B-O sym. stretch 
923 850  845 864,832 Csp2- H bending 
803 803 802 801 814 B-O sym. stretch 
764 733  781,733 703 Boroxole ring 
697, 857  705 
669 
668 672 BO2 out- of -Plane 
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All major peaks of the IR spectra were assigned according to the 
literature98,99  for stoichiometric molar mass ratio products (TA-I-54-2a, TA-I-
54-2b and TA-I-54-2c) which indicates that all expected major functional 
groups were present upon successful co-crystallisation of the two reactants. 
The hydrogen bonded O-H groups were indicated at 3436, 3430, 3436cm-1 
respectively, confirming that the hydrogen bonded network formed a 
supramolecular structure, since neither starting material indicates the 
presence of boroxol ring formation (see Table 6.2). This IR spectrum of 
multicomponent complexes suggests the bidentate bridging nature of 4,4’-
bipyridine as well as the polymeric nature of the complex.  Although, the 
infrared spectrum of 4,4’-bipyridine exhibits fewer absorption bands 
compared with the spectrum of the ligand, on co-ordination they change from 
non-planarity to planarity. 
6.2.1.2  4-Phenylpyridine 
The spectral PXRD data shown in Figure 6.15 noticeably illustrates that the 
samples of TA-I-56-1a, TA-I-56-1b and TA-I-56-1c are neither of the starting 
materials 4-phenylpyridine nor phenylboronic acid. The appearance of new 
peaks in the 1:1 stoichiometric ratio produced (TA-I-56-1a) 8.02, 11, 23 and 
27º, along the 2θ scale, also supports this. The product obtained has also 
demonstrated that more peaks appeared in the multicomponent system 
which demonstrates less amorphous regions than the starting materials and 
therefore allocate it as a more discrete and well structured structure. 
The PXRD results undoubtedly showed that non-stoichiometric molar ratio 
multicomponents TA-I-56-1b(1:2 molar ratio) showed the indication of 
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multicomponent formation with existence of 4-phenylpyridine. However, TA-I-
56-1c (2:1molar ratio) showed peak positions and peak intensities that 
differed from the reference patterns (TA-I-56-1a) and starting material but 
concluding that multicomponent formation had taken place within system(see 
Figure 6.15 and 6.16). These results support the concepts drawn by the 
research conducted by Peddireddi et al., about the optimisation of - 
interactions in these supramolecular synthons74. In this multicomponent 
formation, the trigonal planar boron can act as a Lewis acid, the addition of a 
Lewis base 4-phenylpyridine may lead to the formation of 1:1 adducts. In the 
adduct, a new B-N bond is formed and boron adopts a tetrahedral 
environment. The base donates electron density to the tetrahedral boron, 
which in the Lewis structure carries a formal negative charge (nitrogen has 
the formal positive charge). 
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phenylboronic acid :4-phenylpyridine
TA-1-56-2c 2:1 Me2CO
TA-1-56-2b 1:2 Me2CO
TA-1-56-2a 1:1 Me2CO
TA-1-56-3c 2:1 MeCN
TA-1-56-3b 1:2 MeCN
TA-1-56-3a 1:1 MeCN
TA-1-56-1c 2:1 MeOH
TA-1-56-1b 1:2 MeOH
TA-1-56-1a 1:1 MeOH
Phenylboronic acid (PHBORA)
Tai_56_2c_0m ( single crystal)
4-phenylpyriden (exptl pattern)
 
Figure 6.15: X-ray powder diffraction patterns of 4-phenylpyridine and phenylboronic acid, and products of crystallisation with a range of solvents 
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phenylboronic acid (PBORA)
0.67
0.50
0.33
1.00
0.00
0.33
0.50
0.67
0.00
1.00
MeOH MeCN Me2CO
Xphenylboronic acid X4-phenylpyridine
4-phenylpyridine (exptl pattern)
{[(PhBO)3(4-Phpy)]4(4-Phpy)} 
(TA-1-56-2c) 
[New phase 1]
Graphical representation of crystalline phases identified from co-crystallisations of  
phenylboronic acid : 4-phenylpyridine
New Phase 2
 
Figure 6.16: Representation of crystalline phases identified from co-crystallisations of 4-phenylpyridine and phenylboronic acid 
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Peddireddi et al. concluded that -stacking can be engineered into co-
crystalline condensed ladders using boronic acids74,108.  In their studies they 
used the system of 4-methoxyphenylboronic acid with 4,4’-bpe producing the 
1D infinite ladder (4-methoxyphenylboronic acid, 4,4’-bpe). The structure 
contained both syn and anti conformations of the hydroxyl groups, with O-H--
-O hydrogen bonds being nearest to the neighbour boronic acids. The rungs 
were sustained with O-H---N type hydrogen bonds (see Figure 6.17). 
 
 
 
Figure 6.17: The self-assembly of (1,4-di[bis(4-hydroxyphenyl)methyl]benzene).(4,4-
bpy) into a 1D ladder
108 
Inspired by the work of Peddireddi et al.74, and observing the interaction of 
one N atom in the supramolecular synthons, the predicted structure of this 
multicomponent complex, using 1:1 ratio of the starting material can be 
presented below in Figures 6.18a and 6.18b. 
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Figure 6.18a: Predicted molecular structures of phenyl boronic acid with 4-
phenylpyriden 1:1 ratio  
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Figure 6.18b: Predicted molecular  structures of phenyl boronic acid with 4-
phenylpyriden 1:1 ratio 
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As discussed earlier, self-assembly of 4,4’-bpy with phenylboronic acid 
produced a finite three component assembly.  The assemblies contained only 
syn hydroxyl conformations and were held together via two O-H---N bonds. 
The finite structures were subsequently linked into molecular tapes through 
weak C-H---N forces; however, the hydrogen bonded network of 4-
phenylpyridine with phenylboronic acid is able to produce 1D infinite ladders 
(phenylboronic acid, 4-phenylpyridine) of H2O. As the solvents used to form 
the multicomponent systems were not dried prior to use, the moisture within 
the solvents also participated in the hydrogen bonded assemblies. The 
structure, composed of only syn hydroxyl groups, was propagated through O-
H---O hydrogen bonds.  Thus, water molecules may also have participated in 
forming the rung of the ladder (see Figure 6.19). The fortuitous incorporation 
of the water molecule addresses a further need concerning the 
ability/requirement to reliably construct ladders using a boronic acid-based 
synthon. 
 
Figure 6.19: Ladder structures based on (phenylboronic acid).(4,4’-bpe).H2O
74 
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These initial conclusions have been confirmed by the FT-IR data attained; to 
illustrate, the overlaid spectra (shown in Appendix D) clearly shows the 
differences in peak appearance between TA-I-56-1a, TA-I-56-1b and TA-I-
56-1c (see Table 6.3) for their starting materials.  
Table 6.3: FT-IR assignments for samples TA-I-56-1a, TA-I-56-1b and TA-I-56-1c in 
Me2CO 
Phenyl 
boronic 
acid 
cm
-1
 
4-phenyl 
pyridine 
cm
-1
 
TAI-56-1a 
cm
-1
 
TAI-56-1B 
cm
-1
 
TAI-56-1c 
cm
-1
 
Assignment  
  (cm
-1
) 
 
 3436 3847, 3662 3446 3638 O-H, stretch 
3273 
3081 
3024 
3058 3074 3075 
3056 
3032 
3074 Csp2-H  stretch 
2419      
1964 1958   1962  
1894      
  1710  1722  
 1667 1665 1629 1665,1630 C=N stretch 
1604  1603, 1600 1601 C=C stretch 
1572 1587 1573   C=C stretch 
 1543 1551,1513 1558, 
1543 
1551,1536 
1530,1513 
C=C stretch 
1499 1482 1486 1482 1485, C=C stretch 
1439 1446 1446,1426 1444 1441,1426  
B-O asym. stretch  1409 1402 1408 1402 
1350 1340,1333 1330,1281 1330,1281 1303,1281 
1275, 
1191 
1232 
1189 
1256 
1216 
1256 
1216 
1256 
1216 
C-O  stretch 
1161 1162 1200,1175 1199,1124 1200,1124 C-O  stretch 
1095 1103 1124   C-O  stretch 
1072 1072 1084 1084 1085 C-O  stretch 
B-C stretch 
 
1029 1041 1069,1029 1070,1042 1069 
1007 1002 1001 1001 1001 
972 986 982 982 982 B-O sym. stretch 
923 917 851 829 817,780 Csp2- H bending 
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Although the literature review clearly suggests the well-known 
multicomponent complexes of phenylboronic acid for 1:1 adducts, it also 
indicated that the solvents do not generally participate directly in the 
hydrogen bonding assemblies which lead to multicomponent system 
formation97,109,45,110.  To substantiate this proposal, this contemporary 
research study will now be further expanded in order to categorise the 
potentially stable multicomponent  adducts of the above system in order to 
study the effect of hydrogen bonding in these complexes through the use of 
different solvents and different molar mass ratios.  Interesting aspects of a 
computational study conducted by Kua et al.  anticipated that the “formation 
of 1:2 adducts of arylboroxine*pyridine are less favourable enthalpically as 
compared to 1:1 adducts”111. In order to assess this piece of evidence 
further, the multicomponents adduct were also primed with molar mass ratios 
of 1:2 for: TA-I-56-2b where acetone was used as the solvent, TA-I-56-3b 
where acetonitrile was used as the solvent, and, for: 2:1 for TA-I-56-2c and 
TA-I-56-3c – these samples were then analysed using the PXRD and IR 
techniques (Figure 6.15). 
Wakabayashi et al. studied the chemistry of borylpyridines by explaining how 
changes by structural modification conjecture in the self-assembling attribute 
occurred107. Their aim was to study the planned synthesis of more 
sophisticated systems using 3-[4’-(diethylboryl)phenyl]pyridine (3) and 3-[3’-
803 830 846,816  810 B-O sym. stretch 
764 761 780,746 761,764 768 Boroxole ring 
697, 857 740 729,702, 
691 
729,702 
688 
746,729, 
702,691 
BO2 out- of -Plane 
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(diethylboryl)phenyl]pyridine (4), having a spacer, p and m-phenylene unit, 
respectively, which then became three-dimensional supramolecules107. They 
concluded that three provided an equilibrium mixture of oligomers along with 
cyclic trimer, as a foremost constituent by means of intermolecular boron-
nitrogen co-ordination bonds. The current research pattern of pyridine shows 
somewhat similar behaviours to the work of Wakabayashi et al.  The results 
suggested that scuttling of component molecules involved the breaking of the 
intermolecular B-N coordination112,113 which can be satisfactorily explained by 
the reduced Lewis acidity of the boron atom in three and four, because the 
boron atoms in three and four were bonded to the -electron-donating 
benzene ring but not directly to the pyridine one. 
Although the samples of TA-I-56-1a, 1b and 1c were prepared using 
methanol as the solvent, they showed successful multicomponent formation. 
To study the effect of the solvent on the multicomponent system when using 
the same starting materials but different solvents, acetone (TA-I-56-2a, 2b 
and 2c) and acetonitrile (TA-I-3a, 3b and 3c) were employed. Although all of 
the samples were synthesised in the same way, they differed slightly in their 
physical appearance.  
For this reason, the IR spectra for TA-I-56-1a, TA-I-56-2a and TA-I-56-3a will 
now be compared in order to establish whether they are indeed the same.  
Irrespective of their slight differences in their physical appearance, the results 
obtained clearly indicate (see Table 6.3 and 6.4) that identical peaks in the IR 
spectrum were identified; thus, indicating that despite the visual appearance, 
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the compounds appeared to be identical when FT-IR analysis was 
performed. 
Table 6.4: FT-IR assignments for sample TA-I-56-2a, TA-I-56-2b and TA-I-56-2c in 
Me2CO 
Phenyl 
boronic 
acid 
cm
-1
 
4-phenyl 
pyridine 
cm
-1
 
TAI-56-2a 
cm
-1
 
TAI-56-2B 
cm
-1
 
TAI-56-2c 
cm
-1
 
Assignment  
  (cm
-1
) 
 3436  3436 3436 O-H, stretch 
3273, 
3081 
3024 
3058 3074 
3053 
3032 
2360 
2342 
3074 
3053 
3032 
Csp2-H  stretch 
2419  2360,2342  2360,2342  
1964 1958 1962  1962  
1894  1899  1899  
 1667  1616 1630 C=N stretch 
1604  1603 1601 1601 C=C stretch 
1572 1587 1573  1573 C=C stretch 
 1543 1551 1550 1551 C=C stretch 
1499 1482 1486  1486 C=C stretch 
1439 1446 1426 1444 1444  
B-O asym. stretch 
 1409 1403 1407 1400 
1350 1340,1333 1330,1256 1345,1328 1330,1280 
1275, 
1191 
1232 
1189 
1216 1215 1256 
1216 
C-O  stretch 
1161 1162 1200,1175  1200,1175 C-O  stretch 
1095 1103 1124 1123 1124 C-O  stretch 
1072 1072 1084  1084 C-O  stretch 
B-C stretch 
 
1029 1041 1069 1020 1069 
1007 1002  1003  
972 986    B-O sym. stretch 
923 917    Csp2- H bending 
803 830 846,816 826 846,816 B-O sym. stretch 
764 761 780 782,759 709, Boroxole ring 
697, 857 740 675 710,667 675 BO2 out- of -Plane 
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Figure 6.20: Comparative FT-IR spectra for TA-I-56-3a, 3b and 3c, in ratios 1:1, 1:2 and 
2:1 in MeCN 
6.3  X-Ray Structure Analysis 
6.3.1 Single Crystal Analysis of {[(PhBO)3(4-Phpy)]4(4-Phpy)} (TA-1-56-2c)  
The crystal structure of the co-crystal of phenylboronic acid and 4-
phenylpyridine (t_a), for TA_I_56_2c with a ratio of 1:1 in acetone, displayed 
the space group as P21/c, showing the existence of two molecules of 2,4,6-
triphenyl-1,3,5,2,4,6-trioxatriborinane (cyclotrimeric anhydride of 
phenylboronic acid) and three molecules of 4-phenylpyridine. The crystal 
structure unambiguously exhibited two tetracoordinated adducts of 2,4,6-
triphenyl-1,3,5,2,4,6-trioxatriborinane with 4-phenylpyridine molecules. 
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Figure 6.21: Crystal packing of two molecules of cyclotrimeric anhydride of 
phenylboronic acid and three molecules of 4-phenylpyridine 
The crystal structure of the sample revealed that in each, 2,4,6-triphenyl-
1,3,5,2,4,6-trioxatriborinane was formed by self-condensation of three 
triphenylboronic acid molecules, one boron atom adopted a tetrahedral 
configuration with the 4-phenylpyridine nitrogen atom coordinated; the other 
two boron centres adopted a trigonal planar configuration with the other 4-
phenylpyridine left unbound.  
The boroxine ring was in coordination with 4-phenylpyridine in the 
tetracoordinated adduct, a strong Nδ+–Bδ–dipole that points away from the 
plane of the phenyl ring which may be induced by this B3O3 ring interaction 
which has almost a planar geometry. The two CBO2  planes were fairly 
coplanar with two of the benzene rings, but one of the benzenes was out of 
plane due to the formation of the tetracoordinated adduct. No dimers of 
phenylboronic acid were seen. 
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In packing each of the hydrogen bonded units, the tetracoordinated 2,4,6-
triphenyl-1,3,5,2,4,6-trioxatriborinane and 4-phenylpyridine were bound 
through hydrogen bonds. The 4-phenylpyridine interacted through phenyl 
rings, this is indicative of - interactions; in addition, the 4-phenylpyridine 
molecule was also shown as interacting with another molecule of 
cyclotrimeric phenyl boroxine through a pair of N with the ring carbons. 
 
Figure 6.22: The supramolecular of phenylboronic acid: 4-phenylpyriden showing 
cascade of ladders across horizontal and vertical axes 
Due to the formation of 2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinane and its 
property to form hydrogen bonded supramolecular assemblies, an extended 
network of H-bonds among the assemblage of appropriate functional groups 
was identified as supporting the crystal structure. These findings indicate 
noteworthy co-crystal properties. In this case, the 2,4,6-triphenyl-1,3,5,2,4,6-
trioxatriborinane-4-phenylpyridine supramolecular heterosynthon was formed 
along with an extended network of H-bonds among the assemblage of 
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appropriate functional groups. The supramolecular structure appeared like a 
cascade of ladders across horizontal and vertical axes (see Figure 6.22). 
The crystal structure is also in agreement with the IR spectral analysis, as 
discussed previously. Absence of a band of B-O-H deformation at 1002 and 
929cm-1, in the IR spectrum indicates a triphenylboroxine formation which 
rules out the possibility of phenylboronic acid. Furthermore, the vibrational 
analysis also showed the B-C stretching vibration, a doublet was displayed at 
1104 and 1087cm-1 which corresponds with the presence of 2,4,6-triphenyl-
1,3,5,2,4,6-trioxatriborinane and rules out the possibility of phenylboronic 
acid.   
 
Figure 6.23: the formation of 2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinane 
tetracoordinate adduct within co-crystal TA-I-56-2c- 
Some characteristic modes in the boroxine ring in terms of the stretching of 
the boron and oxygen atoms were observed. The symmetric stretching 
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frequency of the boron atoms of the main ring were observed at 1280.3 and 
1468cm-1 and the symmetric stretching frequency of the oxygen atoms of the 
main ring was observed at 824.5cm-1. These results indicate the formation of 
2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinane tetracoordinate adduct. The 
crystal data and experimental information for sample TA-I-56-2c-0m is given 
in Table 2.21 and Table 2.13 
The x-ray structure analysis of the boroxines gives evidence for the existence 
of a -ring system in 2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinanes. The 
structural data and geometric parameters (B-O bond lengths and O-B-O 
bond angles) of the boroxine derivatives are shown in Table 2.21  In addition, 
there were increases in the bond angles toward 120º, since the phenyl ring 
on the boron pulls the lone pair of oxygen electrons toward boron; thus, 
increasing the molecular aromaticity. 
 
Figure 6.24: Crystal packing showing the symmetric stretching 
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From the table of geometric parameters (Table 2.21), it was also observed 
that the B–O bond of sample TA-I-56-2c increased to around 1.43–1.48 Å, 
which is as much as 0.10 Å longer than the corresponding bonds in 2,4,6-
triphenyl-1,3,5,2,4,6-trioxatriborinanes. As previously discussed, this 
supports the formation of tetracoordinated boroxine adducts. Longer bond 
length of the tetracoordinate adduct shows lesser bond strength than 2,4,6-
triphenyl-1,3,5,2,4,6-trioxatriborinanes whereby the bond strength originates 
from the conjugation between the lone pairs on the oxygen’s and boron’s 
empty orbital; as a result, B–O linkage holds a partial double bond character.  
Operations: Import
TA-I-56-2c - File: TA-I-56-2c.raw - Type: 2Th/Th locked - Start: 5.000 ° - End: 40.000 ° - Step: 0.020 ° - Step time: 2. s - Temp.: 25 °C (Room) - Time Started: 13 s - 2-Theta: 5.000 ° - Theta: 2.500 ° - Chi: 0.00 ° - Phi: 
Operations: Import
File: tai_56_2c_0m.raw - Type: 2Th/Th locked - Start: 5.000 ° - End: 50.000 ° - Step: 0.020 ° - Step time: 0.1 s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-Theta: 5.000 ° - Theta: 2.500 ° - Chi: 0.00 ° - Phi: 0.00 ° - X:
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Figure 6.25: Overlay pattern of PXRD of T-I-56-2c and its single crystal  
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6.3.2 Single Crystal Analysis of {[PhB(OH)2][4,4’-bipy]} (TA-1-54-2a) 
The co-crystal structure of phenylboronic acid and 4-4’dipyridyl (t_a) for TA-I-
54-2a, in ratio 1:1 in methanol as the solvent, displayed the space group as 
P21/c which showed the formation of triphenylboroxine. The structure-
directing potential of boronic acid has led to the development of a self-
organisation in the form of tetracoordinated adduct of 2,4,6-triphenyl-
1,3,5,2,4,6-trioxatriborinane. It is clear within the crystal structure that boron 
(of boroxines) coordinates with 4,4’bipyridyl (basic molecule) to complete its 
octet; furthermore, it also exists as a stable tetracoordinated adduct.    
 
Figure 6.26:  Self-organisation of boronic acid to form tetra-coordinated adduct of 
2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinane 
In the tetracoordinated adduct, where a boroxine ring is coordinating with 4-
4’dipyridyl, a strong Nδ+–Bδ– dipole, that points away from the plane of the 
phenyl ring, may be induced by this interaction. The B–O bond of 
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tetracoordinated 2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinane is increased to 
about 1.44-1.48 Å, which is as much as 0.10 Å longer than the corresponding 
bonds in tricoordinated boroxines.  As previously discussed, this indicates the 
considerable strength of the B–O bonds in trigonal boronic acid derivatives. 
This bond strength originates from the conjugation between the lone pairs on 
the oxygen’s and boron’s empty orbital; as a result, the B–O linkage holds a 
partial double bond character.  The B3O3 ring has almost planar geometry as 
the two CBO2 planes are fairly coplanar with two of the benzene rings. No 
dimers were seen as B---O---H bonds have syn-anti configuration. Each non-
dimeric phenylboronic acid is also linked with the hydrogen bonds 4-
4’dipyridyl molecules which are incorporated into an array of layers. 
In packing one hydrogen bonded unit, it consists of a tetracoordinated adduct 
of 2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinane and 4-4’dipyridyl and other 
phenylboronic acid molecules which are bound through hydrogen bonds. The 
non-dimeric phenylboronic acid molecule is bound to the molecule of 4-
4’dipyridyl through O–H---N. The phenylboronic acid molecule is bound to the 
triphenylboroxine ring oxygen through a pair of O–H(phenylboronic acid) ---O(boroxine) 
hydrogen bonds. Thus, the 4-4’dipyridyl molecule also showed interactions to 
another molecule of phenylboronic acid, through a pair of N, with the ring 
carbons (Figure 6.27) 
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Figure 6.27: Interaction of phenylboronic acid molecule to the triphenylboroxine ring. 
Due to the formation of the tetracoordinated adduct of 2,4,6-triphenyl-
1,3,5,2,4,6-trioxatriborinane and its property which allows it to form hydrogen 
bonded supramolecular assemblies, involving hydrogen bonds between BO2, 
B(OH)2 groups and the 4-4’dipyridyl nitrogens. An extended network of H-
bonds among the assemblage of appropriate functional groups supports the 
crystal structure. These findings indicate noteworthy co-crystal properties. 
This supramolecular heterosynthon is a two-point recognition event as there 
are two ranges corresponding to O−H---O and O-H---N interactions. In this 
case, the supramolecular synthons are entirely different, triphenylboroxine-
4,4’dipyridyl supramolecular heterosynthon is formed along with an extended 
network of H-bonds among the assemblage of appropriate functional groups. 
The supramolecular structure appears like two different ladders running 
across horizontal and vertical axes (see Figure 6.28). 
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Figure 6.28: Supramolecular heterosynthon showing extended network of H-bonds 
corresponding to O−H---O and O-H---N interactions  
The crystal structure is also in agreement with the IR spectral analysis. The 
vibrational analysis showed that the B-C stretching vibration displayed a 
doublet at 1104 and 1087 cm-1 which corresponds to the presence of 
triphenylboroxine. The band is weaker in phenylboronic acid with a 
disappearance of peaks at 1197 and 929 cm-1 which corresponds to B-OH in 
the spectra of phenylboronic anhydride (triphenylboroxine) – this further 
supports this work.  Some characteristic modes for boroxine ring stretching, 
of boron and oxygen atoms, were observed. The symmetric stretching 
frequency of the boron atoms of the main ring were observed at 1281 and 
1467cm-1.  The symmetric stretching frequency of the oxygen atoms of the 
main ring were observed at 824.5 cm-1. These results indicate the formation 
of the tetracoordinate adduct of 2,4,6-triphenyl-1,3,5,2,4,6-trioxatriborinane.  
It was observed that the B-O bond length (1.43-1.47 Å) remained in between 
the B-O single bond length (1.55 Å) and the B-O double bond (1.33 Å) of 
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boron, thereby enhancing the aromaticity of the molecule. Generally, the 
boron atoms in boroxines possess a higher Lewis acidity. Nevertheless, the 
x-ray structure analysis of boroxines provided evidence for the existence of a 
-ring system.  The structural data (B-O bond lengths and O-B-O bond 
angles) of the boroxine derivatives are also shown in the table. The bond 
angles increased toward 120º as the phenyl ring on boron pulls the lone pair 
electrons of the oxygen toward boron; thus resulting in an increase in 
molecular aromaticity.  
6.4   Discussion 
The study of multicomponent systems of phenylboronic acid and 4,4’-
dipyridine and 4-phenylpyridine has been investigated using a mixture of both 
stoichiometrics and non-stoichiometrics, through the use of PXRD, IR and 
NMR. Despite the use of different solvents for the appearance of 
multicomponent systems, the infrared absorption spectroscopy established a 
number of imperative attributes that are linked specifically to the identification 
of strong O-H stretching which is involved with the formation of hydrogen 
bonding networks and the existence of all expected functional groups.  For 
the phenylboronic acid and 4,4’-bipyridine multicomponent systems, boroxine 
ring formation was observed in the non-stoichiometric 1:2 products. As the 
solvents were not dried prior to their use, it is believed that the water 
molecule also contributed to the hydrogen bonded network. 
The results obtained in this research study support the established work of 
Kua and Lovine111.  In particular, the trimerisation of phenylboronic acids to 
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form boroxine rings is thermodynamically unfavourable, however the 
research also revealed that the formation of stable 1:1 adducts in the 
presence of pyridine is highly favourable, as compared to the 1:2 adducts. 
These two observations also support and agree with the experimental results 
presented.  
In addition, this research identified that the substitution of -electron-
withdrawing groups in the para-position of the phenyl ring further destabilised 
the trimer with respect to its monomers; furthermore, the opposite was 
observed for the -electron donors.  To form the adduct, it was found that net 
electron withdrawing and electron-donating ability of the para-substituents is 
important in either stabilising or destabilising the boron that binds the amine. 
This research also confirms that hydrogen bonding and – stacking play an 
important role in crystal packing, molecular recognition and the stability of the 
inclusion complex; however, it should be noted that they are weaker than the 
covalent force45.  
Although this current study focused predominantly on the pyridine ligands 
(4,4’-bipyridine and 4-phenylpyridine) with phenylboronic acid, it was 
observed that 4,4’-bipyridine (bpy) resulted in self-assembly because of its 
bifunctional and bidentate nature which was more vigilant in forming strong 
hydrogen bonded networks as compared to single N carrying 
4,phenylpyridine where the phenyl group acted to block the functional group 
for hydrogen bonded networks. 
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However, ultimately, it is concluded that phenylboronic acid can organise into  
fascinating topological architectures in order to form co-crystals with nitrogen 
carrying ligands (4,4’-bipyridine and 4-phenylpyridine). 
 219 
 
 
 
 
 
 
 
 
 
Chapter 7 
 
 
 220 
 
7.0 Conclusions and Further Work 
7.1 Conclusions  
The main aim of this research was to investigate the multicomponent neutral 
molecular complexes that form a crystalline solid, as these are intrinsically 
less prone to polymorphism than individual components. For this purpose, a 
systematic approach for designing and rationalising multicomponents was 
made by firstly introducing the concept of supramolecular synthesis, whereby 
intermolecular interactions were acknowledged as being reliably able to bring 
together two distinct molecules in a process that is parallel to organic 
covalent synthesis. The multicomponent (co-crystal) formers in this study 
were phenylboronic acid, 4,4’-bipyridine, 4-phenylpyridine, nicotinamide, 
isonicotinamide, L/DL-malic acid and L/DL-phenyllactic acid that were used in 
different molar ratios of the starting material and the different solvents. The 
literature publicised demonstrated that isonicotinamide and nicotinamide 
were polymorphic in their unimolecular states114,115, but they had N carrying 
molecules that were dimorphic in the following combinations: phenylboronic 
acid-4,4’-dipyridine;  phenylboronic acid-4-phenylpyridine; phenylboronic 
acid-nicotinamide; phenylboronic acid-isonicotinamide; L-malic acid-
nicotinamide; DL-malic acid-nicotinamide; L-phenyllactic  acid-nicotinamide; 
and, DL-phenyllactic acid-isonicotinamide. These co-crystals were 
assembled primarily using carboxylic acid and phenol hydrogen bond donors 
which encouraged hydrogen to bond to the pyridine N or amide carbonyl 
acceptors. Conformational differences within the nicotinamide and 
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isonicotinamide molecules led to different packing arrangements that used 
the same combination of hydrogen bonded interactions.  
The research also exploited chiral dicarboxylic acid, racemic mixtures and 
amines so that they could be used as building blocks to constrain the acid-
base interactions and encourage chain formation; the results of which were 
assessed to determine the effect of using chiral versus racemic building 
blocks to prepare a suitable crystalline form. For this purpose, powder 
diffraction data was used to determine the crystal structure. Similarly FT-IR 
analysis was conducted on the co-crystal systems to determine which 
vibrational modes were most affected by the formation and assembly of the 
supramolecular synthons, and to determine the magnitude of perturbation in 
the vibrational frequencies of the involved modes.  
The HNMR study provided a sound overview about the stoichiometric ratios 
and the structure of the molecule.  A slow evaporation method was used to 
maximise and grow enough crystal to allow for further study of the crystal 
structure by single crystal analysis. Most of the multicomponents showed 
new phase formations which were different from their starting material. 
This study also identified hydrogen bonding and – stacking as playing 
important roles in crystal packing, molecular recognition and the stability of 
the inclusion complex; although, it is noteworthy that these forces are weaker 
than the covalent force.  The multicomponent complex of phenylboronic acid 
and pyridine ligands (4,4’-bipyridine and 4-phenylpyridine) showed evidence 
of new phase formation.  The results also revealed the self-assembly of 4,4’-
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bipyridine (bpy) because of its bifunctional and bidentate nature which was 
clearly more vigilant in forming strong hydrogen bonded networks when 
compared to single N carrying 4-phenylpyridine. The co-crystal of 
phenylboronic acid and 4,4’-dipyridyl TA-I-54-2a (ratio 1:1) in the methanol 
solvent displayed the space group as P21/c, this illustrated that the formation 
of triphenylboroxine was an important aspect of this research as it studied the 
dynamic covalent chemistry. The phenylboronic acid molecule was bound to 
the triphenylboroxine ring oxygen through a pair of O–H(phenylboronic acid) ---
O(boroxine) hydrogen bonds. The 4,4’-dipyridyl molecule also demonstrated 
interactions to another molecule of phenylboronic acid through a pair of N, 
with the ring carbons.  However the supramolecular heterosynthon showed 
O-H---O and O-H---N interactions. With regards to this, the supramolecular 
structure visually resembled two different ladders running across horizontal 
and vertical axes.  
The crystal structure of the same starting material for the different molar ratio 
of 2:1 in acetone as the solvent (TA-I-54-1c) showed the space group as C2. 
In this case, the conformation of BOH in boronic acid was observed as syn-
syn; to illustrate, each 4,4’-dipyridyl ring was stacked parallel to the other 
4,4’-dipyridyl ring – this may have been as a result of the - interactions of 
the two aromatic rings.  
The crystal structure of the co-crystal of phenylboronic acid and 4-
phenylpyridine (TA_I-56-2c) in ratio 1:1 in the acetone solution displayed the 
space group as P21/c. The 4-phenylpyridine interacted through phenyl rings 
indicating - interactions; the 4-phenylpyridine molecule also demonstrated 
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interactions with another molecule of cyclotrimeric phenylboroxine through a 
pair of N, with the ring carbons. 
The co-crystal of phenylboronic acid and nicotinamide (TA-I-20-3a) displayed 
the geometry of the crystal as triclinic in the form of supramolecular 
assemblies which involved hydrogen bonds between the B(OH)2 groups and 
the nicotinamide nitrogens and carboxamide group. Each dimeric 
phenylboronic acid ensemble was linked with the hydrogen bonds to the 
other nicotinamide molecules which provided an infinite array of layers. The 
phenylboronic acid molecule was bound to the two distinct molecules of 
nicotinamide through O–H---N–H(Nicotinamide).  In addition, the phenylboronic 
acid molecule was bound to the other molecule of phenylboronic acid through 
a pair of O–H---O hydrogen bonds. 
The system under investigation, using nicotinamide and isonicotinamide with 
DL- and L-malic acid demonstrated that usual carboxylic acid to amide 
hydrogen bonding subsisted – this was further alleviated by the additional 
hydrogen bonding from the amide-amide and carboxylic-carboxylic acid. The 
single crystal analysis of the DL-malic acid and nicotinamide (TA-1-17-3b) 
showed colourless blocks in the orthorhombic space group of Pca21, where 
the nicotinamide essentially bridged the two malic acids of the dimer which 
formed a carboxylate COH to pyridine nitrogen and amide nitrogen to the 
alcohol OH of the second malic acid. This complex network of interconnected 
dimer units was stabilised by aromatic - interactions between the 
nicotinamide – this was in addition to the hydrogen bonded systems. 
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The crystal structure of the co-crystal of L-phenyllactic acid and 
isonicotinamide (TA-I-52-1a) displayed the geometry of the crystal as triclinic. 
The packing revealed that the primary intermolecular interaction was the O-
H---N hydrogen bond between the acid and the N-heterocyclic nitrogen atom 
as well as the amide-amide dimer and the OH---OH interaction; these were 
further stabilised with intermolecular C−H---O and C−H---  interactions. The 
supramolecular heterosynthon corresponded to O−H---N (heteroaryl) and 
N−H---O=C interactions, as well as O-H---O-H interactions.  
The crystal structure of co-crystal DL-phenyllactic acid and isonicotinamide 
(TA-I-31-3c) displayed the geometry of the crystal as triclinic, where the 
isonicotinamide molecule was bound to the other molecule of isonicotinamide  
through C=O(Isonicotinamide)---N–H(isonicotinamide ′)  and N–H---C=O.  The 
isonicotinamide molecule was bound to one molecule of DL-phenyllactic acid 
through N(pyridine ring )---O–Hcarboxyl hydrogen bonds. The nicotinamide molecule 
also showed interactions to another molecule of DL-phenyllactic acid through 
a pair of N(pyridine ring), with the ring carbons.  
The use of different solvents (acetone, acetonitrile and methanol) did not 
indicate that the solvent molecules were directly involved in the bonding 
pattern of multicomponent complexes.  However, slight changes in the PXRD 
pattern could be explained by the consideration of the competition of the 
solvent-solute interactions and the discrete acid-amide interactions which 
suggests that solvent selectivity may be worth considering; consequently, the 
detail provided by this research with regards to the solubility is likely to be of 
value with regards to explicit solvent-solute interactions which could be 
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considered to explain this difference. These results also indicated that 
solvents could play an important role in the selective growth of a desired 
molecular complex. Furthermore, this research confirmed that carboxylic acid 
and boronic acid could develop fascinating topological architectures by the 
formation of co-crystals with nitrogen carrying ligands (pyridine and amides). 
Consequently, it is possible to conclude, from the above discussions, that all 
of the systems under investigation outlined the supramolecular structure 
where chiral and racemic forms of acids resulted in the formation of adducts 
for interactions with the given diamines. The overall stoichiometry of the 
supramolecular structures were very much similar, however they did exhibit 
different spacing groups. 
7.2  Further Work 
Despite the co-crystallisation techniques providing effective means to 
discover new solid state forms, further challenging aspects still need 
investigation with regards to the development of efficient co-crystal screening 
technologies; in particular: 
Solid based techniques, such as neat grinding and liquid assisted grinding, 
should be applied to demonstrate a higher selectivity, as compared to solvent 
based approaches which would reveal the co-crystallisation potential of 
multiple molecular species. 
The experimental results could be further compared with the theoretical 
calculation using a computational method. 
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The use of 13CNMR analysis could provide further evidence with regards to 
crystal structures. 
The unambiguous characterisation by 2D NMR could be completed in order 
to provide verification of the crystal structure. 
Standard technology, such as DSC and thermogravimetric analysis, could 
help to “unveil” the relative stability of new solid state forms when compared 
to their individual component. 
Aromatic solvents, such as benzene and toluene, could be used to 
investigate the - interaction of co-crystals with the solvent. 
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Table AA 3.1: PXRD data for samples TA-I-17-2a (1:1), TA-I-17-2b (1:2), TA-I-17-2c (2:1), in methanol 
DL-Malic acid Iso stnd Iso EHOWIH Iso EHOWIH01 Iso EHOWIH02 TA-I-17-2a TA-I-17-2b TA-I-17-2c 
2-Theta ° 2-Theta° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
 
17.842 
     
8.567 
     
10.08 
 
10.48 
     
13.41 
 
13.81 
    
11.677 
   14.25 
   
14.625 
   
    
16.09 16.05 16.51 16.34 
    
16.52 16.53 16.92 16.97 
 
17.84 17.859 17.84 
 
17.25 
 
17.67 
 
18.85 18.748 18.76 18.63 18.24 18.70 18.58 
18.95 
    
18.68 18.94 
 
 
19.41 19.34 19.34 19.14 19.85 
 
19.07 
20.52 
 
20.48 20.47 20.14 20.32 
 
20.31 
 238 
 
 
20.87 
 
20.99 20.75 
   
    
20.98 
   21.27 
 
21.03 
 
21.94 21.26 
 
21.63 
    
22.21 
   23.92 23.449 23.49 23.48 23.46 
 
23.14 23.72 
 
24.454 24.38 24.39 24.60 24.16 24.73 24.50 
24.91 
    
24.83 
  
    
25.40 
 
25.279 25.011 
 
25.94 
  
25.79 
  
25.223 
  
26.09 26.06 
 
26.33 
  
 
26.64 26.93 26.89 
  
26.787 26.64 
27.09 
    
27.11 27.12 27.44 
27.92 
    
27.72 
  28.33 28.16 28.06 28.07 28.99 28.66 
 
28.09 
  
29.94 29.92 29.78 
 
29.734 29.07 
 239 
 
   
30.83 30.38 30.06 
 
30.38 
 
30.00 30.88 
 
30.75 30.99 
  
 
30.95 
      
 
31.29 31.19 31.16 31.40 
 
31.343 31.38 
32.91 32.46 32.48 32.45 32.53 32.59 32.439 32.23 
33.11 33.33 33.26 33.48 33.49 
 
33.304 33.38 
 
33.89 33.51 33.86 
   
33.84 
  
33.86 
     
    
34.99 
   
 
35.41 35.66 35.61 35.52 
   36.01 36.10 36.15 36.15 
 
36.32 
  
 
36.54 36.56 36.56 
    37.44 
 
37.83 
 
37.28 37.14 37.63 37.13 
37.80 
      
37.64 
 
38.15 38.04 38.04 38.90 38.06 
  
 240 
 
 
38.80 
    
38.85 
 
 
39.32 39.06 39.00 
    
  
39.33 39.33 
    40.48 
   
40.50 
   41.18 41.38 41.28 41.30 
    
  
41.70 
     42.19 42.24 42.04 
     
  
42.81 42.75 
    43.64 43.45 43.97 43.88 
    44.48 44.93 44.90 44.91 
    45.37 
 
45.46 
 
45.32 
   45.37 
       
 
46.81 46.15 
     
 
47.78 47.14 47.74 
    
  
47.75 
     
 241 
 
  
48.09 48.05 
    
  
48.53 
     
 
49.493 49.46 
     
 242 
 
Table AA 3.2: PXRD data for samples TA-I-18-1a (1:1), TA-I-18-1b (1:2), TA-I-18-1c (2:1), in acetone  
DL-Malic acid Iso stnd Iso EHOWIH Iso EHOWIH01 Iso EHOWIH02 TA-I-18-1a TA-I-18-1b TA-I-18-1c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
       
 
7.319 
      
 
8.796 
      
  
10.45 
    11.677 
        13.901 
 
13.8 
14.254    14.625 
 
14.584 
     16.097 
       16.52 16.523 16.365 16.444 
     
  
16.838 
 17.842 17.859 17.843  17.684 17.553 17.607 
 18.855 18.748 18.766 18.626 18.671 18.538 
 18.95     
 
18.937 
 
 
 243 
 
 19.411 19.347 19.347 19.14 19.131 
 
19.139 
20.518 20.874 20.485 20.468 20.138 20.8 
     20.996 20.747 
  
20.689 
    20.988 
   21.275  21.037  21.94 21.241 21.418 21.083 
     21.664 
 
21.633 
    22.214 
 
22.275 
      
 
22.894 
 23.927 23.449 23.498 23.48 23.457 
 
23.75 
 24.911 24.454 24.385 24.396 24.601 24.655 24.325 24.581 
     
 
24.904 
     25.403 25.306 25.152 25.367 
 25.937   25.789 25.52 25.664 
  26.644 26.093 26.059  26.723 26.646 
   26.934 26.898  26.894 
 
 
 244 
 
27.094     27.572 27.968 27.454  
27.92     
   28.333 28.166 28.061 28.076 28.996 28.126 28.525 28.085 
     28.32 
    29.937 29.925 29.781 29.131 29.754 29.008 
   30.836 30.381 30.543 
 
30.387 
 30.007 30.882  30.752 
    30.945    
    31.29 31.198 31.163 31.404 
   32.91 32.456 32.474 32.45 32.533 
   33.111 33.324 33.26 33.485 33.492 
 
33.17 
  33.895 33.51 33.864  
     33.856   
       34.992 
  
34.128 
 35.415 35.658 35.607 35.524 
 
35.401 
 
 245 
 
36.014 36.105 36.156 36.154  
  
36.016 
 36.545 36.556 36.56  36.645 
37.44  37.831  37.284  37.36  
37.806        
 38.154 38.042 38.041 38.903 38.342 38.294 38.163 
 38.803       
 39.321 39.06 39.002  39.5  39.1 
  39.331 39.336   39.317 39.339 
40.48    40.503    
41.176 41.388 41.281 41.302    41.859 
  41.702      
42.195 42.249 42.042      
  42.819 42.754     
43.635 43.456 43.97 43.883     
44.478 44.932 44.902 44.913     
 246 
 
45.372  45.463  45.323    
45.372        
 46.816 46.156      
  47.778 47.141 47.745     
   47.753      
   48.094 48.05     
   48.538      
  49.493 49.468      
 
 
 
 
 247 
 
Table AA 3.3: PXRD data for samples TA-I-18-3a (1:1), TA-I-18-3b (1:2), TA-I-18-3c (2:1), in acetonitrile  
Malic acid Iso stnd Iso EHOWIH Iso EHOWIH01 Iso EHOWIH02 TA-I-18-3a TA-I-18-3b TA-I-18-3c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
        6.766  
     10.39  10.372 
        
    11.677    
     13.759 13.476 13.733 
14.254    14.625    
      15.147  
    16.097 16.397 16.882 16.362 
    16.52 16.912  16.87 
        
 17.842 17.859 17.843  17.555 17.997 17.525 
 18.855 18.748 18.766 18.626    
 248 
 
18.95        
 19.411 19.347 19.347 19.14 19.102  19.064 
20.518 20.874 20.485 20.468 20.138    
   20.996 20.747 20.63 20.302  
    20.988   20.598 
21.275  21.037   21.122   
    21.94 21.592 21.994 21.568 
    22.214 22.511 22.491 22.538 
        
23.927 23.449 23.498 23.48 23.457 23.354 23.864 23.356 
     23.894   
 24.454 24.385 24.396  24.46 24.196 24.506 
24.911    24.601 24.643 24.704   
    25.403 25.4 25.54   
 25.937   25.789      
 249 
 
 26.644 26.093 26.059      26.035 
  26.934 26.898      
27.094     27.426  27.394 
27.92        
28.333 28.166 28.061 28.076  28.086 28.123 28.063 
    28.996 28.485 28.421 28.97 
  29.937 29.925 29.781 29.018   
   30.836 30.381 30.408  30.365 
 30.007 30.882  30.752    
 30.945       
 31.29 31.198 31.163 31.404 31.452  31.211 
 32.456 32.474 32.45 32.533  32.097  
32.91      32.661  
33.111 33.324 33.26 33.485 33.492 33.767  33.752 
 33.895 33.51 33.864     
 250 
 
  33.856      
    34.992 34.078 34.095 34.003 
 35.415 35.658 35.607 35.524 35.95  35.913 
36.014 36.105 36.156 36.154  36.589 36.221 36.619 
 36.545 36.556 36.56  36.589   
37.44  37.831  37.284  37.051  
37.806      37.683  
 38.154 38.042 38.041 38.903 38.125 38.291 38.093 
 38.803   38.903 38.357 38.859 38.356 
  39.06 39.002     
 39.321 39.331 39.336  39.21  39.269 
40.48    40.503    
41.176 41.388 41.281 41.302     
  41.702      
42.195 42.249 42.042      
 251 
 
 
 
 
  42.819 42.754     
43.635 43.456 43.97 43.883     
44.478 44.932 44.902 44.913     
45.372  45.463  45.323    
45.372        
 46.816 46.156      
  47.778 47.141 47.745     
   47.753      
   48.094 48.05     
   48.538      
  49.493 49.468      
 252 
 
Table AA 3.4: PXRD data for samples TA-I-17-3a (1:1), TA-I-17-3b (1:2), TA-I-17-3c (2:1), in methanol  
Malic acid Nicotin-amide Nicoam 01 Nicoam 02 Nicoam TA-I-17-3a TA-I-17-3b TA-I-17-3c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     7.68 7.787 7.645 
 11.67 11.328 11.301 11.296    
14.52  14.839 14.801 14.764  14.903 14.859 
 15.115    15.398 15.465 15.335 
     17.966 17.805 17.272 
18.95     18.545 18.168 18.065 
      18.487  
   19.061     
  19.551 19.52 19.495  19.592 19.292 
 19.822 19.96 19.884 19.858    
20.518 20.19      20.047 
       20.831 
 253 
 
21.275     21.709   
 22.524 22.295 22.215 22.184 22.14 22.309 22.203 
  22.784 22.697 22.68  22.716  
 23.03 23.167 23.348 23.347 23.17 23.271 23.24 
23.927 23.646 23.868    23.986 23.504 
24.91  24.75 24.701 24.662  24.563 24.463 
   25.379 25.366  25.431 25.272 
 25.707 25.871 25.823 25.819  25.925  
 26.114 26.395      
27.094 27.603  27.311 27.266  27.345 27.852 
27.92  27.91   27.811 27.851  
   28.443 28.438    
28.33 28.72 28.905 28.861 28.845   28.766 
  29.378      
 30.37 30.199 30.141 30.088    
 254 
 
  31.602    31.129 31.376 
32.91 32.79 32.899 32.575 32.6   32.542 
33.111  33.145      
  33.708 33.594   33.64 33.373 
 34.61 34.442 34.412   34.713  
  35.153 35.764     
  35.83      
36.014 36.82  36.478 36.935    
   36.981     
37.44 37.212 37.082    37.085 37.466 
37.806        
 38.93 38.802 38.666 38.64    
      39.144  
40.48   40.945     
41.17  41.06 41.466 41.475    
 255 
 
  41.724      
42.19        
43.63        
44.478        
45.37        
   46.593 46.627    
 47.9 47.744 47.307 47.692    
  48.001 47.705     
  48.62 48.809     
 256 
 
Table AA 3.5: PXRD data for samples TA-I-18-2a (1:1), TA-I-18-2b (1:2), TA-I-18-2c(2:1), in acetone 
Malic acid Nicotinamide Nicoam 01 Nicoam 02 Nicoam TA-I-18-2a TA-I-18-2b TA-I-18-2c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     7.881 7.833 7.728 
 11.67 11.328 11.301 11.296    
14.52  14.839 14.801 14.764   14.872 
 15.115    15.053 15.024  
     15.551 15.497 15.414 
18.95     18.233 18.182 18.024 
        
   19.061  19.396 19.385 19.275 
  19.551 19.52 19.495    
 19.822 19.96 19.884 19.858    
20.518 20.19       
     20.951 20.943 20.81 
 257 
 
21.275     21.644 21.614 21.465 
 22.524 22.295 22.215 22.184 22.355 22.349 22.228 
  22.784 22.697 22.68    
 23.03 23.167 23.348 23.347 23.325 23.337 23.234 
23.927 23.646 23.868      
24.91  24.75 24.701 24.662 24.609 24.582 24.444 
   25.379 25.366 25.449  25.341 
 25.707 25.871 25.823 25.819 25.843 25.463  
 26.114 26.395   26.617 26.592 26.494 
27.094 27.603  27.311 27.266 27.22 27.157 27.008 
27.92  27.91    27.986 27.898 
   28.443 28.438 28.008   
28.33 28.72 28.905 28.861 28.845 28.902 28.831 28.721 
  29.378      
 30.37 30.199 30.141 30.088    
 258 
 
  31.602   31.46 31.474  
32.91 32.79 32.899 32.575 32.6    
33.111  33.145   33.24  33.185 
  33.708 33.594  33.539 33.391  
 34.61 34.442 34.412     
  35.153 35.764     
  35.83      
36.014 36.82  36.478 36.935    
   36.981  37.731   
37.44 37.212       
37.806  37.082   37.731   
 38.93 38.802 38.666 38.64    
        
40.48   40.945     
41.17  41.06 41.466 41.475    
 259 
 
  41.724      
42.19        
43.63        
44.478        
45.37        
   46.593 46.627    
 47.9 47.744 47.307 47.692    
  48.001 47.705     
  48.62 48.809     
 
 260 
 
Table AA 3.6: PXRD data for samples TA-I-18-4a (1:1), TA-I-18-4b (1:2), TA-I-18-4c (2:1), in methanol  
DL-malic acid Nicotin amide Std NICOAM NICOAM01 NICOAM02 TA-I-18-4a TA-I-18-4b TA-I-18-4c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     7.83 7.717 7.794 
 11.671 11.296 11.328 11.301    
     10.312   
14.254  14.764 14.839 14.801  14.905 14.994 
 15.115    15.036 15.402 15.479 
     15.505   
      16.71 16.753 
      17.363 17.412 
18.95     18.186 18.084 18.153 
 19.822 19.041 19.137 19.061 19.09 19.015 19.049 
  19.495 19.551 19.52 19.431 19.331 19.405 
  19.858 19.96 19.884    
 261 
 
20.518 20.19    20.93 20.854 20.917 
21.275     21.627 21.497 21.577 
 22.524 22.184 22.295 22.215 22.365 22.285 22.347 
  22.68 22.784 22.697  22.76 22.827 
 23.031 23.347 23.167 23.348 23.328 23.276 23.334 
23.927 23.646  23.868     
24.911  24.662 24.75 24.701 24.601 24.484 24.575 
  25.366  25.379 25.443 25.335 25.399 
 25.707 25.819 25.871 25.823  25.61 25.699 
 26.114  26.395 26.601 26.603 26.487 26.569 
27.094  27.266 27.017 27.311   27.05 
27.92 27.603  27.91  27.966 27.895 27.952 
28.333  28.438  28.443    
 28.724 28.845 28.905 28.861 28.904 28.771 28.859 
 29.158  29.378 29.64  29.102 29.171 
 262 
 
 30.375 30.088 30.199 30.141 30.209 30.072 30.191 
 31.399 31.207 31.602 31.193 31.526 31.404 31.483 
  32.6 32.388 32.575 32.209  32.143 
32.91 32.798  32.899     
33.111   33.145   33.15 33.237 
 33.892 33.557 33.708 33.594 33.377 33.404 33.489 
 34.61 34.09, 34.37 34.442 34.05, 34.412 34.284 34.155 34.22 
 34.743 34.758  34.763 34.75 34.623 34.652 
   35.153     
  35.72 35.839 35.764    
36.014  36.494  36.478    
 36.82 36.935 36.808 36.981  36.852 36.85 
37.44 37.212       
37.806   37.082  37.686 37.585 37.604 
 38.935 38.64 38.802 38.666 38.515 38.42 38.477 
 263 
 
   39.294   39.437 39.441 
  39.567 39.702 39.612    
40.48  40.166 40.467 40.167 40.215 40.094 40.194 
  40.914  40.945    
41.176 41.339 41.475 41.06 41.466    
 41.656 41.822 41.724 41.861    
42.195        
43.635 43.688 43.464   43.877   43.856 
44.478  44.413       
45.372         
  46.627 46.539 46.593     
  47.9 47.312 47.137 47.307   47.47 47.527 
   47.692 47.744 47.705     
    48.001 48.809      
     48.62       
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  49.148   49.526       
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Table AA 3.7: PXRD data for samples TA-I-22-2a (1:1), TA-I-22-2c (2:1), in methanol  
L-Malic acid Iso stnd Iso EHOWIH Iso EHOWIH01 Iso EHOWIH02 TA-I-22-2b TA-I-22-2c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
7.558         
    11.677  11.995 
       
    14.625   
     15.134  
    16.097   
    16.52 16.807 16.93 
       
17.917 17.842 17.859 17.843  17.895  
 18.855 18.748 18.766 18.626   
       
19.375 19.411 19.347 19.347 19.14   
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20.147 20.874 20.485 20.468 20.138   
20.809   20.996 20.747    
    20.988   
21.067  21.037    21.15 
21.981    21.94 21.865  
22.405    22.214 22.442  
       
 23.449 23.498 23.48 23.457 23.813 23.891 
       
24.443 24.454 24.385 24.396  24.219  
    24.601 24.634  
    25.403 25.495 25.478 
 25.937   25.789   
26.008 26.644 26.093 26.059    
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26.314       
  26.934 26.898    
27.045        
27.782     27.991  
 28.166 28.061 28.076  28.398   
    28.996    
29.487       
29.762  29.937 29.925 29.781    
30.324 30.007   30.381    
 30.945 30.882 30.836 30.752    
        
31.911 31.29 31.198 31.163 31.404   31.533 
 32.456 32.474 32.45 32.533 32.802  
       
 268 
 
 33.324 33.26 33.485 33.492   
 33.895 33.51 33.864  33.991  
  33.856     
34.106       
    34.992   
35.496 35.415 35.658 35.607 35.524  35.039 
35.81       
 36.105 36.156 36.154   36.081 
 36.545 36.556 36.56    
37.09      37.191 
37.779  37.831  37.284 37.562  
38.4 38.154 38.042 38.041   38.284 
 38.803   38.903 38.844  
  39.06 39.002    
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39.477 39.321 39.331 39.336   39.379 
40.014       
40.742    40.503   
 41.388 41.281 41.302    
41.575  41.702     
42.219 42.249 42.042     
  42.819 42.754    
47.871 43.456 43.97 43.883    
 44.932 44.902 44.913    
  45.463  45.323   
 46.816 46.156     
  47.141     
47.871 47.778 47.753 47.745    
  48.094 48.05    
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  48.538     
 49.493 49.468     
 
 
 
 271 
 
Table AA 3.8: PXRD data for samples TA-I-22-3a (1:1), TA-I-22-3b (1:2), TA-I-22-3c (2:1), in acetone 
L-Malic acid Iso stnd Iso EHOWIH Iso EHOWIH01 Iso EHOWIH02 TA-I-22-3a TA-I-22-3b TA-I-22-3c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta °   
6.71       6.717 6.681   
    11.677     
      13.406   
    14.625     
     15.156 15.156   
    16.097     
    16.52 16.806 16.791   
17.917 17.842 17.859 17.843  17.898 17.893   
 18.855 18.748 18.766 18.626     
         
19.375 19.411 19.347 19.347 19.14     
20.147 20.874 20.485 20.468 20.138 20.171 20.128   
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20.809   20.996 20.747     
    20.988     
21.067  21.037       
21.981    21.94 21.873  21.859   
22.405    22.214 22.444  22.432   
 23.449 23.498 23.48 23.457       
     23.837  23.822    
24.443 24.454 24.385 24.396  24.232  24.225    
    24.601 24.613  24.593     
    25.403 25.484  25.477   
 25.937   25.789       
26.008 26.644 26.093 26.059        
26.314         
  26.934 26.898      
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27.045          
27.782      27.999   
 28.166 28.061 28.076  28.017 28.367   
    28.996 28.384    
29.487         
29.762  29.937 29.925 29.781     
30.324 30.007   30.381     
 30.945 30.882 30.836 30.752     
        
31.911 31.29 31.198 31.163 31.404    
 32.456 32.474 32.45 32.533 32.058 32.052  
      32.834  
 33.324 33.26 33.485 33.492    
 33.895 33.51 33.864  33.987 33.967  
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  33.856      
34.106        
    34.992    
35.496 35.415 35.658 35.607 35.524    
35.81        
 36.105 36.156 36.154     
 36.545 36.556 36.56     
37.09        
37.779  37.831  37.284 37.565 37.536  
38.4 38.154 38.042 38.041     
 38.803   38.903 38.851 38.829  
  39.06 39.002  39.156 39.149  
39.477 39.321 39.331 39.336     
40.014        
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40.742    40.503    
 41.388 41.281 41.302     
41.575  41.702      
42.219 42.249 42.042      
  42.819 42.754     
47.871 43.456 43.97 43.883     
 44.932 44.902 44.913     
  45.463  45.323    
 46.816 46.156      
  47.141      
47.871 47.778 47.753 47.745     
  48.094 48.05     
  48.538      
 49.493 49.468      
 
 276 
 
Table AA 3.9: PXRD data for samples TA-I-22-4a (1:1), TA-I-22-4b (1:2), TA-I-22-4c (2:1), in acetonitrile  
L-Malic acid Iso stnd Iso EHOWIH Iso EHOWIH01 Iso EHOWIH02 TA-I-22-4a TA-I-22-4b TA-I-22-4c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
          
6.717     6.637   
     9.21   
     10.545   
    11.677  11.688  
     12.436   
     13.101   
     13.592   
    14.625    
     15.241  15.112 
    16.097 16.373   
    16.52  16.65 16.695 
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     17.182   
17.917 17.842 17.859 17.843  17.43  17.834 
     18.315   
 18.855 18.748 18.766 18.626    
     18.6   
19.375 19.411 19.347 19.347 19.14 19.065   
     19.637   
20.147 20.874 20.485 20.468 20.138 20.252   
20.809   20.996 20.747  20.953 20.908 
    20.988    
21.067  21.037   21.235   
21.981    21.94 21.858  21.979 21.842 
22.405    22.214    22.395 
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 23.449 23.498 23.48 23.457 23.228  23.55 23.777 
          
24.443 24.454 24.385 24.396   24.335    24.275 
    24.601 24.87   24.515 
    25.403   25.203 25.246 
 25.937   25.789    25.463 
26.008 26.644 26.093 26.059  26.27  26.654 26.876 
26.314         
  26.934 26.898      
27.045      27.506  27.498  
27.782        27.991 
 28.166 28.061 28.076     28.326 
    28.996     
29.487        
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29.762  29.937 29.925 29.781 29.626 29.365  
30.324 30.007   30.381  30.30  
 30.945 30.882 30.836 30.752    
31.911 31.29 31.198 31.163 31.404  31.23  
 32.456 32.474 32.45 32.533    
 33.324 33.26 33.485 33.492    
 33.895 33.51 33.864   33.976 33.967 
  33.856      
34.106        
    34.992  34.653 34.886 
35.496 35.415 35.658 35.607 35.524  35.553  
35.81       35.841 
 36.105 36.156 36.154   36.222  
 36.545 36.556 36.56     
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37.09      37.084 37.012 
37.779  37.831  37.284   37.532 
38.4 38.154 38.042 38.041   38.023  
 38.803   38.903   38.87 
  39.06 39.002   39.003 39.17 
39.477 39.321 39.331 39.336     
40.014         
40.742    40.503   40.767 
 41.388 41.281 41.302     
41.575  41.702      
42.219 42.249 42.042      
  42.819 42.754     
47.871 43.456 43.97 43.883     
 44.932 44.902 44.913     
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  45.463  45.323    
        
 46.816 46.156      
  47.141      
47.871 47.778 47.753 47.745     
  48.094 48.05     
  48.538      
 49.493 49.468      
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Table AA 3.10: PXRD data for samples TA-I-23-2a (1:1), TA-I-23-2b (1:2), TA-I-23-2c (2:1), in acetone 
L-Malic acid Nicotinamide Std NICOAM NICOAM01 NICOAM02 TA-I-23-2a TA-I-23-2b TA-I-23-2c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta °  2-Theta ° 2-Theta ° 
6.717           8.597  
 
11.671 11.296 11.328 11.301    
    14.764 14.839 14.801 14.39 14.629  
  15.115          
          18.99 18.509  
17.917             
 19.375 
 
19.041 19.137 19.061    
   19.822 19.495 19.551 19.52  19.705  19.425 
    19.858 19.96 19.884     
20.147  20.19           
20.809             
21.067 
    
21.08   21.097 
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21.981 
    
 21.455  21.491 
 22.405 22.524 22.184 22.295 22.215      
    22.68 22.784 22.697     22.975 
  23.031 23.347 23.167 23.348      
 
23.646   23.868        
     
 24.076 24.01 
24.44 
    
 24.41  
 
  24.662 24.75 24.701   24.912   
 
  25.366   25.379 25.20 25.447    
 
25.707 25.819 25.871 25.823 25.98    25.849 
 26.008 26.114   
 
26.601      
26.314 
  
26.395 
 
 26.217    
27.045    27.266 27.017 27.311      
27.782 27.603   27.91   27.74 27.982    
 
  28.438   28.443     28.212 
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  28.724 28.845 28.905 28.861 28.89     
29.487  29.158   29.378 
 
    29.145 
29.762 
   
29.64  29.109    
30.324  30.375 30.088 30.199 30.141      
31.911 31.399 31.207 31.602 31.193   31.659   
    32.6 32.388 32.575      
  32.798   32.899    32.649    
      33.145        
 
33.892 33.557 33.708 33.594      
34.106 34.61 34.09, 34.37 34.442 34.05, 34.412      
  34.743 34.758   34.763      
35.496     35.153        
35.81   35.72 35.839 35.764     35.284 
    36.494   36.478      
  36.82 36.935 36.808 36.981      
 285 
 
 
 
37.09 37.212    37.082        
37.779     
 
   37.305    
38.4 38.935 38.64 38.802 38.666  38.098    
      39.294        
 39.477   39.567 39.702 39.612      
40.014   40.166 40.467 40.167      
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Table AA 3.11: PXRD data for samples TA-I-22-3a (1:1), TA-I-22-3b (1:2), TA-I-22-3c (2:1), in acetone 
L-Malic acid Nicotinamide Std NICOAM NICOAM01 NICOAM02 TA-I-24-1a TA-I-24-1b TA-I-24-1c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
6.717            
    11.671 11.296 11.328 11.301   
              12.232 
     14.764 14.839 14.801   14.371 
   15.115         
  
 
        17.327 17.32 
 17.91          17.923 
            18.963 18.984 18.913 
 19.375   19.041 19.137 19.061   
     19.822 19.495 19.551 19.52   19.453 
     19.858 19.96 19.884   
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20.147  20.19       20.154 20.16 20.586 
20.809         20.638 20.633 20.996 
21.067         21.058  21.081    
21.981               
 22.405 22.524 22.184 22.295 22.215 22.24  22.193 22.145 
    22.68 22.784 22.697  22.54 22.549 22.476 
  23.031 23.347 23.167 23.348 23.571  23.576  23.509 
  23.646   23.868     
 
  
24.443            
 
  
    24.662 24.75 24.701   24.646   
    25.366   25.379   25.255  25.368 
  25.707 25.819 25.871 25.823 25.424  25.953   
 26.008 26.114     26.601   
 
  
26.314     26.395   26.471  26.481  26.421 
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27.045    27.266 27.017 27.311   
 
  
27.782 27.603   27.91   27.721  27.746  27.673 
    28.438   28.443 
 
28.701   
  28.724 28.845 28.905 28.861 28.657 28.88  28.595 
29.487  29.158   29.378   29.289 29.315  29.237 
29.762       29.64 
 
    
30.324  30.375 30.088 30.199 30.141 
 
30.141    
31.911 31.399 31.207 31.602 31.193 31.277 31.295   31.238 
    32.6 32.388 32.575 
 
    
  32.798   32.899   
 
    
      33.145   33.257  33.276  33.199 
  33.892 33.557 33.708 33.594 
 
33.837    
34.106 34.61 34.09, 34.37 34.442 34.05, 34.412 
 
    
  34.743 34.758   34.763 34.857 34.857   34.79 
 289 
 
35.496     35.153   
 
    
35.81   35.72 35.839 35.764 35.999  35.996   
    36.494   36.478 
 
   36.973 
  36.82 36.935 36.808 36.981 
 
    
37.09 37.212    37.082   37.037  37.058   
37.779           37.914    
38.4 38.935 38.64 38.802 38.666   38.696    
      39.294         
 39.477   39.567 39.702 39.612       
40.014   40.166 40.467 40.167 40.262 40.27    
40.742   40.914   40.945       
41.575  41.339 41.475 41.06 41.466       
  41.656 41.822 41.724 41.861       
 
 
 290 
 
Table AA 3.12: PXRD data for samples TA-I-23-3a (1:1), TA-I-23-3c (2:1), in methanol 
L-Malic acid Nicotinamide Std NICOAM NICOAM01 NICOAM02 TA-I-23-3a TA-I-23-3c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
 
2-Theta ° 2-Theta ° 
6.717            
     
7.47  
 
11.671 11.296 11.328 11.301   
   14.764 14.839 14.801   
  15.115         
17.917          17.62  
     
18.25  
19.375 
 
19.041 19.137 19.061 19.27 19.25 
  19.822 19.495 19.551 19.52   
    19.858 19.96 19.884   
20.147  20.19       20.02  
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20.809         20.91 20.89 
21.067 
    
21.33 21.31 
21.981 
    
  
 22.405 22.524 22.184 22.295 22.215 22.42  
    22.68 22.784 22.697 22.82 22.67 
  23.031 23.347 23.167 23.348   
 
23.646   23.868   23.89 23.79 
24.443  
    
  
 
 24.662 24.75 24.701 24.72  
 
  25.366   25.379   
 
25.707 25.819 25.871 25.823 25.71 25.68 
26.008 26.114   
 
26.601 26.76  
26.314 
  
26.395 
 
  
27.045   27.266 27.017 27.311 27.05  
 292 
 
27.782 27.603   27.91     
 
  28.438   28.443 28.01 28.03 
 28.724 28.845 28.905 28.861 28.95 28.93 
29.487  29.158   29.378 
 
  
29.762 
   
29.64 29.56  
30.324  30.375 30.088 30.199 30.141 30.17  
 
31.399 31.207 
 
31.193 31.02  
31.911 
  
31.602 
 
31.57  
   32.6 32.388 32.575   
  32.798   32.899     
      33.145     
 
33.892 33.557 33.708 33.594 33.50  
34.106 34.61 34.09, 34.37 34.442 34.05,34.412 34.06  
  34.743 34.758   34.763   
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35.496     35.153   35.12  
35.81   35.72 35.839 35.764   
    36.494   36.478 36.11  
  36.82 36.935 36.808 36.981 36.82  
37.09 37.212    37.082   37.28  
37.779     
 
  37.67  
     
38.33  
38.4 38.935 38.64 38.802 38.666 38.95  
      39.294   39.37  
 39.477   39.567 39.702 39.612   
40.014   40.166 40.467 40.167   
40.742   40.914   40.945   
41.575  41.339 41.475 41.06 41.466   
  41.656 41.822 41.724 41.861   
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Table AA 3.13: FT-IR assignments for samples TA-I-18-1a (1:1), TA-I-18-1b (1:2), TA-I-18-1c (2:1), and its starting materials in acetone 
Isonicotinamide DL-Malic acid TA-I-18-1a  TA-I-18-1b TA-I-18-1c 
Assignment 
 (cm-1)  (cm-1) (cm-1)  (cm-1)  (cm-1) 
  3445 s  3488  3400 _(OH) of CHOH 
3370, 3186   3386, 3204 3388 3389 ύ NH2 (100), ύ NH2 (100) 
3076, 3064, 3053, 
3041 
  3099 3102  ύ CH (99), ύ CH (100) 
  3030 s, br  3089  
_(OH) of COOH hydrogen bond mode 
_s(CH2) 
  2911 sh 2926 2985, 2978 2925 ύ CH2 
  2624 m, br    Combinations H2 bond mode,dimer 
  
1739 vvs, 1716 
vvs, 1690 vvs 
1712 1680 1716 (C= O) of dimeric COOH out-of-phase 
         
1667    1636 1636 ύ CO  
1624, 1596   1616 1616  δNH2 , ύ ring +δCCH , ύ ring 
1552   1551 1557 1557 ύ ring 
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1496     1457 δCCH +ύ ring  
1410   1414 1413 1414 δCCH +ύ ring 
  
   
 
  1442 s-m    _(C–O) Cυ(OH) of COOH, (acid II) 
  1410 s-m    υ(CH2_scis 
1395   1397 1397  ύ CN + δCC , δCCH+δCCO 
  1385 w    υ(CH) of CHOH 
  1359 m.-w  1308  δ(CH2) SCIS, δ(CH2)wag 
  1290 s, d    υ(OH) C_(C–O) of COOH(acid III) 
  1277 sh    υ(CH2)twist,(OH), (C–O) 
  1267 sh   1263 δ(CH) of CHOD 
1265   1262   ῡ ring 
1228    1249  δCCH +ύ ring  
  1219 m   1222 δ(CH2) 
  1185 s    δ(CH2) twist, δ(CH2)scis 
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1148   1157   ring+CCH+CN+CC 
1122      CCH+ ring 
  1103 s 1110   (CH2)SCIS,  ῡ(C-O),δ(OH) 
1085      δ CCH +ύ ring  
1063   1056  1055 NH2 rock  +ύCN 
  1033 w 1023  1023 ύ(C–C), (CH) 
994    980  Ring 
969   963  965 CH 
  968 m    (C–C), υ(C-O)tors (acid IV) 
955      ῡ CH 
  951m    δ(OD)+ υ(C-O)of COOD(acidIII) 
  885m,  882   δ(C-O), (C-CH2), (C-H) 
875      ᵞCH 
853      ᵞCH+ᵞ CC +ᵞCO 
  825vvw    δ(C-O), (C-CH2), (C-H) 
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  790 vw 796  796 δ(CH2) 
778      γring +γco 
755     751 δ ring + ύcc + ύring 
  750 vw 751 746   O-C=Odef.coupled with OH 
  724 vvw    Def 
708      ring  + CO  
  667 m 677   υ(C–H), υ(C–CH2), 
669      ring+ring 
629      δ CCO  + ύ ring  
542        NH2 twist  + ring + CC 
 
S=strong, v=very, m=medium, w=week, sh=shoulder, as=antisymmetric, symsymmetric, i.p=in-plane 
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Table AA 3.14: FT-IR assignment of TA-I-18-2(a) (b) (c) for DL-malic acid and isonicotinamide and products of crystallisation (1:1), (1:2) and (2:1) 
Assignment is made using the literature 
16,22 
Isonicotinamide DL-Malic acid TA-I-18-3a 1:1 TA-I-18-3b 1:2 TA-I-18-3c 2:1 
Assignment 
 (cm
-1
) (cm
-1
) cm
-1
)  (cm
-1
) (cm
-1
) 
  3445 s  3491 3460 3490 _(OH) of CHOH 
3370, 3186   3383,3203, 3203 3386, 3166 3383, 3204 ύ NH2 (100), ύ NH2 (100) 
3076, 3064, 3053, 
3041 
  3096,  3096 ύ CH (99), ύ CH (100) 
  3030 s, br    _(OH) of COOH hydrogen bond mode 
_s(CH2) 
  2911 sh 2894 2836 2895 ύ CH2 
  2624 m, br 2772 2782 2771 Combinations H2 bond mode dimer 
    2462 2469 2463   
         
  1739 vvs, 1716 
vvs, 1690 vvs 
1714 1693, 1693 1716, 1684 (C= O) of dimeric COOH out-of-phase 
1667      ύ CO  
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1624, 1596   1588  1587 δNH2 , ύ ring +δCCH , ύ ring 
1552   1547 1550 1547 ύ ring 
1496      δCCH +ύ ring  
1410   1416  1416 δCCH +ύ ring 
  1442 s-m    _(C–O) Cυ(OH) of COOH, (acid II) 
  1410 s-m    υ(CH2_scis) 
1395    1339  ύ CN + δCC , δCCH+δCCO 
  1385 w    υ(CH) of CHOH 
  1359 m.-w  1323  δ(CH2) SCIS, δ(CH2)wag 
  1290 s, d    υ(OH) C_(C–O) of COOH(acid III) 
  1277 sh    υ(CH2)twist,(OH), (C–O) 
  1267 sh    δ(CH) of CHOD 
1265     1262 ῡ ring 
1228   1220 1239 1220 δCCH  +ύ ring  
  1219 m    δ(CH2) 
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  1185 s  1168 1168 δ(CH2) twist, δ(CH2)scis 
1148      ring+ CCH+CN+CC 
1122      CCH+ ring 
  1103 s 1107  1108 (CH2)SCIS 
1085    1092  δ CCH +ύ ring  
1063    1053 1046 NH2 rock  +ύCN 
  1033 w 1028 1028 1028 ύ(C–C), (CH) 
994      Ring 
969   962  965 CH 
  968 m    (C–C), υ(C-O)tors (acid IV) 
955      ῡ CH 
  951m  947  δ(OD)+ υ(C-O)of COOD(acid) 
  885m,  893 860 894 δ(C-O), (C-CH2), (C-H) 
875      ᵞCH 
853   854  853 ᵞCH+ᵞ CC +ᵞCO 
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  825vvw  808  δ(C-O), (C-CH2), (C-H) 
  790 vw 798  798 δ(CH2) 
778      γring +γco 
755   759 752 760 δ ring (30)+ ύcc(17)+ ύring 
  750 vw     O-C=Odef.coupled with OH 
  724 vvw    Def 
708      ring  + CO  
  667 m 675 669 676 υ(C–H), υ(C–CH2), 
669      ring+ring 
629      δ CCO  + ύ ring  
542        NH2 twist  + ring + CC 
 
S=strong, v=very, m=medium, w=week, sh=shoulder, as=antisymmetric, symsymmetric, i.p=in-plane 
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Table AA 3.15: FT-IR assignments for samples TA-I-18-2a (1:1), TA-I-18-2b (1:2), TA-I-18-2c (2:1), and its starting materials in acetone 
Assignment is made using the literature. 
16,22 
Nicotinamide  DL-Malic acid TA-I-18-2a  TA-I-18-2b  TA-I-18-2c  
Assignment 
FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  3445 s  3408 3475, 3400 3475, 3404 _(OH) of CHOH 
3366, 3167   3207 3220 3343, 3220 ύ NH2 (100), ύ NH2 (100) 
  3030 s, br 3079   _(OH) of COOH hydrogen bond mode 
_s(CH2_ 
  2911 sh  2983, 2930 2931 ύ CH2 
  2897, 2833 2850 2852  
 2782, 2316    2767 2761 ύ CH (99), ύ CH (100)  
  2624 m, br     Combinations H2 bond mode,dimer  
  2480 2480 2486  
  1739 vvs, 1716 
vvs, 1690 vvs 
 1717 1722 (C= O) of dimeric COOH out-of-phase 
 1962   1919 1921 1922   
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1680   1695 1681 1676 ύ CO  
1483, 1618   1602 1615 1615 CN amide Stretch 
  1562 1575 1575  
1341      CH ip bend 
1410      δCCH +ύ ring  
  1442 s-m 1443  1425 _(C–O) Cυ(OH) of COOH, (acid II) 
  1410 s-m 1408 1417  υ(CH2_scis 
1395    1399 1399 ύ CN + δCC , δCCH+δCCO 
  1385 w    υ(CH) of CHOH 
  1359 m.-w 1308  1369 δ(CH2) SCIS, δ(CH2)wag 
  1290 s, d 1281 1299 1299 υ(OH) C_(C–O) of COOH(acid III) 
  1277 sh    υ(CH2)twist,(OH), (C–O) 
  1267 sh  1240 1243 δ(CH) of CHOD 
1230   1232 1224 1222 CC stretch 
1200      CH ip bend 
 304 
 
  1219 m    δ(CH2) 
  1185 s 1178 1192 1192 δ(CH2) twist, δ(CH2)scis 
1154   1147   CC strech 
1122      CH ip bend 
  1103 s 1105 1108 1108 (CH2)SCIS,        ῡ(C-O),δ(OH) 
1027   1046 1044 1044 NH2 rock 
1063      NH2 rock  +ύCN 
  1033 w   1005 ύ(C–C), (CH) 
972   991   CH op bend 
936      CH op bend 
  968 m  943 943 (C–C), υ(C-O)tors (acid IV) 
  951m 951  902 δ(OD)+ υ(C-O)of COOD(acidIII) 
  885m,  882 897, 860  δ(C-O), (C-CH2), (C-H) 
827      CH op bend 
853   841   Vvw 
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  825vvw  831 831 δ(C-O), (C-CH2), (C-H) 
  790 vw 794 798 796 δ(CH2) 
777      γring + ring def 
  750 vw 751  752  O-C=Odef.coupled with OH 
  724 vvw    Def 
702   704 702  Ring op. Bend γ ring 
  667 m    υ(C–H), υ(C–CH2), 
 
 
 
 306 
 
Table AA 3.16: FT-IR assignments for samples TA-I-18-4a (1:1), TA-I-18-4b (1:2), TA-I-18-4c (2:1), and its starting materials in acetonitrile  
Assignment is made using the literature. 
16,22 
Nicotinamide  DL-Malic acid TA-I-18-4a  TA-I-18-4b  TA-I-18-4c  
Assignment 
FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  3445 s  34454 3445 3446 _(OH) of CHOH 
3366, 3167   3361,3300 3361,3300 3364,3301 ύ NH2 (100), ύ NH2 (100) 
2782, 2316      ύ CH (99), ύ CH (100) 
  3030 s, br 3114 3112 3114 _(OH) of COOH hydrogen bond mode 
_s(CH2_ 
  2911 sh 2913 2913 2913 ύ CH2 
  2831  2832  
  2624 m, br 2683 2684 2683 Combinations H2 bond mode,dimer 
    2156 2155 2155   
    1822 1818 1819   
  1739 vvs, 1716 vvs, 
1690 vvs 
1695 1695 1696 (C= O) of dimeric COOH out-of-phase 
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1680   1641 1640 1640 ύ CO  
  1591 1591 1591  
1483, 1618   1491 1492 1492 CN amide Stretch 
1341      CH ip bend 
1410   1411 1411 1411 δCCH +ύ ring  
  1442 s-m    _(C–O) Cυ(OH) of COOH, (acid II) 
  1410 s-m    υ(CH2_scis 
1395      ύ CN + δCC , δCCH+δCCO 
  1385 w 1385 1385 1385 υ(CH) of CHOH 
  1359 m.-w 1331 1333 1333 δ(CH2) SCIS, δ(CH2)wag 
  1290 s, d    υ(OH) C_(C–O) of COOH(acid III) 
  1277 sh    υ(CH2)twist,(OH), (C–O) 
  1267 sh 1269 1268 1268 δ(CH) of CHOD 
1230   1234 1233 1233 CC strech 
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1200   1207 1207 1207 CH ip bend 
  1219 m    δ(CH2) 
  1185 s    δ(CH2) twist, δ(CH2)scis 
1154   1136 1136 1137 CC strech 
1122      CH ip bend 
  1103 s    (CH2)SCIS,        ῡ(C-O),δ(OH) 
1027      NH2 rock 
1063   1065 1067 1066 NH2 rock  +ύCN 
  1033 w 1019 1020 1021 ύ(C–C), (CH) 
972      CH op bend 
936      CH op bend 
  968 m    (C–C), υ(C-O)tors (acid IV) 
  951m 951 952 953 δ(OD)+ υ(C-O)of COOD(acidIII) 
  885m,  856 859 859 δ(C-O), (C-CH2), (C-H) 
827      CH op bend 
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853      Vvw 
  825vvw    δ(C-O), (C-CH2), (C-H) 
  790 vw    δ(CH2) 
777      γring + ring def 
  750 vw     O-C=Odef.coupled with OH 
  724 vvw  732  Def 
702      Ring op. Bend γ ring 
  667 m 672  672 υ(C–H), υ(C–CH2), 
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Table AA 3.17: FT-IR assignments for samples TA-I-23-2a (1:1), TA-I-23-2b (1:2), TA-I-23-2c (2:1), and its starting materials in acetone  
Nicotinamide L-Malic acid TA-I-23-2a TA-I-23-2b TA-I-23-2c 
Assignment 
FT-IR(cm-1) FT-IR (cm-1) FT-IR (cm-1) FT-IR (cm-1) FT-IR (cm-1) 
  3537 vs, br     3446  3407 _(OH) of CHOH 
3366, 3167    3206, 3109, 3075  3207, 3058  3206 ύ NH2 (100), ύ NH2 (100) 
2782, 2316         ύ CH (99), ύ CH (100) 
  2996, 2966 2987 2996, 2967  
  3393 sh 
   3380   
_(OH) of COOH hydrogen bond mode 
_s(CH2_ 
  2670 sh       ύ (OD) of CHOD 
  1924 
  
 
  1721 vs  1716    1717 (C= O) of dimeric COOH out-of-phase 
1680    1609  1677  1682 ύ CO 
  1566 
 
1566  
1483, 1618    1444,1401 1613, 1484  1443 CN amide Stretch 
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  1413 s-m    1424   υ(CH)2_scis 
1410         δCCH +ύ ring 
1395    1362  1396  1362 ύ CN + δCC , δCCH+δCCO 
1341    1308  1339, 1313  1308 CH ip bend 
  1288 m  1270  1262  1271 (OD)+(C-O)of COOD 
1230    1244    1244 CC stretch 
  1224 m       δ(CH2) 
1200    1213  1204  1213 CH ip bend 
  1186 m  1169  1171  1170 δ(CH2) twist, δ(CH2)scis 
1154    1148  1131  1148 CC stretch 
1122         CH ip bend 
1063    1098  1079  1098 NH2 rock  +ύCN 
  1036 w  1049  1049  1048 ύ(C–C), (CH) 
1027      1040   NH2 rock 
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  1107 s      1013 (CH2)SCIS,        ῡ(C-O),δ(OH) 
972      965  992 CH op bend 
936      945  950 CH op bend 
  899 vw  
 891  831   
δ(C-O), (C-CH2), (C-H) 
827         CH op bend 
853   846    846 Vvw 
777      761  781 γring + ring def 
  757 vw  741    741 δ(CH2) 
702         Ring op. Bend γ ring 
  660 m  686  691  696 υ(C–H), υ(C–CH2), 
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Table AA 3.18: FT-IR assignments for samples TA-I-24-1a (1:1), TA-I-24-1b (1:2), TA-I-24-1c (2:1), and its starting materials in acetonitrile   
Nicotinamide L-Malic acid TA-I-24-1a TA-I-24-1b TA-I-24-1c 
Assignment 
FT-IR(cm-1) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  3537 vs, br   3405    3406 _(OH) of CHOH 
3366, 3167    3206, 3072  3380, 3206  3206, 3072 ύ NH2 (100), ύ NH2 (100) 
  2964 2964 2992, 2965  
  2855 2853 2856  
2782, 2316      2515   ύ CH (99), ύ CH (100) 
  3393 sh 
      
_(OH) of COOH hydrogen bond 
mode _s(CH2_ 
  2670 sh       ύ (OD) of CHOD 
  1918 1917 1918  
  1721 vs 
 1713    1714 
(C= O) of dimeric COOH out-of-
phase 
1680    1677  1677  1678 ύ CO 
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1483, 1618    1607, 1563  1604, 1563  1601, 1563 CN amide Stretch 
  1413 s-m  1446  1444  1446 υ(CH)2_scis 
1410    1404  1400  1404 δCCH +ύ ring 
1395         ύ CN + δCC , δCCH+δCCO 
1341    1307  1307  1307 CH ip bend 
          ύ CN + δCC , δCCH+δCCO 
  1288 m  1275  1275  1275 (OD)+(C-O)of COOD 
1230         CC strech 
  1224 m  1212  1211  1212 δ(CH2) 
1200         CH ip bend 
  1186 m  1167  1167  1167 δ(CH2) twist, δ(CH2)scis 
1154         CC strech 
1122         CH ip bend 
  1107 s 
      
(CH2)SCIS,        ῡ(C-O),δ(OH) 
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1063    1098  1098  1097 NH2 rock  +ύCN 
  1036 w       ύ(C–C), (CH) 
1027    1047  1047  1047 NH2 rock 
972    991  990  991 CH op bend 
936    958  955  958 CH op bend 
  899 vw  
      
δ(C-O), (C-CH2), (C-H) 
827    846     CH op bend 
853    886  880  871 Vvw 
777    796    786 γring + ring def 
  757 vw  741  743   δ(CH2) 
702         Ring op. Bend γ ring 
  660 m  691  690  691 υ(C–H), υ(C–CH2), 
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Table AA 3.19: IR-FT assignments for samples TA-I-23-2a (1:1), TA-I-23-2b (1:2), TA-I-23-2c (2:1), and its starting materials in acetone  
Nicotinamide L-Malic acid TA-I-23-2a TA-I-23-2b TA-I-23-2c 
Assignment 
FT-IR(cm-1) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  3537 vs, br     3446  3407 _(OH) of CHOH 
3366, 3167    3206, 3109, 3075  3207, 3058  3206 ύ NH2 (100), ύ NH2 (100) 
2782, 2316         ύ CH (99), ύ CH (100) 
  2996, 2966 2987 2996, 2967  
  3393 sh 
   3380   
_(OH) of COOH hydrogen bond 
mode _s(CH2_ 
  2670 sh       ύ (OD) of CHOD 
  1924 
  
 
  1721 vs 
 1716    1717 
(C= O) of dimeric COOH out-of-
phase 
1680    1609  1677  1682 ύ CO 
  1566 
 
1566  
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1483, 1618    1444,1401  1613, 1484  1443 CN amide Stretch 
  1413 s-m    1424   υ(CH)2_scis 
1410         δCCH +ύ ring 
1395    1362  1396  1362 ύ CN + δCC , δCCH+δCCO 
1341    1308  1339, 1313  1308 CH ip bend 
  1288 m  1270  1262  1271 (OD)+(C-O)of COOD 
1230    1244    1244 CC stretch 
  1224 m       δ(CH2) 
1200    1213  1204  1213 CH ip bend 
  1186 m  1169  1171  1170 δ(CH2) twist, δ(CH2)scis 
1154    1148  1131  1148 CC stretch 
1122         CH ip bend 
1063    1098  1079  1098 NH2 rock  +ύCN 
  1036 w  1049  1049  1048 ύ(C–C), (CH) 
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1027      1040   NH2 rock 
  1107 s      1013 (CH2)SCIS,        ῡ(C-O),δ(OH) 
972      965  992 CH op bend 
936      945  950 CH op bend 
  899 vw  
 891  831   
δ(C-O), (C-CH2), (C-H) 
827         CH op bend 
853   846    846 Vvw 
777      761  781 γring + ring def 
  757 vw  741    741 δ(CH2) 
702         Ring op. Bend γ ring 
  660 m  686  691  696 υ(C–H), υ(C–CH2), 
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Table AA 3.20: FT-IR assignments for samples TA-I-24-1a (1:1), TA-I-24-1b (1:2), TA-I-24-1c (2:1), and its starting materials in acetonitrile   
Nicotinamide L-Malic acid TA-I-24-1a TA-I-24-1b TA-I-24-1c 
Assignment 
FT-IR(cm-1) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) FT-IR (cm
-1
) 
  3537 vs, br   3405    3406 _(OH) of CHOH 
3366, 3167    3206, 3072  3380, 3206  3206, 3072 ύ NH2 (100), ύ NH2 (100) 
  2964 2964 2992, 2965  
  2855 2853 2856  
2782, 2316      2515   ύ CH (99), ύ CH (100) 
  3393 sh 
      
_(OH) of COOH hydrogen bond mode 
_s(CH2_ 
  2670 sh       ύ (OD) of CHOD 
  1918 1917 1918  
  1721 vs  1713    1714 (C= O) of dimeric COOH out-of-phase 
1680    1677  1677  1678 ύ CO 
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1483, 1618    1607, 1563  1604, 1563  1601, 1563 CN amide Stretch 
  1413 s-m  1446  1444  1446 υ(CH)2_scis 
1410    1404  1400  1404 δCCH +ύ ring 
1395         ύ CN + δCC , δCCH+δCCO 
1341    1307  1307  1307 CH ip bend 
          ύ CN + δCC , δCCH+δCCO 
  1288 m  1275  1275  1275 (OD)+(C-O)of COOD 
1230         CC strech 
  1224 m  1212  1211  1212 δ(CH2) 
1200         CH ip bend 
  1186 m  1167  1167  1167 δ(CH2) twist, δ(CH2)scis 
1154         CC strech 
1122         CH ip bend 
  1107 s 
      
(CH2)SCIS,        ῡ(C-O),δ(OH) 
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1063    1098  1098  1097 NH2 rock  +ύCN 
  1036 w       ύ(C–C), (CH) 
1027    1047  1047  1047 NH2 rock 
972    991  990  991 CH op bend 
936    958  955  958 CH op bend 
  899 vw  
      
δ(C-O), (C-CH2), (C-H) 
827    846     CH op bend 
853    886  880  871 Vvw 
777    796    786 γring + ring def 
  757 vw  741  743   δ(CH2) 
702         Ring op. Bend γ ring 
  660 m  691  690  691 υ(C–H), υ(C–CH2), 
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NMR ANALYSIS 
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Figure AA 3.1: 1HNMR TA-I-17-2b 1:2 ratio using (CD3) 2OD as solvent. 1HNMR 
400MHz ((CD3)2OD-d6): δ = 8.70(dd, 2H), 7.77(dd, 2H), 4.5 (dd, 1H), 2.6(dd, 1H), 2.8(dd, 
1H) 
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Figure AA 3.2: 1HNMR of malic acid and isonicotinamid product (from 1:1 starting 
ratio) using (CD3)2CO as solvent. 1HNMR 400MH 
 
3a,5a 
2a,6a 
11a 
12a 
12b 
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Figure AA 3.3: 1HNMR of malic acid and isonicotinamid product (from 1:2 starting 
ratio) using (CD3)2CO as solvent. 1HNMR 400MH 
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Figure AA 3.4: 1HNMR of malic acid and isonicotinamide product (from 2:1 starting 
ratio) using (CD3)2CO as solvent. 1HNMR 400M 
 324 
 
TA-I-18-3A D2O.010.001.1R.esp
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0
Chemical Shift (ppm)
0
0.05
0.10
0.15
0.20
0.25
0.30
N
or
m
al
iz
ed
 In
te
ns
ity
1.001.010.931.952.00
 
Figure AA 3.5: 1HNMR of DL-malic acid and isonicotinamide (from 1:1 starting ratio) 
using acetone-d6 as solvent. 1HNMR 400MH ((CD3)3OD-d6): δ = 8.70(dd, 2H), 7.77(dd, 
2H), 4.5 (dd, 1H), 2.6 (dd, 1H), 2.8 (dd, 1H) 
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Figure AA 3.6: 1HNMR of DL-malic acid and isonicotinamide (from 1:2 starting ratio) 
using acetone-d6 as solvent. 1HNMR 400MH ((CD3)3OD-d6): δ = 8.70(dd, 2H), 7.77(dd, 
2H), 4.5 (dd, 1H), 2.6(dd, 1H), 2.8(dd, 1H) 
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Figure AA 3.7: 1HNMR of DL-malic acid and isonicotinamide (from 2:1 starting ratio) 
using acetone-d6 as solvent. 1ΗΝΜΡ 400ΜΗ ((ΨΔ3)3ΟΔ-δ6):¨δ = 8.70(δδ, 2Η), 7.77(δδ, 
2Η), 4.5 (δδ, 1Η), 2.6(δδ, 1Η), 2.8(δδ, 1Η) 
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Appendix B: Chapter 4 
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Table AB 4.1: PXRD data for samples TA-I-52-1a (1:1), TA-I-52-1b (1:2), in acetone  
L-phenyllactic 
acid 
Iso stnd Iso EHOWIH Iso EHOWIH01 Iso EHOWIH02 
TA-I-52-1a TA-I-52-1B 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
10.28         7.63 7.77 
11.698         10.05 10.23 
14.668         11.815 15.303 
15.911       11.677 15.159 17.913 
18.2         15.71 18.244 
18.762         17.735 18.665 
19.119         18.534 20.342 
19.805       14.625 20.191 23.025 
20.2         23 23.194 
20.611       16.097 23.981 24.157 
20.945       16.52 25.291 25.44 
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21.644         28.69 28.773 
23.128 17.842 17.859 17.843   30.571 30.24 
24.105         35.971 30.752 
26.255 18.855 18.748 18.766 18.626   37.678 
27.785             
29.666 19.411 19.347 19.347 19.14     
30.305 20.874 20.485 20.468 20.138     
30.927     20.996 20.747     
31.98       20.988     
33.34   21.037         
33.534       21.94     
33.913       22.214     
35.314             
35.946 23.449 23.498 23.48 23.457     
36.49             
 329 
 
36.942 24.454 24.385 24.396       
37.674       24.601     
38.706       25.403     
39.761 25.937     25.789     
  26.644 26.093 26.059       
    26.934 26.898       
              
              
  28.166 28.061 28.076       
        28.996     
    29.937 29.925 29.781     
      30.836 30.381     
  30.007 30.882   30.752     
  30.945           
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  31.29 31.198 31.163 31.404     
  32.456 32.474 32.45 32.533     
              
  33.324 33.26 33.485 33.492     
  33.895 33.51 33.864       
    33.856         
        34.992     
  35.415 35.658 35.607 35.524     
  36.105 36.156 36.154       
  36.545 36.556 36.56       
    37.831   37.284     
              
  38.154 38.042 38.041 38.903     
  38.803     38.903     
    39.06 39.002       
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  39.321 39.331 39.336       
        40.503     
              
  41.388 41.281 41.302       
    41.702         
  42.249 42.042         
    42.819 42.754       
  43.456 43.97 43.883       
  44.932 44.902 44.913       
    45.463   45.323     
              
  46.816 46.156         
  47.778 47.141 47.745       
    47.753         
    48.094 48.05       
 332 
 
    48.538         
  49.493 49.468         
  
    
    
 
 
 333 
 
Table AB 4.2: PXRD data for samples TA-I-53-3a (1:1), TA-I-53-3b (1:2), in methanol 
L-phenyllactic 
acid Nicotinamide Std NICOAM NICOAM01 NICOAM02 TA-I-53-3a TA-I-53-3b 
2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 
10.28         18.005 5.16 
11.698 11.671 11.296 11.328 11.301 20.26 14.883 
14.668         25.561 17.641 
15.911   14.764 14.839 14.801 27.212 19.85 
18.2 15.115         22.28 
20.611           25.189 
20.945           25.798 
21.644           27.322 
23.128           37.023 
24.105 19.822 19.041 19.137 19.061   38.737 
26.255   19.495 19.551 19.52     
 334 
 
27.785   19.858 19.96 19.884     
29.666 20.19           
30.305             
30.927 22.524 22.184 22.295 22.215     
31.98   22.68 22.784 22.697     
33.34 23.031 23.347 23.167 23.348     
33.534 23.646   23.868       
33.913   24.662 24.75 24.701     
35.314   25.366   25.379     
35.946 25.707 25.819 25.871 25.823     
36.49 26.114   26.395 26.601     
36.942   27.266 27.017 27.311     
37.674 27.603   27.91       
38.706   28.438   28.443     
  28.724 28.845 28.905 28.861     
 335 
 
  29.158   29.378 29.64     
  30.375 30.088 30.199 30.141     
  31.399 31.207 31.602 31.193     
    32.6 32.388 32.575     
  32.798   32.899       
      33.145       
  33.892 33.557 33.708 33.594     
  34.61 34.09, 34.37 34.442 34.05, 34.412     
  34.743 34.758   34.763     
      35.153       
    35.72 35.839 35.764     
    36.494   36.478     
  36.82 36.935 36.808 36.981     
  37.212           
      37.082       
 336 
 
  38.935 38.64 38.802 38.666     
      39.294       
    39.567 39.702 39.612     
    40.166 40.467 40.167     
    40.914   40.945     
  41.339 41.475 41.06 41.466     
  41.656 41.822 41.724 41.861     
              
  43.688 43.464         
    44.413         
              
    46.627 46.539 46.593     
  47.9 47.312 47.137 47.307     
    47.692 47.744 47.705     
      48.001 48.809     
 337 
 
      48.62       
  49.148    49.526       
  38.154 38.042 38.041       
  38.803     38.903     
    39.06 39.002       
  39.321 39.331 39.336       
              
        40.503     
  41.388 41.281 41.302       
    41.702         
  42.249 42.042         
    42.819 42.754       
  43.456 43.97 43.883       
  44.932 44.902 44.913       
    45.463   45.323     
 338 
 
              
  46.816 46.156         
    47.141         
  47.778 47.753 47.745       
    48.094 48.05       
    48.538         
  49.493 49.468         
 
 
 
 
 
 
 339 
 
Table AB 4.3: PXRD data for samples TA-I-53-4a (1:1), TA-I-53-4b (1:2), TA-I-52-2c (2:1), in acetonitrile  
L-phenyllactic 
acid Nicotinamide Std NICOAM NICOAM01 NICOAM02 TA-I-53-4a TA-I-53-4b 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
10.28         14.841 25.77 
11.698 11.671 11.296 11.328 11.301 15.412 25.016 
14.668         22.253 34.438 
15.911   14.764 14.839 14.801 22.842 30.256 
18.2 15.115       27.723   
20.611         37.01   
20.945         39.101   
21.644             
23.128             
24.105 19.822 19.041 19.137 19.061     
26.255   19.495 19.551 19.52     
 340 
 
27.785   19.858 19.96 19.884     
29.666 20.19           
30.305             
30.927 22.524 22.184 22.295 22.215     
31.98   22.68 22.784 22.697     
33.34 23.031 23.347 23.167 23.348     
33.534 23.646   23.868       
33.913   24.662 24.75 24.701     
35.314   25.366   25.379     
35.946 25.707 25.819 25.871 25.823     
36.49 26.114   26.395 26.601     
36.942   27.266 27.017 27.311     
37.674 27.603   27.91       
38.706   28.438   28.443     
  28.724 28.845 28.905 28.861     
 341 
 
  29.158   29.378 29.64     
  30.375 30.088 30.199 30.141     
  31.399 31.207 31.602 31.193     
    32.6 32.388 32.575     
  32.798   32.899       
      33.145       
  33.892 33.557 33.708 33.594     
  34.61 34.09, 34.37 34.442 34.05, 34.412     
  34.743 34.758   34.763     
      35.153       
    35.72 35.839 35.764     
    36.494   36.478     
  36.82 36.935 36.808 36.981     
  37.212           
      37.082       
 342 
 
  38.935 38.64 38.802 38.666     
      39.294       
    39.567 39.702 39.612     
    40.166 40.467 40.167     
    40.914   40.945     
  41.339 41.475 41.06 41.466     
  41.656 41.822 41.724 41.861     
              
  43.688 43.464         
    44.413         
              
    46.627 46.539 46.593     
  47.9 47.312 47.137 47.307     
    47.692 47.744 47.705     
      48.001 48.809     
 343 
 
      48.62       
  49.148    49.526       
  38.154 38.042 38.041       
  38.803     38.903     
    39.06 39.002       
  39.321 39.331 39.336       
              
        40.503     
  41.388 41.281 41.302       
    41.702         
  42.249 42.042         
    42.819 42.754       
  43.456 43.97 43.883       
  44.932 44.902 44.913       
    45.463   45.323     
 344 
 
              
  46.816 46.156         
    47.141         
  47.778 47.753 47.745       
    48.094 48.05       
    48.538         
  49.493 49.468         
 
 
 345 
 
Table AB 4.4: PXRD data for samples TA-I-31-1a (1:1), TA-I-31-1b (1:2), TA-I-31-1c (2:1), in acetone  
DL-Phenyllactic acid Iso stnd EHOWIH EHOWIH01 EHOWIH02 TA-I-31-1a TA-I-31-1b TA-I-31-1c 
2-Theta° 2-Theta° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
8.328         8.089 8.015 8.028 
10.939         
 
10.222 
           
           11.677 
   13.183         
   14.88       14.625 
   15.044         
   
     
15.894 
 
15.719 
16.24         
   16.443       16.097 
   16.68       16.52 
 
  
 
 346 
 
          
 
  
   17.842 17.859 17.843   17.81  17.801 17.72 
18.54 18.855 18.748 18.766 18.626 
 
  18.666 
18.737          18.899   
 19.354 19.411 19.347 19.347 19.14     19.339 
                
    20.485 20.468 20.138       
20.333  20.874   20.996 20.747       
20.541       20.988      20.499 
    21.037           
21.848       21.94       
22.481       22.214       
             23.009   
23.405 23.449 23.498 23.48 23.457 23.719   23.783  23.56 
           23.9    23.796 
 347 
 
24.174 24.454 24.385 24.396      24.475   
24.78       24.601  24.618    24.522 
25.52       25.403  25.567  25.391  25.476 
25.763 25.937     25.789       
  
 
26.093 26.059        26.172 
 26.358  26.644             
 
  26.934 26.898         
27.547               
27.813               
28.58 28.166 28.061 28.076         
28.99       28.996  28.759  28.583  28.716 
29.174               
29.94   29.937 29.925 29.781       
30.151 30.007     30.381  30.463     
30.784 30.945 30.882 30.836 30.752      30.624 
 348 
 
                
31.241 31.29 31.198 31.163 31.404      31.393 
     
31.462 31.493 
 32.781 32.456 32.474 32.45 32.533       
                
  33.324 33.26           
    33.51 33.485 33.492        
33.04 33.895  33.856  33.864         
34.137               
34.53              34.484 
        34.992       
                
35.764 35.415 35.658 35.607 35.524       
                
  36.105 36.156 36.154         
 349 
 
 36.724 36.545 36.556 36.56         
 37.396       37.284        
37.902    37.831      37.984     
  38.154 38.042 38.041         
  38.803     38.903       
 39.087   39.06 39.002    39.184     
 39.557 39.321 39.331 39.336         
                
        40.503       
  41.388 41.281 41.302         
    41.702           
  42.249 42.042           
    42.819 42.754         
  43.456 43.97 43.883         
                
 350 
 
  44.932 44.902 44.913         
    45.463   45.323       
    46.156            
  46.816             
    47.141           
  47.778 47.753 47.745         
    48.094 48.05         
    48.538           
  49.493 49.468           
 
 
 
 351 
 
Table AB 4.5: PXRD data for samples TA-I-31-2a (1:1), TA-I-31-2b (1:2), TA-I-31-2c (2:1), in methanol 
DL-Phenyllactic  
acid 
Iso  
Stnd 
Iso  
EHOWIH 
Iso  
EHOWIH01 
Iso  
EHOWIH02 
TA-I-31-2a TA-I-31-2b TA-I-31-2c 
2-Theta° 2-Theta° 2-Theta° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
8.328         8.119 8.11 8.158 
10.939         10.283   
             
        11.677    
       12.279 
13.183            
14.88       14.625    
15.044           15.09 
      15.979 15.964 
16.24            
 352 
 
16.443       16.097 16.003   
16.68       16.52    
            17.04 
  17.842 17.859 17.843   17.857 17.833 17.883 
18.54 18.855 18.748 18.766 18.626    
18.737         18.968 18.889  
19.354 19.411 19.347 19.347 19.14    19.493 
               
    20.485 20.468 20.138      
20.333  20.874   20.996 20.747      20.718 
20.541       20.988       
    21.037           
21.848       21.94      21.666 
22.481       22.214       
       22.824 
 353 
 
             23.249   
23.405 23.449 23.498 23.48 23.457    23.62  23.963 
           23.908  23.893   
24.174 24.454 24.385 24.396         
24.78       24.601  24.621  24.698  24.629 
25.52       25.403  25.59  25.617  25.641 
25.763 25.937     25.789       
  26.644 26.093 26.059         
 26.358          26.367     
   26.934 26.898      26.638   
27.547               
27.813               
28.58 28.166 28.061 28.076         
28.99       28.996  28.832  28.862  28.889 
29.174               
 354 
 
29.94   29.937 29.925 29.781       
30.151 30.007     30.381       
30.784 30.945 30.882 30.836 30.752  30.684     
                
31.241 31.29 31.198 31.163 31.404  31.438  31.512   
     32.065   
32.781 32.456 32.474 32.45 32.533     32.646 
                
  33.324 33.26           
    33.51 33.485 33.492        
33.04 33.895  33.856  33.864    33.684     
34.137               
34.53              34.777 
        34.992       
                
 355 
 
35.764 35.415 35.658 35.607 35.524       
                
  36.105 36.156 36.154         
 36.724 36.545 36.556 36.56      36.636   
 37.396       37.284        
37.902    37.831           
  38.154 38.042 38.041    38.233     
  38.803     38.903    38.884   
 39.087   39.06 39.002         
 39.557 39.321 39.331 39.336        39.459 
                
        40.503       
  41.388 41.281 41.302         
    41.702           
  42.249 42.042           
 356 
 
 
 
 
    42.819 42.754         
  43.456 43.97 43.883         
                
  44.932 44.902 44.913         
    45.463   45.323       
    46.156            
  46.816             
    47.141           
  47.778 47.753 47.745         
    48.094 48.05         
    48.538           
  49.493 49.468           
 357 
 
Table AB 4.6: PXRD data for samples TA-I-31-3a (1:1), TA-I-31-3b (1:2), TA-I-31-3c (2:1), in acetonitrile  
DL-
Phenyllactic 
acid 
Iso stnd EHOWIH EHOWIH01 EHOWIH02 TA-I-31-3a TA-I-31-3b TA-I-31-3c 
2-Theta° 2-Theta° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
8.328        
10.939        
      11.249  
    11.677    
13.183        
14.88    14.625    
15.044        
16.24        
16.443    16.097    
 358 
 
16.68    16.52    
     17.497 17.468 17.537 
 17.842 17.859 17.843     
18.54 18.855 18.748 18.766 18.626    
18.737        
19.354 19.411 19.347 19.347 19.14    
        
  20.485 20.468 20.138    
20.333 20.874  20.996 20.747    
20.541    20.988    
  21.037      
21.848    21.94    
22.481    22.214  22.046  
     22.871 22.833 22.874 
23.405 23.449 23.498 23.48 23.457 23.308 23.329 23.346 
 359 
 
        
24.174 24.454 24.385 24.396   24.25  
24.78    24.601    
25.52    25.403 25.234 25.17 25.125 
25.763 25.937   25.789    
 26.644 26.093 26.059     
        
26.358  26.934 26.898     
27.547        
27.813        
28.58 28.166 28.061 28.076  28.352 28.387 28.365 
28.99    28.996    
29.174        
29.94  29.937 29.925 29.781    
30.151 30.007   30.381    
 360 
 
30.784 30.945 30.882 30.836 30.752    
        
31.241 31.29 31.198 31.163 31.404    
32.781 32.456 32.474 32.45 32.533    
        
 33.324 33.26      
  33.51 33.485 33.492    
33.04 33.895 33.856 33.864     
34.137        
34.53      34.663  
    34.992    
        
35.764 35.415 35.658 35.607 35.524    
        
 36.105 36.156 36.154     
36.724 36.545 36.556 36.56   36.543  
 361 
 
37.396    37.284    
37.902  37.831      
 38.154 38.042 38.041     
 38.803   38.903    
39.087  39.06 39.002     
39.557 39.321 39.331 39.336     
        
    40.503    
 41.388 41.281 41.302     
  41.702      
 42.249 42.042      
  42.819 42.754     
 43.456 43.97 43.883     
        
 44.932 44.902 44.913     
 362 
 
 
 
  45.463  45.323    
  46.156      
 46.816       
  47.141      
 47.778 47.753 47.745     
  48.094 48.05     
  48.538      
 49.493 49.468      
 363 
 
Table AB 4.7: PXRD data for samples TA-I-32-2a (1:1), TA-I-32-2b (1:2), TA-I-32-2c (2:1), in acetone 
DL-
Phenyllactic  
acid 
Nicotinamide 
 Std NICOAM NICOAM01 NICOAM02 TA-I-32-2a TA-I-32-2b TA-I-32-2c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
       
5.914 
      
7.989 
 8.328     8.157 
 
8.277 
      
8.995 
 
     
9.77 9.827 9.871 
10.939 
       
 
11.671 11.296 11.328 11.301 
   
      
12.107 12.881 
13.183     
 
13.284 
 
     
14.436 
  14.88  14.764 14.839 14.801 
 
14.693 
 
 364 
 
15.044 15.115       
   16.24         
  
16.428 
16.443         16.321 16.411 
 16.68         16.826 
 
16.977 
      
17.405 
 
       
17.795 
18.54     18.126 18.136 18.471 
18.737   
   
18.697 18.504 
 
      
18.857 18.672 
19.354 
 
19.041 19.137 19.061 
   
 
 19.495 19.551 19.52 
   
 
 19.822 19.858 19.96 19.884 19.711 19.726 19.77 
20.333 20.19       
   20.541         
  
20.9 
 
        21.054 
 
21.114 
 365 
 
21.848         21.678 21.633 
 22.481 22.524 22.184 22.295 22.215 22.364 22.388 
 
 
  22.68 22.784 22.697 22.967 22.987 
 23.405 23.031 23.347 23.167 23.348 23.464 
 
23.281 
 
23.646   23.868   23.828 
 
  
24.174           
 
 24.003 
24.78   24.662 24.75 24.701  24.87 24.939  24.929 
25.52   25.366   25.379   
 
  
25.763 25.707 25.819 25.871 25.823   
 
  
 
26.114     26.601     26.513 
26.358     26.395      26.744   
27.547   27.266 27.017 27.311       
27.813 27.603   27.91      27.928   
28.58   28.438   28.443  28.039    28.251 
28.99 28.724 28.845 28.905 28.861  28.822     
 366 
 
29.174 29.158   29.378         
29.94       29.64       
30.151 30.375 30.088 30.199 30.141    30.032   
30.784 
       31.241 31.399 31.207 31.602 31.193 31.017 31.134  
 
  32.6 32.388 32.575       
32.781 32.798   32.899         
33.04     33.145    33.12     
 
33.892 33.557 33.708 33.594  33.399  33.623   
34.137 
 
34.09, 
 
34.05, 
   34.53 34.61 34.37 34.442 34.412    
 
34.743 34.758   34.763       
 
    35.153         
35.764   35.72 35.839 35.764       
 
  36.494   36.478       
 367 
 
 36.724 36.82 36.935 36.808 36.981    36.796   
 37.396 37.212    37.082      37.426  37.685 
37.902                
  38.935 38.64 38.802 38.666       
 39.087     39.294         
 39.557   39.567 39.702 39.612       
    40.166 40.467 40.167       
    40.914   40.945       
  41.339 41.475 41.06 41.466       
  41.656 41.822 41.724 41.861       
                
  43.688 43.464           
    44.413           
                
    46.627 46.539 46.593       
 368 
 
  47.9 47.312 47.137 47.307       
    47.692 47.744 47.705       
      48.001 48.809       
      48.62         
  49.148    49.526         
  38.154 38.042 38.041         
  38.803     38.903       
    39.06 39.002         
  39.321 39.331 39.336         
                
        40.503       
  41.388 41.281 41.302         
    41.702           
  42.249 42.042           
    42.819 42.754         
 369 
 
 
  43.456 43.97 43.883         
  44.932 44.902 44.913         
    45.463   45.323       
                
  46.816 46.156           
    47.141           
  47.778 47.753 47.745         
    48.094 48.05         
    48.538           
  49.493 49.468           
 370 
 
Table AB 4.8: PXRD data for samples TA-I-32-3a (1:1), TA-I-32-3b (1:2), TA-I-32-3c (2:1), in methanol 
DL-Phenyllactic acid Nicotinamide Std NICOAM NICOAM01 NICOAM02 TA-I-32-3a TA-I-32-3b TA-I-32-3c 
2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 
        
8.328     8.348   
      9.731  
        
     10.203   
10.939        
 11.671 11.296 11.328 11.301   11.613 
     12.477   
      12.029  
13.183        
        
14.88  14.764 14.839 14.801    
15.044 15.115      15.085 
 371 
 
16.24        
      16.318  
16.443        
16.68        
     16.774   
      17.314  
     17.79   
      18.053  
18.54     18.498   
18.737        
       19.289 
19.354  19.041 19.137 19.061    
  19.495 19.551 19.52    
      19.639  
 19.822 19.858 19.96 19.884   19.733 
 372 
 
     20.098  20.034 
20.333 20.19       
20.541        
      21.557  
21.848        
     22.021   
  22.184  22.215    
22.481   22.295   22.305 22.34 
 22.524      22.496 
  22.68 22.784 22.697 22.75   
      22.921  
23.405 23.031  23.167     
  23.347  23.348 23.353   
 23.646  23.868     
        
 373 
 
24.174        
24.78  24.662 24.75 24.701  24.844  
       24.917 
     25.08   
25.52  25.366  25.379 25.31   
25.763 25.707 25.819 25.871 25.823   25.994 
 26.114   26.601    
26.358   26.395     
        
  27.266 27.017 27.311    
27.547       27.563 
27.813 27.603  27.91   27.842  
     28.311   
28.58  28.438  28.443    
       28.645 
 374 
 
28.99 28.724 28.845 28.905 28.861    
29.174 29.158  29.378     
29.94    29.64    
30.151 30.375 30.088 30.199 30.141 30.378   
30.784        
31.241  31.207 31.602 31.193    
 31.399    31.46   
  32.6 32.388 32.575    
32.781 32.798  32.899     
33.04   33.145     
       30.426 
  33.557 33.708 33.594    
 33.892    33.93  33.882 
34.137  34.09,  34.05,    
34.53 34.61 34.37 34.442 34.412    
 375 
 
 34.743 34.758  34.763   34.712 
   35.153     
35.764  35.72 35.839 35.764    
  36.494  36.478    
36.724 36.82 36.935 36.808 36.981  36.708  
37.396 37.212  37.082  37.178  37.194 
37.902     37.814   
 38.935 38.64 38.802 38.666   38.90 
        
39.087   39.294     
39.557  39.567 39.702 39.612    
  40.166 40.467 40.167    
  40.914  40.945    
 41.339 41.475 41.06 41.466    
 41.656 41.822 41.724 41.861    
 376 
 
        
 43.688 43.464      
  44.413      
        
  46.627 46.539 46.593    
 47.9 47.312 47.137 47.307    
  47.692 47.744 47.705    
   48.001 48.809    
   48.62     
 49.148  49.526     
 38.154 38.042 38.041     
 38.803   38.903    
  39.06 39.002     
 39.321 39.331 39.336     
        
 377 
 
    40.503    
 41.388 41.281 41.302     
  41.702      
 42.249 42.042      
  42.819 42.754     
 43.456 43.97 43.883     
 44.932 44.902 44.913     
  45.463  45.323    
        
 46.816 46.156      
  47.141      
 47.778 47.753 47.745     
  48.094 48.05     
  48.538      
 49.493 49.468      
 378 
 
Table AB 4.9: PXRD data for samples TA-I-32-4a (1:1), TA-I-32-4b (1:2), TA-I-32-4c (2:1), in acetonitrile  
DL-Phenyllactic 
acid Nicotinamide Std NICOAM NICOAM01 NICOAM02 TA-I-32-4a TA-I-32-4b TA-I-32-4c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
          6.024 
 
6.326 
          
   8.328         
 
8.481 
           
  
10.178 
          9.891 
 
9.242 
      
10.285 10.178 
10.939     
     11.671 11.296 11.328 11.301 
  
11.888 
          
 
12.588 
 13.183         
  
13.31 
          
  
13.673 
 379 
 
14.88   14.764 14.839 14.801 
   15.044 15.115       
   16.24         
   16.443         
   16.68         16.549  
  
      
16.881 16.821 
     17.098    
           17.89   17.838 17.406 
       
18.166 
18.54       
 18.737         18.69   18.608 18.981 
                
19.354   19.041 19.137 19.061       
    19.495 19.551 19.52       
   19.822 19.858 19.96 19.884 19.812      
 380 
 
       
20.063 
20.333 20.19     20.192   
20.541               
           21.144   21.362  
21.848               
       
21.6 
      
22.106 
 22.481 22.524 22.184 22.295 22.215 22.595   22.831  
    22.68 22.784 22.697       
23.405 23.031 23.347 23.167 23.348       
  23.646   23.868   23.515   23.466 23.723  
        24.174        
24.78   24.662 24.75 24.701     24.571  
     
25.088 
  
 381 
 
25.52   25.366   25.379    25.348   
25.763 25.707 25.819 25.871 25.823       
  26.114     26.601       
26.358     26.395         
     
26.938 
 
26.901 
27.547  27.266 27.017 27.311     27.164 
27.813 27.603   27.91         
     
28.27 28.329 
 28.58  28.438  28.443 
 
  28.625  
28.99 28.724 28.845 28.905 28.861      
29.174 29.158   29.378         
29.94       29.64       
30.151 30.375 30.088 30.199 30.141       
30.784               
31.241 31.399 31.207 31.602 31.193       
 382 
 
    32.6 32.388 32.575       
32.781 32.798   32.899         
33.04     33.145        33.338 
  33.892 33.557 33.708 33.594       
34.137   34.09,   34.05,    34.02   
34.53 34.61 34.37 34.442 34.412       
  34.743 34.758   34.763       
      35.153         
35.764   35.72 35.839 35.764       
    36.494   36.478       
 36.724 36.82 36.935 36.808 36.981       
 37.396 37.212    37.082      37.222   
37.902             37.898   
  38.935 38.64 38.802 38.666       
 39.087     39.294         
 383 
 
 39.557   39.567 39.702 39.612       
    40.166 40.467 40.167       
    40.914   40.945       
  41.339 41.475 41.06 41.466       
  41.656 41.822 41.724 41.861       
                
  43.688 43.464           
    44.413           
                
    46.627 46.539 46.593       
  47.9 47.312 47.137 47.307       
    47.692 47.744 47.705       
      48.001 48.809       
      48.62         
  49.148    49.526         
 384 
 
  38.154 38.042 38.041         
  38.803     38.903       
    39.06 39.002         
  39.321 39.331 39.336         
                
        40.503       
  41.388 41.281 41.302         
    41.702           
  42.249 42.042           
    42.819 42.754         
  43.456 43.97 43.883         
  44.932 44.902 44.913         
    45.463   45.323       
                
  46.816 46.156           
 385 
 
    47.141           
  47.778 47.753 47.745         
    48.094 48.05         
    48.538           
  49.493 49.468           
 
 
 
 386 
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 387 
 
Table AC 5.1: PXRD data for samples TA-I-19-3a (1:1), TA-I-19-3b (1:2), TA-I-19-3c (2:1), in methanol 
Phenylboronic 
 Acid 
Isostnd EHOWIH EHOWIH01 EHOWIH02 TA-I-19-3a TA-19-3b TA-I-19-3c 
2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 
         7.903 
9.94     9.236 9.261 9.429 
      10.398  
      10.883  
      11.368 11.528 
    11.677  11.993  
12.05        
12.86      12.926  
13.84      13.934  
    14.625  14.468 14.592 
15.27     15.406 15.383  
 388 
 
       15.79 
    16.097  16.48  
16.62    16.52 16.81 16.802  
17.31       17.046 
 17.842 17.859 17.843  17.565 17.768 17.558, 
18.26     18.494   
18.72 18.855 18.748 18.766 18.626  18.663 18.72 
        
 19.411 19.347 19.347 19.14 19.428 19.298  
      19.973 19.744 
20.88 20.874 20.485 20.468 20.138 20.6 20.16  
   20.996 20.747  20.712  
    20.988    
21.17  21.037   21.168 21.542 21.43 
    21.94   21.665 
 389 
 
22.00    22.214 22.244 22.28 22.244 
       22.67 
     23.007 23.16 23.102 
 23.449 23.498 23.48 23.457 23.317 23.456 23.406 
      23.786 23.56 
24.01        
24.39 24.454 24.385 24.396     
    24.601  24.571  
      24.919 24.98 
25.74    25.403 25.83 25.472 25.493 
 25.937   25.789   25.78 
26.02  26.09 26.06   26.22 26.13 
 26.64 26.93 26.89     
     27.44   
     27.75 27.74 27.75 
 390 
 
     27.96   
 28.16 28.06 28.07   28.12 28.20 
28.48     28.49   
    28.99 28.76 28.885 28.72 
     29.14 29.22 29.10 
  29.94 29.92 29.78  29.69  
   30.83 30.38    
 30.00 30.88  30.75    
 30.94       
31.07  31.19 31.16     
31.72 31.29   31.40   31.73 
 32.45 32.47 32.45 32.53    
        
 33.32 33.26 33.48 33.49    
33.61 33.89 33.51 33.86     
 391 
 
  33.85      
     34.34   
       35.10 
    34.992    
 35.41 35.66 35.60 35.52 35.40  35.67 
 36.10 36.15 36.15   36.071 36.13 
 36.54 36.55 36.56    36.71 
  37.83  37.28 37.52   
     37.90   
 38.15 38.04 38.04    38.11 
38.98 38.80   38.90    
  39.06 39.00     
39.62 39.32 39.33 39.33    39.75 
40.21    40.50  40.523  
40.31        
 392 
 
 
 41.38 41.28 41.30    41.08 
  41.70      
 42.25 42.04     42.11 
  42.82 42.75     
 43.45 43.97 43.88     
 44.93 44.90 44.91     
  45.46  45.32   45.07 
       45.76 
 46.82 46.15      
 47.77 47.14 47.74    47.31 
  47.753      
  48.094 48.05     
   48.538     48.564 
  49.493 49.468      
 393 
 
Table AC 5.2: PXRD data for samples TA-I-19-2a (1:1), TA-I-19-2b (1:2), TA-I-19-2c (2:1), in acetonitrile  
 
Phenylboronic 
 Acid 
IsoStnd EHOWIH EHOWIH01 EHOWIH02 TA-I-19-2a TA-I-19-2b TA-I-19-2c 
2-Theta° 2-Theta° 2-Theta ° 2-Theta ° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 
9.94      9.558  
    11.67   11.57 
12.05       12.10 
12.86       12.49 
13.84        
    14.62    
15.27        
     15.96 15.91  
    16.09    
16.62    16.52   16.99 
 394 
 
17.31     17.26 17.32  
 17.84 17.86 17.84  17.86 17.79  
18.26     18.25   
18.72 18.85 18.75 18.76 18.63    
      18.51 18.90 
 19.41 19.35 19.34 19.14  19.42  
      19.80  
20.88 20.87 20.48 20.46 20.14    
   20.99 20.75   20.87 
    20.98  20.89  
21.17  21.04   21.46   
    21.94 21.68 21.74  
22.00    22.21   22.09 
     23.12   
 23.45 23.49 23.48 23.46 23.41 23.54  
 395 
 
     23.65 23.72 23.61 
24.01     24.14  24.16 
24.39 24.45 24.38 24.39     
    24.60   24.79 
    25.40   25.13 
25.74 25.94   25.79    
26.02 26.644 26.093 26.059   26.02  
  26.934 26.898     
 28.166 28.061 28.076  28.34 28.27 28.46 
28.48    28.99 28.909   
      29.16  
     29.442 29.44 29.38 
  29.937 29.925 29.78   29.85 
   30.836 30.38    
 30.007     30.055  
 396 
 
 30.945 30.882  30.752    
31.07      31.045  
      31.48  
31.72 31.29 31.198 31.163 31.40 31.94 31.92  
 32.456 32.474 32.45 32.53    
        
 33.324 33.26 33.485 33.49    
33.61 33.895 33.51 33.864     
  33.856      
    34.99 34.998 34.86  
 35.415 35.658 35.607 35.524    
 36.105 36.156 36.154  36.042 36.10  
 36.545 36.556 36.56     
  37.831  37.284    
        
 397 
 
 38.154 38.042 38.041  38.157 38.129  
38.98 38.803   38.903    
  39.06 39.00     
39.62 39.32 39.33 39.33  39.93   
40.21    40.503    
40.31        
 41.38 41.28 41.30  41.37   
  41.70      
 42.25 42.04      
  42.82 42.75     
 43.45 43.97 43.88     
 44.93 44.90 44.91     
  45.463  45.323 45.45   
  46.15      
 46.81       
 398 
 
 
 
  47.141   47.53   
 47.78 47.753 47.74     
  48.094 48.05     
   48.538      
 399 
 
Table AC 5.3 PXRD data for samples TA-I-20-2a (1:1), TA-I-20-2b (1:2), TA-I-20-2c (2:1), in acetone 
Phenylboronic acid Nicotinamide Nicoam1 Nicoam2 Nicoam TA-I-20-2a TA-I-20-2b TA-I-20-2c 
2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 
       5.183 
       6.532 
     7.812 7.793 7.101 
       8.102 
       8.519 
       8.923 
9.94         9.222 9.232 9.529 
       10.396 
  11.67 11.328 11.301 11.296   11.508 
          
12.05     12.28  12.444 
12.86        
 400 
 
       13.006 
13.84       13.783 
  14.839 14.801 14.764 14.529 14.51 14.509 
 15.27 15.115       15.48  15.852 
     15.99   
16.62          16.016 16.295 
       16.546 
 17.31         17.773  17.111 
18.26           18.163 
18.72     18.737 18.79  
     19.061     19.04 
    19.551 19.52 19.495   19.518 
 19.822 19.96 19.884 19.858 19.966  19.863 
 20.19        20.048 20.282 
 401 
 
20.88         20.872 20.913  
21.17           21.173 
      21.949 21.803 
22 22.524 22.295 22.215 22.184 22.034   
    22.784 22.697 22.68    
  23.03 23.167 23.348 23.347 23.213 23.303 23.228 
  23.646 23.868       23.647 
24.01         
24.39  24.75 24.701 24.662   24.334 
       24.839 
     25.379 25.366  25.175  
25.74  25.707 25.871 25.823 25.819 25.685 25.67  
26.02 26.114 26.395     26.378  26.062 
  27.603   27.311 27.266 26.777 26.99 26.662 
 402 
 
       27.066 
   27.91     27.924 27.927  
     28.443 28.438   28.082 
 28.48 28.72 28.905 28.861 28.845   28.3 
   29.378       29.566 
 30.37 30.199 30.141 30.088 30.053 30.067  
31.07            
31.72  31.602      
  32.79 32.899 32.575 32.6    
    33.145        
33.61   33.708 33.594      
  34.61 34.442 34.412      
    35.153 35.764      
    35.83        
 403 
 
    36.478   36.312  
  36.82   36.981  36.935    
  37.212 37.082        
             
38.98 38.93 38.802 38.666 38.64    
 39.62            
40.21      40.945      
    41.06 41.466 41.475    
   41.724        
            
            
            
             
 46.31     46.593 46.627    
 404 
 
 
 
  47.9 47.744 47.307 47.692    
    48.001 47.705      
    48.62 48.809      
 405 
 
Table AC 5.4: PXRD data for samples TA-I-20-3a (1:1), TA-I-20-3b (1:2), TA-I-20-3c (2:1), in methanol  
Phenylboronic  
acid 
Nicotinamide Nicoam1 Nicoam2 Nicoam TA-I-20-3a TA-I-20-3b TA-I-20-3c 
2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta° 2-Theta ° 
       6.549 
         7.417   
9.94     9.285 9.591 9.122 
     10.951  10.465 
  11.67 11.328 11.301 11.296  11.295  
 12.05        12.07 
12.86       12.349 
       13.02 
13.84       13.526 
  14.839 14.801 14.764 14.229 14.906  
 15.27 15.115         15.171 
 406 
 
16.62         16.008 16.374 16.266 
       17.081 
 17.31           17.358 
18.26         18.052  18.241 
18.72     18.786  18.51 
     19.061   19.232 19.099  
    19.551 19.52 19.495  19.57 19.545 
 19.822 19.96 19.884 19.858    
 20.19         20.168 
20.88         20.704   
     20.93   
21.17          21.256 21.177 
       21.794 
22 22.524 22.295 22.215 22.184 22.148 22.375  
 407 
 
    22.784 22.697 22.68 22.778   
  23.03 23.167 23.348 23.347 23.307  23.128 
  23.646 23.868      23.609  
24.01        24.255 
24.39  24.75 24.701 24.662  24.762 24.767 
     25.379 25.366 25.205 25.506  
25.74  25.707 25.871 25.823 25.819  25.944  
26.02 26.114 26.395     26.638  26.188 
  27.603   27.311 27.266 27.407 27.425 27.425 
   27.91     27.999   
     28.443 28.438  28.316  
 28.48 28.72 28.905 28.861 28.845   28.921 
   29.378     29.688 29.984  
 30.37 30.199 30.141 30.088 30.12 30.456  
 408 
 
31.07            
31.72  31.602      
  32.79 32.899 32.575 32.6 32.577 32.944  
    33.145        
33.61   33.708 33.594   33.722   
      34.039  
  34.61 34.442 34.412      
    35.153 35.764      
    35.83        
 36.82   36.478 36.935    
     36.981      
  37.212 37.082        
          38.243 38.54  
38.98 38.93 38.802 38.666 38.64    
 409 
 
 
 
 39.62            
40.21      40.945      
    41.06 41.466 41.475    
   41.724     41.61   
 46.31     46.593 46.627    
  47.9 47.744 47.307 47.692    
    48.001 47.705      
    48.62 48.809      
 410 
 
Table AC 5.5: PXRD data for samples TA-I-20-4a (1:1), TA-I-20-4b (1:2), TA-I-20-4c (2:1), in acetonitrile  
Phenyl-boronic 
 acid 
Nicotinamide Nicoam1 Nicoam2 Nicoam TA-I-20-4a TA-I-20-4b TA-I-20-4c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     
  
7.799 
     
 
8.201 
      
 
8.457 
 9.94         
  
9.66 
  11.67 11.328 11.301 11.296 
 
11.956 11.185 
       
   12.05         
  
12.202 
12.86         
   13.84         
  
13.44 
  14.839 14.801 14.764 
 
14.798 14.564 
 15.27 15.115       
  
15.614 
 411 
 
16.62         
 
16.26 16.322 
 17.31         
  
17.843 
18.26         
   18.72         
 
18.548 
       19.061   
  
19.336 
    19.551 19.52 19.495 
  
19.45 
  19.822 19.96 19.884 19.858 
     20.19       
  
20.003
20.88         
 
20.545 
 21.17         
        
  
21.906 
22 22.524 22.295 22.215 22.184 
       22.784 22.697 22.68 
     23.03 23.167 23.348 23.347 
 
23.487 23.016 
 412 
 
  23.646 23.868     
   24.01      
  
24.003 
24.39   24.75 24.701 24.662 
 
24.408 
      
  
25.17 
      25.379 25.366 
 
25.437 25.611 
25.74  25.707 25.871 25.823 25.819 
   26.02     
 
26.086 
  26.114 26.395     
 
26.739 26.325 
     
 
27.017 27.049 
     27.311 27.266 
 
27.361 
    27.603 27.91     
  
27.992 
      28.443 28.438 
    28.48 28.72 28.905 28.861 28.845 
       29.378     
  
29.824 
 413 
 
  30.37 30.199 30.141 30.088 
   31.07          
   31.72   31.602     
     32.79 32.899 32.575 32.6 
  
32.295 
    33.145     
   33.61   33.708 33.594   
     34.61 34.442 34.412   
       35.153 35.764   
       35.83     
      36.478  
     36.82   36.981 36.935 
  
36.678 
  37.212 37.082     
             
   38.98 38.93 38.802 38.666 38.64 
  
38.428 
 414 
 
 39.62         
   40.21      40.945   
  
40.55 
    41.06 41.466 41.475 
       41.724        
                
                
                
                
 46.31     46.593 46.627       
  47.9 47.744 47.307 47.692       
    48.001 47.705         
    48.62 48.809         
 
 
 
 415 
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 416 
 
Table AD 6.1: PXRD data for samples TA-I-54-1a (1:1), TA-I-54-1b (1:2), TA-I-54-1c (2:1), 
in acetone 
Phenylboronic 
acid 4,4’-bipyridine 
TA-I-54-1a 
 
TA-I-54-1b 
 
TA-I-54-1c 
 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     
    9.33 
9.94 9.94   9.99 
   11.25  
12.05  12.04 12.02  
 12.36    
12.86 13.03 13.18 13.17  
13.84     
15.27    15.46 
    16.14 
16.62    16.88 
17.31 17.50, 17.67    
18.26 18.31  18.12  
18.72    18.51 
 19.36    
  19.68 19.58 19.99 
 20.13 20.16 20.12  
20.88 20.82    
21.17   21.27 21.23 
 21.59    
22.00 22.37    
 22.98   22.83 
    23.58 
 417 
 
24.01  24.15 24.17  
24.39     
 25.03    
25.74 25.78 25.54 25.44 25.54 
26.02 26.24  26.19  
  26.46 26.42 26.46 
  27.32 27.17  
 27.81    
28.48   28.74  
 29.12 29.35 29.32 29.33 
 30.38    
31.07 30.68  31.05  
31.72 31.92    
 32.40    
33.61 33.60 33.46 33.44  
 35.24    
   36.01  
  37.12 37.08  
   38.27  
38.98   38.52  
39.62     
40.21     
46.31     
 
 418 
 
Table AD 6.2: PXRD data for samples TA-I-54-2a (1:1), TA-I-54-2b (1:2), TA-I-54-2c (2:1), 
in methanol 
Phenylboronic 
acid 
4,4’-bipyridine TA-I-54-2a TA-I-54-2b TA-I-54-2c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
  5.74  5.72 
  7.42   
    8.19 
    9.37 
9.94 9.94 10.26  10.14 
  10.80   
  11.28 11.14, 11.33 11.31 
12.05  12.10 12.04 12.00 
 12.36 12.40  12.61 
12.86 13.03 13.01 13.00, 13.24 13.26 
13.84  14.33  13.96 
  14.62  14.67 
15.27  15.13  15.60 
  16.10   
16.62  16.54  16.61 
   17.03 17.09 
17.31 17.50, 17.67 17.45  17.42 
18.26 18.31 18.23 18.28 18.15 
18.72  18.72  18.75 
 19.36 19.24 19.26 19.02 
  19.68 19.58 19.76 
 20.13 20.23 20.21 20.12 
20.88 20.82    
21.17  21.54 21.49 21.46 
 419 
 
 21.59    
22.00 22.37 22.21  22.28 
   22.67 22.66 
 22.98 22.85   
  23.60  23.48 
24.01  24.06 24.33 24.00 
24.39  24.62  24.23 
 25.03    
25.74 25.78 25.53 25.56 25.56 
26.02 26.24  26.32 26.31 
  26.48 26.51 26.58 
  27.32 27.12 27.16 
 27.81 27.84 27.54  
28.48  28.26   
 29.12 29.33 29.41 29.41 
  29.68 29.99  
 30.38 30.30   
 30.68 30.81 30.74 30.87 
31.07  31.00 30.92  
   31.30 31.22 
31.72 31.92 31.66   
     
 32.40 32.56 32.12 32.58 
33.61 33.60 33.50 33.54 33.60 
  34.61  34.16 
 35.24    
  35.90   
 420 
 
  36.40   
  37.05 37.13 37.16 
  38.34 38.46 38.23 
38.98  38.53  38.59 
39.62     
40.21     
46.31     
 
 
 
 
 
 
 421 
 
Table AD 6.3: PXRD data for samples TA-I-55-1a (1:1), TA-I-55-1b (1:2), TA-I-55-1c (2:1), 
in acetonitrile  
Phenylboronic 
acid 
4,4’-bipyridine TA-I-55-1a TA-I-55-1b TA-I-55-1c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
    5.621 
    9.06 
9.94 9.94    
    10.40 
  11.34 11.40 11.11, 11.64 
12.05  12.11 12.18  
 12.36   12.29 
12.86 13.03 13.25 13.37 12.88 
13.84     
   14.71 14.03, 14.61 
15.27    15.36 
16.62    16.36 
17.31 17.50, 17.67   17.12, 17.35 
18.26 18.31 18.23 18.27  
18.72    18.66 
 19.36   19.22 
  19.74 19.83  
 20.13 20.23 20.29 20.23 
20.88 20.82   20.58 
21.17    21.28 
 21.59 21.61 21.74 21.70 
22.00 22.37    
 22.98 23.25 23.33 23.04,23.52 
24.01     
 422 
 
24.39   24.41 24.38 
 25.03   25.22 
25.74 25.78 25.59 25.67  
26.02 26.24   26.30 
  26.53 26.54 26.63,26.80 
  27.32 27.32 27.52 
 27.81    
28.48    28.55 
 29.12 29.41 29.41 29.12 
    29.78 
 30.38    
31.07 30.68 31.18 31.27 30.79 
31.72 31.92   31.89 
 32.40   32.38 
  32.80 32.85  
33.61 33.60  33.62 33.21 
 35.24    
  37.15 37.21  
  38.36 38.42  
38.98   38.80  
39.62    39.25 
40.21     
46.31     
 
 423 
 
Table AD 6.4: FT-IR assignments for samples TA-I-55-1a (1:1), TA-I-55-1b (1:2), TA-I-55-
1c (2:1), and its starting materials in acetonitrile)  
Assignment is made using the literature.
36
 
Phenylboronic 
acid 
 
4,4’-
bipyridine 
 
TAI-55-1a 
1:1 
TAI-55-1b 
1:2 
TAI-55-1c 
2:1 
Assignment 
[36] 
cm-1 cm-1 cm-1 cm-1 cm-1 cm-1 
 3429 3429 3429 3437 O-H, stretch 
3273 
3081 
3024 
3025 
2927 
2895 
3044 3044 
3075 
3052 
Csp2-H  stretch 
2419 2362     
1964 
1896 
1942 
1868 
1932   
 
 1654 1665 1665 1665 C=N stretch 
1604 
1647 1619  
1624,160
2 
C=C stretch 
1572 1592 1594 1594 1543 C=C stretch 
 1540 1531 1531  C=C stretch 
1499 
1488 
1483,144
7 
1483,1447 
1493,144
3 
C=C stretch 
1439 1406 1417  1413  
B-O asym. 
stretch 
1350 
 
1400,137
6 
1400,1376 1391 
1275 
 
1341,131
3 
1341,1313 
1343,132
7 
1191 
1218 1211 1212 
1225, 
1208,119
8 
C-O  stretch 
1161 1123 1125 1127 1124 C-O  stretch 
     C-O  stretch 
1095 1075 1073 1098 1069 C-O  stretch 
B-C stretch 
1072 1038 1066 1066 1051 
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1029  1042 1042  
 
  1023 1023 1020 
1007  1001 1001 1001 
972 988 990 990 982 B-O sym. stretch 
923  845 845  Csp2- H bending 
 850 801 801 810 B-O sym. stretch 
804 803 781   Boroxole ring 
764 
733 733 716 747 
BO2 out- of -
Plane 
 425 
 
Table AD 6.5:  PXRD data for samples TA-I-56-1a (1:1), TA-I-56-1b (1:2), TA-I-56-1c 
(2:1), in methanol   
Phenylboronic 
acid 
4-phenyl pyridine TA-I-56-1a TA-I-56-1b TA-I-56-1c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     
   7.94  
  8.02 8.15 8.01, 8.20 
  8.99 8.95  
 9.37  9.73  
9.94  10.10  10.12 
    11.09 
  11.96  11.95 
    11.54 
12.05   12.02  
     
12.86     
  13.41 13.43 13.33 
13.84    14.29 
   14.80  
15.27    15.49 
  15.88 15.51 15.96 
16.62  16.57  16.62 
    16.93 
17.31  17.02 17.02 17.53 
  17.51,1782 17.64  
18.26  18.25 18.17 18.17 
18.72  18.53 18.49 18.50 
 18.93 18.75 18.82  
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 19.44 19.12 19.27  
  19.85 19.78 19.68 
  20.14 20.04 19.96,20.16 
20.88  20.71 20.75 20.69 
21.17 21.16 21.12  21.12 
  21.28 21.47  
22.00 22.20 22.03 22.06 22.04 
   22.79 22.52 
 22.83   22.82 
 23.34 23.33 23.23 23.36 
24.01  23.85 23.70  
24.39  24.53 24.05 23.97 
  24.79  24.84 
25.74     
26.02    26.40 
 27.05  27.31  
     
 27.92 27.80 27.75 27.78 
28.48 28.74 28.74 28.71 28.57 
 29.17 29.56 29.52  
  29.96   
  30.18  30.33 
 30.71 30.71   
31.07    31.18 
31.72  31.67   
    32.16 
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33.61 33.96 33.65  33.59 
 34.66 34.79 34.13  
   34.96  
  35.08   
  35.79   
 36.38 35.96  36.02 
    37.91 
38.98 38.86  39.24  
39.62    39.38 
40.21     
46.31     
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Table AD 6.6: PXRD data for samples TA-I-56-2a (1:1), TA-I-56-2b (1:2), TA-I-56-2c (2:1), 
in acetone  
Phenylboronic 
acid 
4-phenyl 
pyridine 
TA-I-56-2a TA-I-56-2b TA-I-56-2c 
2-Thet° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     
  5.83   
  6.88   
  7.76  7.75 
  8.02  8.00 
    8.83 
  9.08 9.788 9.56,9.94 
9.94  10.14 10.61  
    11.54 
12.05  11.97  11.81 
 12.36 12.77 12.72  
12.86 13.03 13.26  13.09 
13.84  13.95  14.29 
  14.59   
15.27  15.34  15.64 
  15.88   
16.62  16.87 16.66 16.44 
    16.94 
17.31 17.50, 17.67 17.53  17.53 
  17.95 17.80 17.76 
18.26 18.31 18.21  18.14 
18.72  18.51 18.68 18.58 
 19.36 19.36 18.94 19.02 
  19.61 19.72 19.46 
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 20.13  20.00 20.56 
20.88 20.82 20.89 20.68 20.74 
21.17  21.15  21.19 
 21.59  21.50 21.88 
22.00 22.37 22.05 22.04  
  22.34 22.25 22.64 
 22.98 22.72 23.00 23.19 
  23.24 23.52 23.83 
24.01  23.89 23.75  
24.39  24.62  24.61 
 25.03 24.89 25.09 24.90 
25.74 25.78 25.39 25.83 25.41 
26.02 26.24 25.62 26.20 26.17 
  26.21 26.29  
  27.32  27.16 
 27.81 27.79 27.78 27.71 
28.48  28.61  28.55 
 29.12 29.49 29.32  
   29.87 29.71 
 30.38   30.00 
 30.68  30.57  
31.07    31.16 
    31.55 
31.72 31.92    
 32.40 32.99 32.37 32.78 
   33.13  
33.61 33.60 33.65  33.56 
 430 
 
  34.79   
 35.24   35.12 
  35.08 35.83 35.89 
  35.79 36.82  
    37.20 
   38.31  
38.98   38.91 38.73 
39.62     
40.21     
46.31     
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Table AD 6.7: PXRD data for samples TA-I-56-3a (1:1), TA-I-56-3b (1:2), TA-I-56-3c (2:1), 
in acetone  
Phenylboronic 
acid 
4-phenyl pyridine TA-I-56-3a TA-I-56-3b TA-I-56-3c 
2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 2-Theta ° 
     
  7.96   
   8.16 8.06 
  9.06 9.20 9.05 
9.94  9.70 9.68 9.68 
  10.13 9.89 10.13 
  11.87   
12.05   12.11 12.05 
 12.36 12.94   
12.86 13.03   12.96 
  13.35  13.48 
13.84    14.28 
   15.01  
15.27  15.45   
    15.83 
16.62  16.96  16.64 
     
17.31 17.50, 17.67 17.49 17.06 17.13 
  17.77 17.75 17.84 
18.26 18.31 18.22 18.38 18.24 
18.72  18.68  18.58 
  18.99   
 19.36 19.30 19.30 19.20 
  19.78 19.48 19.69 
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   19.90 19.88 
 20.13   20.14 
20.88 20.82 20.74 20.90 20.77 
21.17  21.21  21.23 
 21.59 21.41 21.47  
22.00 22.37 22.10 22.14 22.12 
   22.61 22.74 
 22.98 22.90   
  23.28 23.35 23.25 
24.01  23.81 23.85  
24.39    23.92 
 25.03 25.08 25.13 24.69 
25.74 25.78   25.78 
26.02 26.24  26.41 26.56 
  26.43 26.73  
 27.81 27.75 27.96 27.74 
28.48  28.24 28.71 28.76 
  28.62 28.39  
 29.12 29.42 29.58  
  29.77  29.60 
 30.38  30.93 29.99 
 30.68   30.83 
31.07     
31.72 31.92    
 32.40    
33.61 33.60   33.38 
 35.24  35.14  
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   36.10 36.07 
38.98     
39.62  39.09   
40.21     
46.31     
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Table AD 6.8: FT-IR assignments for samples TA-I-56-3a (1:1), TA-I-56-3b (1:2), TA-I-56-
3c (2:1), and its starting materials in Acetonitrile 
Assignment is made using the literature.
36
 
Phenylboronic 
acid 
4-phenyl 
pyridine 
TAI-56-3a TAI-56-3b TAI-56-3c Assignment 
[36]
 
cm
-1
 cm
-1
 cm
-1
 cm
-1
 cm
-1
 cm
-1
 
 3436 3436 3447 3533 O-H, stretch 
3273, 
3081 
3024 
3058 3074 
2924 
2920 3074 
3053 
3032 
Csp2-H  stretch 
2419  2348    
1964 1958     
1894      
   1749 1710,1692  
 1667 1630 1629 1665,1630 C=N stretch 
1604  1601 1601 1601 C=C stretch 
1572 1587 1550 1550 1573 C=C stretch 
 1543  1544,1507 1551,1513 C=C stretch 
1499 1482 1485 1481 1486 C=C stretch 
1439 1446 1444 1441 1450,1444  
B-O asym. 
stretch 
 1409  1406 1403 
1350 1340,1333 1345,1329 1339,1329 1345,1330 
1275, 
1191 
1232 
1189 
1281 
1200 
1281,1258 
1199 
1281,1256 C-O  stretch 
1161 1162 1175  1200,1175 C-O  stretch 
1095 1103 1124  1125 C-O  stretch 
1072 1072 1084  1085 C-O  stretch 
B-C stretch 
1029 1041 1069,1029   
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1007 1002    
 
972 986    B-O sym. 
stretch 
923 917 846 852 851,846 Csp2- H bending 
803 830 826 848  B-O sym. 
stretch 
764 761 779 720 702 Boroxole ring 
697, 857 740 702, 
679 
665 675 BO2 out- of –
Plane 
